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SUMMARY 
While the knowledge of sleep disorders in renal transplant recipients is severely limited, 
preliminary evidence shows that issues with poor sleep quality (SQ) and daytime sleepiness 
(DS) are highly prevalent. Non-pharmacological interventions such as light therapy, used to 
treat certain sleep and mood disorders, have not yet been tested as a means to improve 
sleep in this population. Therefore, the aims of this research program were:  
1) a) to evaluate the validity of a single-item daytime sleepiness measure integrated 
in the Swiss Transplant Cohort Study (STCS) (study 1; chapter 3); 
b) to determine the prevalence of immunosuppressive non-adherence (NA) in renal 
transplant recipients patients (study 1; chapter 4); 
c) to assess the association between daytime sleepiness (DS), depressive 
symptomatology, and non-adherence to the immunosuppressive regimen (study 1; 
chapter 4); 
2) to diagnose renal transplant recipients patients with sleep disorders following the 
ICSD-2 classification system (study 2; chapter 5); 
3) a) to determine the prevalence and evolution of sleep quality from pre- to 2 years 
post-transplantation in kidney, liver, lung and heart recipients included in the Swiss 
Transplant Cohort study (a prospective nation-wide cohort study) (secondary data 
analysis of the Swiss Transplant Cohort Study; chapter 6); 
b) to assess the impact of sleep quality on  perceived health status from pre- to 2 
years post-transplant (secondary data analysis of the Swiss Transplant Cohort Study; 
chapter 6); and 
4)   to assess the feasibility and effect size of bright light therapy in home dwelling 
renal transplant patients with sleep-wake disturbances (study 3; chapter 7). 
Figure 1 shows the flow chart of the research project.  
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Figure 1: Flowchart of the research program  
 
 
 
 
 
 
 
 
 
Legend: SQ= Sleep quality; DS = Daytime sleepiness 
 
STUDY 1; CHAPTER 3:  
Using a cross-sectional multicenter design including a convenience sample of 926 adult 
renal transplant patients (36.9% female; mean age: 58.0±12.3 y.; mean years since 
transplantation: 10.6±7.6) transplanted at 3 Swiss transplant centers, we found a 65.2% 
prevalence of poor sleep quality and a 51% prevalence of daytime sleepiness.  
Based on the ROC curve analysis, a score > 4 on the Swiss Transplant Cohort Study-
daytime sleepiness item indicates daytime sleepiness. The Swiss Transplant Cohort Study-
daytime sleepiness content validity is high as expert reviews were unanimous. Concurrent 
validity is moderate (Spearman’s rho, rs: 0.531, p < .001) and, although low, convergent 
validity with depression and poor sleep quality was significant (rs: 0.235, p < .001 and rs: 
0.318, p = .002, respectively). Regarding group difference validity, renal transplant 
recipients with moderate, severe and extremely severe depressive symptomatology scores 
showed, respectively,  3.4, 4.3 and 5.9 times higher odds of daytime sleepiness than those 
with none [Burkhalter, H., et al., Validation of a single item to assess daytime sleepiness 
for the Swiss Transplant Cohort Study. Prog Transplant, 2013. 23(3)]. 
STUDY 1; CHAPTER 4:  
Using a cross-sectional multicenter design including a convenience sample of 926 adult 
renal transplant recipients (36.9% female; mean age: 58.0±12.3 y.; mean years since 
transplantation 10.6±7.6) transplanted at 3 Swiss Transplant centers, we found non-
adherence levels of 16% for taking, 42% for timing, and a median overall non-adherence 
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level of 0%. Based on the multivariate logistic regression analysis, daytime sleepiness was a 
significant predictor (p < 0.001) for taking (1.09 [1.04-1.14]), timing (1.06 [1.03-1.10]) and 
overall non-adherence (1.09 [1.05-1.13]). The STCS-DS item yielded very similar predictive 
values. [Burkhalter H., et al., Daytime sleepiness is associated with immunosuppressive 
non-adherence in renal transplant recipients: a cross-sectional multi-center study. 2013. 
Submitted.] 
STUDY 2; CHAPTER 5:  
This cross-sectional study included 249 renal transplant recipients, each of whom was 
transplanted at one of three Swiss transplant centers. All had reported poor sleep quality 
and / or daytime sleepiness in the previous study (study 1). With the Survey of Sleep (SOS), 
a detailed self-report questionnaire, we screened for sleep and health habits, sleep 
history, main sleep problems and sleep disturbances. Of these 249 participants, 48 
participated in an in-person interview session and 118 in a telephone interview to 
determine a preliminary sleep diagnosis according to the International Classification of 
Sleep Disorders (ICSD). Descriptive statistics were used to analyze the Survey of Sleep itself 
and the frequencies of sleep disorders in renal transplant recipients. The sample had a 
mean age of 59.1±11.6 years, 60.2% were male and the mean time since transplantation 
was 11.1±7.0 years. The most frequent sleep problem was difficulty staying asleep (49.4%), 
followed by problems falling asleep (32.1%). The most prevalent sleep disturbance was the 
need to urinate (62.9%), and 27% reported impaired daytime function. The interview 
showed that most suffered from insomnia. [Burkhalter, H., et al., Self-reported Sleep 
Disturbances in Renal Transplant Recipients. Submitted, 2013.] 
SECONDARY DATA ANALYSIS OF THE SWISS TRANSPLANT COHORT STUDY; CHAPTER 6) 
Sleep quality was assessed pre-transplant, then at 6, 12 and 24 months post-
transplantation using a single question (see study 1) with responses ranging from 0 (very 
poor) to 10 (very good), where the cut-off for poor sleep quality was < 6. Random 
intercept regression analysis was used to identify statistically significant associations. 
The study included 1076 patients (age: 52.38±13.05 years; 65% males; 639 kidney, 
215 liver, 126 lung, 96 heart). For all groups, poor sleep quality decreased significantly 
from pre-transplantation (39.41%) to 12 months post- transplantation (24.75%). Liver and 
heart recipients had the highest prevalence of poor sleep quality pre- transplantation, 
while sleep quality in transplant recipients of all organs except lungs decreased to a 
prevalence of 22-30% at 12 months and remained constant at 24 months. Lung recipients' 
mean sleep quality actually increased from 22%to 42% in the final 12 months. [Burkhalter, 
H., Denhaerynck K., and S. De Geest, Sleep Quality Improves from Time of Listing to 2 
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Years PostTransplant in Solid Organ Transplant Recipients: A Prospective Cohort Study. In 
preparation for submission 2013.] 
STUDY 3; CHAPTER 7:  
This was a non-blinded, randomized controlled pilot trial to study the efficacy of light 
therapy. Thirty home-dwelling renal transplant recipients aged 56.9±13.5y, all previously 
screened for sleep-wake disturbances, were randomly assigned to receive either an 
immediate or a delayed (end of study) light therapy intervention.  
The intervention process had 3 stages of 3 weeks each, during which subjects' wrist 
actimeter (DaQtix) data were collected for analysis of circadian rhythm and sleep 
parameters. The first was a baseline measurement period. For the second, additionally 
morning light (10’000 lux) was scheduled (according to chronotype) for 30 min daily. The 
final stage was for follow-up. Depressive symptomatology was assessed four times–at the 
beginning of the baseline period, then at the end of each 3-week stage–using the 
Depression, Anxiety and Stress scale (DASS) (scoring: 0-21; >4 indicates depressive 
symptomatology). We used a random-intercept regression model to test group-time 
interaction. Effect sizes reflect the interaction estimated for standardized outcome 
variables. For the outcome variables bedtime, get up time, sleep efficiency and sleep 
latency, we added a step to the analysis in which we controlled for the presence of Beta 
Blockers and acetylsalicylic acid, both of which are frequently taken by renal transplant 
patients but are known to impact levels of melatonin, which contributes to consolidated 
sleep.  
The trial showed that light therapy induced a phase advance in bedtime of 19 min and get-
up time of 22 min. The pre-post analysis showed a phase advance only in get-up time. 
Post-hoc analysis revealed that light therapy significantly increased sleep efficiency 
(Standardized Estimates (SE): 0.42) and decreased sleep latency (SE: -0.28) in renal 
transplant recipients taking neither beta-blockers nor acetylsalicylic acid. Light therapy 
improved depression and mood in the whole group without affecting selective attention. 
Renal transplant recipients not taking beta blockers and/or acetylsalicylic acid showed a 
non-significant phase advance for bedtime (Standardized Estimates (SE): -0.08) and get up 
time (SE: 0.11). However, sleep efficiency increased (4.9%) and sleep latency decreased (6 
min) significantly for those not taking beta blockers (SE: -0.28) or acetylsalicylic acid (SE: 
0.42). The power for the improvement in sleep efficiency is 87% and for sleep latency 96%. 
[Burkhalter, H., et al., A Pilot Randomized Controlled Study of Light Therapy for Sleep-
Wake Disturbances in Renal Transplant Recipients, in preparation for submission, 2013.] 
Conclusions 
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This research program, which was the first to comprehensively address sleep quality 
aspects in renal transplant patients, generated new evidence that sleep quality and 
daytime sleepiness are highly prevalent throughout the transplant course in all 4 large 
organ transplant groups. It also established validity for the single Swiss Transplant Cohort 
Study daytime sleepiness (STCS DS) item, and showed that daytime sleepiness is a risk 
factor for immunosuppressive medication adherence in renal transplant recipients. Sleep 
assessment revealed that most renal transplant recipients had difficulty staying asleep, 
followed by problems falling back asleep. Insomnia was the most common sleep diagnosis, 
indicating that these patients might benefit from cognitive-behavioral sleep-wake 
interventions as used in general sleep medicine.  
Analysis of the Swiss Transplant Cohort Study data confirmed that sleep quality 
improves from pre-to post-transplantation, and that poor sleep quality is predictive of 
overall poor health status. Finally, in the pilot randomized controlled trial, bright light 
therapy showed favorable outcomes on selected sleep parameters as well as improving 
depressive mood, and may therefore be added to sleep disorder treatment options for 
renal transplant recipients. The influence of beta blockers and /or non-steroidal anti-
inflammatory drugs regarding sleep disorders requires further study, as does the potential 
use of supplementary melatonin and the classical approach of promoting sleep hygiene 
rules. 
Dissertation 
This dissertation is organized into 9 chapters: 
Chapter 1 introduces sleep, circadian rhythms and chronotypes, and sleep-wake 
disturbances. The emphasis is on the theoretical underpinning driving this research 
project. The behavioral part of the hypothesis is based on the integrated model of 
behavioral prediction [1], while the sleep-wake association is based on the two-process 
model of sleep regulation [2] and the Spillman model [3]. The chronotherapeutic 
intervention of bright light therapy is based on research indicating that it safely and 
reliably improves the patient's sleep-wake disturbance, thereby stabilizing sleep patterns. 
In the final part, gaps in the scientific literature are summarized. 
Chapter 2 describes the aims of this dissertation.  
Chapter 3 presents the results of a multicenter survey study describing the prevalence of 
daytime sleepiness, as measured via the validated Epworth Sleepiness Scale and the Swiss 
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Transplant Cohort Study's newly developed daytime sleepiness item. This study addresses 
content validity and validity related to other variables. 
Chapter 4 presents further results of the multicenter survey study introduced in Chapter 
3, describing the association between immunosuppressive drug non-adherence and daytime 
sleepiness. Daytime sleepiness is therefore seen as a barrier to immunosuppressive 
medication adherence. 
Chapter 5 summarizes the range of sleep diagnoses found in our renal transplant recipients 
based on a detailed questionnaire and an in-depth sleep assessment interview.  
Chapter 6 presents the prevalence and evolution of sleep quality from pre- to post-
transplant in kidney, liver, lung and heart recipients included in the Swiss Transplant 
Cohort Study (a prospective nation-wide cohort study). Further, it shows the impact of 
sleep quality on perceived health status from pre- to 2 years post-transplant. 
Chapter 7 presents the feasibility and effect size of a pilot RCT of bright light therapy in 
renal transplant recipients with sleep-wake disturbances, analyzing sleep, circadian, 
psychosocial and neurocognitive parameters.  
Chapter 8 summarizes all the new results and discusses the overall research project, 
including future research perspectives. 
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1.1. Introduction 
Sleep problems are a widespread and growing general health issue [1, 2], hindering daily 
functionality and weakening overall health [3]. In a survey of 10’132 individuals, Léger et 
al (2008) reported a 56% prevalence of sleeping problems in the US, 31% in Western Europe 
and 23% in Japan [4]. An epidemiological study summarizing studies in France between 
1980 and 2009 reported that 30-50% of the adult population had at least one sleep disorder 
and 15 -20% had insomnia [5]. In another epidemiological study, Ohayon and Lemoine 
(2004) reported a 20% - 40% prevalence of insomnia symptoms in the overall population of 
Western Europe, with women and the elderly the most affected groups [6].  
The prevalence of sleep medication use among different age groups reflect the 
growth of sleep disorders with age: 3.2% in subjects aged 44 years or younger, 13.3% for 
ages 45 - 64, 22% for ages 65 - 74, and 32% for 75 years or older [6]. Repercussions of sleep 
problems on daytime functioning were reported by most insomnia subjects (67%) [7]. 
Whether intentional or unintentional, sleep loss (being awake for over 20 hours) impairs 
performance comparably to a blood alcohol concentration of 0.10% [8]. About one-third of 
renal transplant recipients report poor sleep quality [9] and 34.1% report poor daytime 
functioning [9]. These are worrisome figures, as transplant recipients require full alertness 
for their self-care and chronic illness pathway management.  
This introductory chapter will give an overview of the evidence concerning sleep-
wake disorders in general as well as their particular significance to solid organ transplant 
recipients. This section will cover: sleep regulation (1.1), importance of sleep-wake 
function (1.2), general adverse effects of inadequate sleep (1.3), sleep disturbances 
classified in sleep medicine (1.4), measurement tools (1.5), diagnosis and treatment of 
sleep disorders (1.6), sleep in solid organ transplant recipients (1.7), and finally, gaps in 
the transplant literature with respect to sleep (1.8). 
1.2. Introduction to sleep regulation 
Sleep is defined as “a reversible state of perceptual disengagement from and 
unresponsiveness to the environment” [10]. Healthy sleep accounts for about one third of a 
person's life, i.e., ca. 8 hours per 24-hour period. However, if minimum levels of sleep 
quality and quantity are not met, problems arise during wakefulness (particularly in the 
performance of long and monotonous tasks without feedback) [11].  
Chapter 1 
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Sleep is divided into different stages, defined by changes in brain activity, i.e., 
electroencephalographic (EEG) patterns. A normal night of sleep includes 5 to 6 sleep 
cycles, each of which involves moving from stage 1 (light sleep) to stage 4 (deep sleep) and 
back again, with intervals of Rapid Eye Movement (REM) sleep. The proportion of time 
spent in each stage changes throughout the night. At the beginning of the night, deep 
sleep is prominent; in the morning hours, REM sleep lasts longer.  
This study's theoretical basis is the “two process model of sleep regulation” [12], 
which proposes that the interaction of a sleep-wake dependent homeostatic process and a 
circadian process generate the timing and structure of sleep and waking [13]. The 
homeostatic process is often compared to an hourglass that is turned twice in 24 hours. 
During the day, sleep pressure accumulates until the person goes to sleep and the 
hourglass is turned. The longer a person is awake, the higher his sleep pressure. 
Independent of sleep pressure, the circadian process is genetically programmed [14], with 
a periodicity close to 24 hours [15], and synchronized to the environmental rhythms of 
day/night and light/dark [16]. This rhythm differs among individuals in terms of periodicity 
and phase (timing). Interindividual variations in timing are known as chronotypes [17]. 
Persons exhibiting extreme chronotypes are often called “larks” for the early type and 
“owl” for the late type. The Horne-Östberg Morningness-Eveningness Questionnaire (MEQ) 
[18] is commonly used to establish individual circadian phase preference. As sleep and 
daytime functioning are linked to the activity of the circadian clock, individual preferences 
for morning and evening activity have biological bases [19]. 
During the aging process, the proportions of the different sleep elements and stages 
change [20]. One very obvious change in chronotype occurs in young people entering 
adolescence, as they experience a delay in their circadian timing system, resulting in a 
tendency to stay up later and sleep in later [21]. In contrast, elderly people tend to shift 
to earlier chronotypes, resulting in very early wakeup and bedtimes [22] (see figure 2). 
Additionally, wake-time after sleep onset increases, i.e., whereas adolescents may 
commonly experience long periods of unbroken sleep, it is normal for an aged person to 
perceive (accurately) that he is often awake during the night. 
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Figure 2: Epidemiology of the human circadian clock 
age  
Image credit: Roenneberg, T., et al., Epidemiology of the human circadian clock. Sleep 
Med Rev, 2007. 11(6): p. 429-38. 
1.3. Importance of sleep for waking functionality 
1.3.1. Theoretical underpinning: The two process model of sleep 
regulation 
The two process model of sleep regulation (figure 3a and 3b) posits that sleep is regulated 
by a homeostatic process and a circadian process [23]. The homeostatic process is a 
quantitative need for sleep that rises while a person is awake and declines during sleep, 
i.e., homeostatic sleep pressure varies with prior time awake and on the characteristics of 
the preceding sleep. The circadian process is independent of time awake or asleep and 
provides time-of-day input, synchronized through the external signal of light. 
Theoretically, these two processes are relatively independent; however, in real life they 
interact to determine timing and duration of sleep [15]. Further, both systems can be 
consciously overridden. For example, a week of working night shifts can temporarily reset 
the body's synchronized processes to keep a person awake when he would ordinarily be 
sleeping or vice-versa. 
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Figure 3a: Schematic representation of the two process model of sleep regulation. This 
figure represents an awake person. 
Circadian  
Pendulum  
 
 
 
 
 
 
 
 
Homeostatic 
 Pendulum 
Figure 3b: Schematic representation of the two process model of sleep regulation. This 
figure represents a sleeping person. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Images 2 & 3 credit: Double pendulum model for the regulation of sleep/wake rhythms http://www.sommeil-
mg.net/spip/Chronobiology-Have-to-sleep,216 used with permission: Dr Guilhem Pérémarty ProSmg Association 
15.07.2013 
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The internal master clock is situated in the suprachiasmatic nuclei of the anterior 
hypothalamus (figure 4). However, clock genes tick at their own endogenous circa-24 hour 
(i.e., circadian) frequency in every cell and organ of the body, and peripheral oscillators 
(middle-level timekeepers) are found in the esophagus, lungs, liver, kidneys, pancreas, 
spleen, thymus and skin [24]. Both the master clock and peripheral oscillators need to be 
synchronized by so-called Zeitgebers (external “time givers”). However, not all Zeitgebers 
act equally on all clocks, e.g., physical activity is a Zeitgeber for the muscles, and food is 
a Zeitgeber for the liver.  
The most powerful Zeitgeber is light, which works with melatonin as a Zeitgeber for 
the internal master clock. This principle has been developed into a useful therapy to 
synchronize the master clock [25]. Guidelines have been published to help time bright light 
therapy to achieve the desired effect [26]. 
Figure 4: Location of the master clock – the suprachiasmatic nuclei 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image credit: http://thebrain.mcgill.ca (Copyleft) 
1.3.2. Sleep-wake interaction 
The homeostatic process is determined by individual behavior, which, in turn, is influenced 
by work or social constraints. To varying degrees, all humans can adapt to an irregular 
sleep rhythm; however, a quantitative lack of sleep (homeostatic process) or a qualitative 
lack of sleep (circadian process) will be perceived respectively as sleepiness or tiredness 
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[13, 27-29]. This can happen any time a person has been awake too long or at the wrong 
time of day: the homeostatic and circadian processes fall out of synchronization, resulting 
in sleepiness or tiredness at odd times (jet-lag or shift work are obvious examples). Thus, 
the sleep-disordered individual must learn to schedule sleep time to match his circadian 
process and his sleep need to his homeostatic process until the sleep-wake cycle is again in 
harmony with the external world and social requirements.  
1.4. General adverse effects of inadequate sleep 
This section will address the main adverse effects of inadequate sleep, beginning 
with general impairment, then, in more detail, impacts on work (economic and safety 
burdens) and overall health 
1.4.1. Human errors and public health burden caused by sleep 
disorders and sleep deficit in the general population 
In 2012, the American Academy of Sleep Medicine and the Sleep Research Society 
developed a statement to communicate the importance of sufficient sleep and circadian 
alignment for adult health to national health stakeholders [30]. Quantitative and / or 
qualitative lack of sleep creates an overwhelming and uncontrollable need to sleep, 
causing problems with memory and attention [31], complex thought processes, motor 
responses to stimuli, performance in school or on the job, emotion control [8, 32], 
physiological factors [33], neurobehavioral factors [34], and cognitive performance [34]. 
And as the number of adults sleeping less than 7 hours per night is increasing [35], so 
is the magnitude of the problem. Inadequate sleep duration has consequences on 
physiological and neurobehavioral factors that become progressively worse under chronic 
short sleep conditions [33]. Van Dongen et al. (2003) adds that: “chronic restriction of 
sleep to 6 h or less per night produces ongoing cognitive performance deficits equivalent to 
up to 2 nights of total sleep deprivation” (page 1) [34]. Sleep deficits seriously impair 
waking neurobehavioral functions (lapses in behavioral alertness) in healthy adults [34]. 
The obvious and notable consequence of sleep deprivation is daytime sleepiness [36].  
Full-time exposure to artificial light enables us to reduce sleep time to meet the 
demands of a 24/7 society with long and late hours for business, commutes, or free time 
activities. Social jet-lag, i.e., discord between an individual’s chronotype and his socially 
set sleep times, results in insufficient sleep before work days and "rebound sleep" on 
weekends. The greater the social jet-lag, the greater the occupational hazards: sleep 
deficits are a societal health problem with economic impact [37]. Working around the 
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clock (i.e., shiftwork) is a factor for the growing rate of human error in industrial and 
transportation accidents [2]. The consequences of such preventable accidents (caused by 
poor sleep quality or daytime sleepiness) are a society-wide economic burden [38]. Shift 
workers (people working permanent night shifts, rotating shifts and evening shifts) are at 
very high risk of sleepiness due to sleep deprivation and the desynchronization of sleep and 
wakefulness [39]. The highest rate of industrial accidents is found among night shift 
workers [40] and high error rates are found among shift workers in general [41]. People 
with daytime sleepiness have a significantly higher accident rate [42], and adults with 
daytime sleepiness have cognitive and memory problems [43, 44]. Balkin et al. (2008) in 
their review wrote that sleep deprivation impairs the entire spectrum of mental abilities, 
ranging from simple psychomotor performance to executive mental functions [45]. Durmer 
at al. (2005) adds the aspect of neurocognitive consequences of sleep deprivation [46] and 
Killgore et al. (2006) the impaired decision making following sleep deprivation [47].  
Perhaps the most frightening consequence of sleep loss is impaired driving [48, 49]. 
Being awake for over 20 hours impairs performance comparably to a blood alcohol 
concentration of 0.10% [8]. Driving at night or in the early to mid-afternoon further 
increases the risk of an accident because these are times that our internal clock is most 
vulnerable to sleepiness [50]. But these figures only represent the tip of a very large 
iceberg, as driving is only one of many tasks demanding full alertness. Our daily lives, 
including work performance and precise execution of essential tasks (i.e., remembering 
timed immunosuppressive intake) are all also affected by sleep deficits [51].  
1.4.2. Health problems caused by sleep disorders and sleep 
deficits in the general population 
Sleep disorders and sleep deficits are precipitating a growing public health burden [2, 52]. 
Although few articles have been published linking sleep with clinical outcomes, poor sleep 
is associated with poor quality of life [53], impaired resilience to stress, and vulnerability 
to psycho-physiological disorders [54] including depression [55, 56]. Sleep disturbances are 
further associated with higher risks of cardiovascular disease [57], metabolic disorders [58-
62], diabetes [63], chronic inflammation [64, 65] and accelerated mortality [66-70] in the 
general population. Short sleep (<5hours) is associated with coronary artery calcification 
[71], and an increased risk of overall cardiovascular events, including myocardial infarction 
[72]. Finally, sleep durations of less than 6 hours or more than 8 hours have been 
associated with depression [73]. The best longevity rates are found among those who sleep 
an average of 7 hours per night [74]. 
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Considerable evidence supports a close interaction between immune function and 
sleep [75]. Luyster et al. (2012) in his review summarizes that: “Sleep deprivation 
contributes to a number of molecular, immune, and neural changes that play a role in 
disease development, independent of primary sleep disorders [30]. Cytokine changes 
triggered by infection increase sleep drive and alter sleep architecture [76, 77]. A growing 
body of evidence suggests non-causal links between cytokines (molecules involved in 
immune responses) and excessive daytime sleepiness. Kapsimalis et al. (2007) hypothesized 
that these molecules play important roles both in mediating excessive daytime sleepiness 
because of sleep loss or insomnia, and in the pathogenesis and cardiovascular 
consequences of obstructive sleep apnea [78]. In their review of the topic, Palma et al. 
(2007) [79] concluded that sleep deprivation and the immune system influence one another 
bi-directionally [79]. Enough sleep keeps the immune system working properly, which in 
turn protects against both infection and malignancy [80]. 
1.5. Sleep disturbances as classified in sleep medicine 
The International Classification of Sleep Disorders [81] classifies sleep disorders into a total 
of eight categories, beginning with the six main disorder types: 1) Insomnia, 2) Sleep 
Related Breathing Disorders, 3) Hypersomnias, 4) Circadian Sleep-Wake Disturbances, 5) 
Parasomnias, and 6) Sleep Related Movement Disorders. The two remaining categories are 
grouped: 7) Isolated Symptoms, Apparent Normal Variants, and Unresolved Issues, and 8) 
Other Sleep Disorders. This dissertation will focus on insomnia and circadian sleep-wake 
disturbances.  
1.5.1. Insomnia 
Skalski summarizes insomnia as "a subjective feeling of not getting enough sleep in 
terms of its length and quality together with its consequences, such as being unproductive 
and in bad mood during daytime” [82]. It can be symptomatic of primary medical illnesses, 
mental disorders, use or abuse of certain substances, or other sleep disorders. As an 
overarching term, it includes a number of more specific diagnoses: adjustment sleep 
disorder (associated with a specific stressor), psychophysiologic insomnia (heightened 
arousal and learned sleep-preventing associations), paradoxical insomnia (where subjective 
reports of severe sleeplessness are incongruent with the absence or minor degree of 
daytime impairment), insomnia due to a mental disorder (insomnia constitutes a distinct 
symptom); idiopathic insomnia (onset in infancy or early childhood); inadequate sleep 
hygiene (associated with activities that are inconsistent with optimal sleep); behavioral 
insomnia of childhood (resulting from inappropriate sleep associations or inadequate limit 
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setting); insomnia due to a drug or substance; or insomnia due to a medical condition [81]. 
According to the international classification of sleep disorders (ICSD-2) [81], the main 
symptoms are difficulties with sleep onset and sleep maintenance, or early wakening, 
combined with deteriorating daytime functioning. One commonly used theoretical 
underpinning is Spielman's "3P" model [83], i.e., predisposing factors (e.g., genetics, 
comorbidities), precipitating factors (e.g., life stresses such as surgery, or corticosteroids 
against acute graft rejection [84]), and perpetuating factors (unintentionally maintained 
bad behaviors, such as lying in bed awaken). Precipitating factors might trigger acute 
insomnia; however, unless perpetuating factors come into play, the problem will disappear 
as these factors diminish. In the general population, depending on the definition used, 
prevalence rates of insomnia range from 4% to 48% [85, 86]. 
1.5.2. Circadian sleep-wake disturbances 
Sleep-wake disturbances are mainly categorized under the sleep diagnoses of either 
circadian rhythm sleep disorders (CRSD) or insomnia. Circadian rhythms are the circa-24-
hour cycle of daily physiological functions, especially sleep onset and waking times [14]. 
Poor sleep quality (especially difficulties with sleep onset and/or sleep maintenance) and 
daytime sleepiness are the main symptoms of this class of sleep disorder [87]. In the 
international classification of sleep disorders, circadian disorders of the sleep-wake rhythm 
are further specified. They may be delayed or advanced, i.e., 3 or more hours later or 
earlier than the desired or socially acceptable sleep and wake times.  More rarely, a free-
running rhythm is present, i.e., the sleep-wake rhythm is no longer synchronized to the 24-
hour day and follows its endogenous genetic periodicity, which is usually somewhat longer 
than 24 hours. Totally blind individuals often suffer from free running circadian rhythm 
sleep disorders, as light cannot function as their main Zeitgeber (time giver). To 
synchronize them to the 24 h rhythm, they are therefore commonly treated with melatonin 
as the zeitgeber for darkness. Irregular sleep-wake rhythms with scarcely detectable 24-
hour patterns are most common in advanced Alzheimer’s dementia and occasionally in 
patients with Parkinsonism [88]. This deregulation results in a slow progressive change in 
temporal organization until death [89]. The consequences include behavioral disturbances, 
such as daytime agitation and nighttime restlessness [89]. Both Alzheimer's and Parkinson 
patients can be treated with bright light therapy [90].  
Environmental and lifestyle factors such as shift work, jetlag, or social jetlag can 
bring on circadian rhythm sleep disorders, but a dysfunction of the circadian clock can also 
be responsible [87]. Affected individuals most commonly suffer from impaired social and 
occupational functioning, as they are tired and awake at inappropriate times for work or 
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social activities [87]. The late ("owl") chronotype usually accumulates a sleep debt during 
the week and compensates via extensive sleep duration during the weekend [91]. During 
the weekdays, however, late chronotypes consume more stimulants [91] and are more 
depressed [92, 93]. In fact, evidence is accumulating that sleeping at the wrong biological 
time has a depressogenic effect [94, 95]. 
A circadian rhythm sleep disorder is normally a stand-alone diagnosis; however, in 
patients presenting with symptoms of insomnia or excessive sleepiness, it can also be a 
differential or secondary sleep diagnosis [96]. For an accurate sleep diagnosis, a detailed 
sleep assessment is often necessary to rule out common morbidities related to daytime 
sleepiness (e.g., cardiovascular disease, metabolic disorders, mood impairment) [97]. The 
prevalence of circadian rhythm sleep disorders in the general population is not well 
characterized, but is estimated at around 1% [98, 99] in adults. Delayed circadian rhythm 
sleep disorders have a prevalence of 8.4% in adolescents and young adults [100].  
1.6. Measurement tools for sleep-wake disturbances 
In the following sections only measurement tools for insomnia and circadian rhythm 
sleep disturbances are summarized. The overview ranges from questionnaires with their 
psychometric properties to objective measurement tools. 
1.6.1. Measurement tools for Insomnia 
This section describes the questionnaires, assessment interviews and other tools most 
often used to screen and diagnose sleep disturbances. In the case of screening tools used 
to detect sleep disturbances, a positive result has to be followed by an in-depth 
questionnaire and an assessment. Further, a diagnosis of insomnia will require a sleep 
assessment and follow-up visits. For this diagnosis, three conditions have to be fulfilled: 
adequate sleep opportunity, persistent sleep difficulty, and associated daytime 
dysfunction. Defining the cause of a sleep-wake disturbance in insomnia patients is very 
complex since it is often multifactorial [81]. 
1.6.1.1. Questionnaires used for screening 
Hundreds of instruments are available for measuring aspects of sleep, however there are 
really no instruments to diagnose insomnia. Two of the most popular are the Epworth 
Sleepiness Scale (ESS) [101], an 8-item questionnaire based on Spielman's 3P model [83], 
measuring daytime sleepiness, and the Pittsburgh Sleep Quality Index (PSQI) [102], a 25-
item questionnaire measuring poor sleep quality. Even together, these represent only part 
of the insomnia diagnostic, but are often used as preparatory “homework” for a sleep 
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assessment, and their combined range is broad enough to impede false negatives. Other 
questionnaires are available for very specific diagnoses (e.g., the Restless Legs 
questionnaire). If insomnia is already suspected, the Insomnia Severity Index can be used 
as a screening tool. 
The Epworth Sleepiness Scale is a validated questionnaire that measures a subject’s 
expectation of dozing, i.e., falling into a light sleep [103], in eight hypothetical situations. 
Response ratings range from 0 (no probability) to 3 (high probability). Scores for the eight 
items are summed, yielding a total dozing score between 0 and 24. An Epworth Sleepiness 
Scale sum score ≥6 indicates DS [101]. A score of ≥10 indicates that the subject is very 
sleepy and should seek medical advice [101]. Total ESS scores show high test-retest 
reliability (rho = 0.82, p < 0.001)[104] and a high level of internal consistency (Cronbach’s 
alpha = 0.74-0.88 in 4 separate chronically ill groups)[105]. A factor analysis of ESS item 
scores of 150 patients and 104 students isolated a single factor [104], and the full 
questionnaire has been validated for application in German-speaking populations [106] . 
The Pittsburgh Sleep Quality Index is a self-rated questionnaire assessing a wide 
variety of sleep quality related factors, including estimates of sleep duration and latency, 
and of the frequency and severity of specific sleep-related problems, over the previous 
month. Its 19 items are grouped into seven component scores, each weighted equally on a 
4-point (i.e., 0-3) scale. The seven component scores are summed to yield a global PSQI 
score of 0-21; higher scores indicate lower sleep quality. A cut-off of >5 points indicates 
poor sleep quality [102]. Tested as a marker for sleep disturbances in insomnia patients 
versus healthy controls, this cut-off showed a sensitivity of 98.7 and a specificity of 84.4 
[107]. Backhaus et al. translated it into German using the back-translation method [107], 
after which item analysis confirmed internal consistency of the German version 
(Cronbach’s alpha of 0.85) [107]. The test–retest reliability for a short interval (2 days) was 
high for both the global and the subscale scores (0.76 to 0.92). For a longer interval (45.6 ± 
18 days), the test–retest reliability was low for the “sleep quality” (r = 0.23) and “sleep 
disturbance” (r = 0.27) subscores, but remained moderate to high for the global score (r = 
0.86) and four of seven subscores (reliability: 0.59 - 0.83) [107]. Sleep diaries show a high 
correlation with the PSQI [107] indicating good validity (evidence based on relationship to 
other variables) based on relation to sleep parameters [107]. 
The Insomnia Severity Index (ISI) is a screening questionnaire used to assess the 
nature, severity, and impact of insomnia, and to monitor treatment response in adults 
[108]. A self-reported questionnaire with a recall period of 2 weeks, the ISI is mostly used 
in studies to confirm insomnia symptoms. Its 7 items are scaled on a 5-point Likert-type 
scale (0=no problem, 4=very severe problem). While no German version is available, the 
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scoring internal consistency of the English version has a Cronbach's αlpha of 0.90[108], as 
well as face and content validity. It is correlated with sleep diaries, polysomnography, and 
interviews. The cutoff score of 10 had a sensitivity of 86.1% and a specificity of 87.7% for 
detecting insomnia cases in the interview-assessed community sample [109]. 
More than one follow-up session is often necessary to exclude all similar disorders 
(e.g., a high score on the Epworth Sleepiness Scale could indicate insomnia, but oxygen 
saturation during night-time sleep must first be measured). In this context, the 9-question 
Berlin Questionnaire [110] is used to screen for sleep apnea by focusing on one very 
common symptom: snoring. The questionnaire is divided into three categories related to 
the probability of sleep apnea. Patients can be classified as high- or low-risk. The 
questionnaire assesses snoring severity, excessive daytime sleepiness, and history of high 
blood pressure or obesity, with a Cronbach's alpha of 0.86 - 0.92 for internal scoring 
consistency [110]. In primary care patients, using an apnea-hypopnea index of > 5 as a 
cutoff, its sensitivity and specificity were respectively 86% and 77%. An apnea-hypopnea 
index cutoff of >15.7 [111] yielded a sensitivity of 54%  and a specificity of 97%. Measured 
concurrently with polysomnography, using a respiratory disturbance index of >5, the 
sensitivity and specificity of the Berlin questionnaire were respectively 68% and 49%. A 
respiratory disturbance index of >10 yielded a sensitivity of 62% and a specificity of 43%, 
and a respiratory disturbance index greater than 15.9 yielded sensitivity and specificity 
figures respectively of 57% and 43% [112]. 
1.6.1.2. Sleep assessment interview 
As mentioned in the introduction to this section (1.5.1), insomnia is difficult to screen with 
questionnaires alone; an in-depth assessment interview and clinical history are generally 
necessary to identify insomnia-contributing factors [113]. The temporal, quantitative and 
qualitative aspects of sleep, behavioral and environmental factors, symptoms of other 
sleep disorders, and daytime causes and consequences of disturbed sleep are key elements 
of the sleep history [113]. At the time of data collection for the current study, several 
sleep assessment questionnaires were considered, including the Holland Sleep Disorders 
Questionnaire (40 items) [114], the Global Sleep Assessment Questionnaire (including 
various questionnaires) [115], the SLEEP-50 questionnaire (50 items) [116] and the Survey 
of Sleep (SOS) [117]. However, of these, to our knowledge only the SOS had a German 
translation.  
As it is a self-report questionnaire, the SOS is a helpful tool to prepare for the 
assessment interview. Developed at the University of Pittsburgh and later translated into 
German by Dr. Daniel Brunner (Somnologist at the Hirslanden center of sleep medicine), it 
Chapter 1 
 
30 
is commonly used to report sleep disturbances in insomnia patients [117]. It has 7 parts: 
(1) an overview; (2) sleep habits; (3) sleep disturbances ; (4) daytime function ; (5) health 
habits; (6) sleep history; and (7) medical history [118]. As the SOS is only regarded as a 
preparation for an interview (rather than a stand-alone data collection instrument), 
neither validity nor reliability results have been published for it. 
1.6.1.3. Other tools or tests  
Normally a sleep assessment is combined with a clinical check-up. Patients can support the 
information gathering by providing the sleep expert with hospital records and clinical 
reports. The first diagnostic step is the evaluation of these documents, the preparatory 
questionnaire, the assessment itself and the functional analysis of the sleep complaints, all 
of which will narrow the field of possible diagnoses. To further facilitate this step, sleep-
wake diaries could be a highly cost-effective tool both to define sleep/wake patterns and 
to identify behaviorally treatable patterns of sleep hygiene (section 1.6.2).  
The second step, wrist actigraphy (see section 1.5.2.3), gathers continuous objective 
data on rest-activity patterns over many days. The actimeter is a wrist-worn device that 
records body movement to determine sleep patterns.  
Another method of sleep data collection is polysomnography, a comprehensive 
diagnostic test measuring brain wave activity, eye and jaw muscle movement, leg muscle 
movement, nasal airflow, snoring activity, respiratory effort (chest and abdominal 
excursion), heart rate and oxygen saturation. As this test measures all these physiological 
parameters with great accuracy, the American Academy of Sleep Medicine considers it the 
gold standard for quantifying and qualifying sleep disorders. It can quickly test for sleep 
apnea or parasomnias mentioned in the sleep history [113], and is also commonly used to 
diagnose narcolepsy, idiopathic hypersomnia, periodic limb movement disorder, rapid eye 
movement behavior disorder, and sleep apnea. However, the diagnosis of insomnia and 
circadian rhythm sleep disorders requires several weeks and one laboratory night adds 
little informative value. 
1.6.2. Measurement tools for circadian rhythm sleep disorders 
The following sections describe the most commonly used measurement tools for circadian 
rhythm sleep disorders. As noted in section 1.4.2, the screening instruments for these 
disorders are the same as for insomnia. Questionnaires and a sleep assessment help narrow 
the range of possible diagnoses. To qualify as a circadian problem, a disorder has to fulfill 
two main criteria: it must be persistent, i.e., a recurrent pattern of sleep disturbance 
(signaling disruption of the circadian time-keeping system or misalignment between the 
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endogenous circadian rhythm and the exogenous factors that affect the timing or duration 
of sleep); and it must lead to insomnia and / or daytime sleepiness with impairment of 
social, occupational or other daytime functioning tasks [81]. 
1.6.2.1. Questionnaires used for screening 
Screening for circadian misalignment requires knowledge of the subject's effective bedtime 
and get-up time, the environmental constraints and the chronotype. The degree of 
interindividual variation in circadian sleep timing indicates whether the subject's current 
bedtime is misaligned. The Horne-Östberg Morningness-Eveningness Questionnaire (MEQ) 
[18] is a commonly used measure of circadian phase preference (chronotype). This tool 
provides a subjective measure of interindividual variation in circadian sleep timing, 
ranging from the early (“lark”) type to the late (“owl”) type. When interventions are 
planned to shift the biological clock, knowing an individual's internal time is crucial, as a 
given clock time of application may correspond to significantly different internal times for 
owls and larks, thus producing unwanted results.  
The Morningness-Eveningness Questionnaire consists of 19 items in 2 formats: 5-
point multiple-choice (5) and 4-point multiple choice (14) with different scoring weights 
ranging from 0 to 6. The sum gives a score ranging from 16 to 86; scores of 41 and below 
indicate "evening types", scores between 42-58 indicate "intermediate types", and scores of 
59 and above indicate "morning types" [119]. The internal consistency established in the 
general population in New Zealand was very good (Cronbach's alpha =0.83). The 
questionnaire's accuracy has also been measured against oral temperature curves (a 
measure of circadian rhythm). Morning types had a significantly earlier peak time in the 
circadian rhythm cycle compared to evening types. They also tended to have a higher 
daytime temperature and a lower post-peak temperature [18]. There are different scoring 
of the Morningness-Eveningness Questionnaire. With the original scoring 49.8% of the total 
population was classified as morning type compared to 5.6% with evening-type chronotypes 
[120]. In a validation study in a sample of middle-aged workers- (non-students), anyone 
scoring under 53 was considered an evening type, whereas anyone scoring above 64 where 
classed as an morning type. This reclassification resulted in 28.1% morning type, 51.7% 
intermediate, and 20.2% evening type [121]. 
Whereas the Morningness-Eveningness Questionnaire assumes a single schedule 
throughout the week, the Munich Chronotype one (MCTQ) takes into account different 
sleep timing during the week and at week-ends [22]. The MCTQ uses 13 rated items to 
assess individual phases of entrainment on working and work-free days. Aimed at subjects 
aged 6 to > 65 years, it collects clock-time data including get-up and bedtimes, the time 
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the subject becomes fully awake, and the lengths of sleep latency and inertia periods 
[122]. 
1.6.2.2. Sleep logs or diaries 
The diary is an easy and very effective measure to evaluate a subject's sleep-wake pattern. 
Most diaries have predetermined slots or lines to insert daily bedtime, lights-out times, 
subjective sleep latency, rising up during the night, and wakeup time. Sleep diaries often 
also include simple Likert scales for subjective measures such as mood, well-being, 
tension, or tiredness. Diary data also assist researchers in validating, editing and 
interpreting actimetry measurements [123, 124]. Example shown in figure 5. 
Figure 5: Example of a sleep diary showing entries made before bedtime (grey part) and 
after getting up (yellow part)(in German): 
 
 
 
Image credit: Sleep diary developed by H.Burkhalter for the study described in chapter 7. 
1.6.2.3. Actimetry  
Circadian rhythms can be objectively measured through actimetry. Polysomnography is 
used to measure sleep parameters (e.g.: REM and non REM cycles) for single night, 
however cannot measure activity rhythms. Polysomnography normally measures brain 
electroencephalographic activity, eye movements, muscle activity or skeletal muscle 
activation, heart rhythm and chest movement (breathing) over one night in a sleep center 
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under “laboratory” conditions. Though indispensable for many sleep diagnoses, 
polysomnography is very expensive and time-consuming, and does not reflect the patient's 
normal home environment. For measuring circadian rhythms, then, the current study 
focused on actimetry. 
The actimeter is a wristwatch-shaped device to continuously measure arm 
movements/unit of time. Normally it is worn on the non-dominant wrist. Actigraphy has 
been established as a reliable and objective method for the naturalistic study of sleep and 
wakefulness in a 24-hour context [124-126]. Several models of actimeter are available. In 
the study reported in chapter 7 we used Daqtometers (Daqtometer by Daqtix GbR, Oetzen 
Germany), which include an integrated light sensor [127]. The light sensor on the upper 
surface of the device measures the individual’s light exposure during the entire 
measurement period. The light data helps to interpret the circadian sleep-wake rhythms, 
and is well suited to an intervention study involving light, i.e., to assess adherence to light 
therapy. In addition to wearing the device, users must keep a diary indicating any periods 
when they are not wearing the actimeter [128], and entering their bedtimes, wake up 
times, get-up times and exceptional events (e.g., parties, very cold days, or periods when 
the actimeter was under a sleeve). Practical parameters for the role of actigraphy in the 
study of sleep and circadian rhythm can be found in Littner at al. (2003) [129]. 
Standardized protocols exist for editing and analyzing actimetry data [130]. The 
stored values on the actimeter are downloaded to a personal computer, then edited with 
the aid of diary entries to determine adherence levels. After the editing of the raw data, 
the main analysis software [88] yields three figures regarding the subject's overall 
circadian rhythm ((1) interdaily stability (IS); (2) intradaily variability (IV); (3) relative 
amplitude (RA)), four focusing on sleep variables ((1) bed time, (2) get up time, (3) sleep 
efficiency, (4) sleep latency) and one more for light (intensity measured in Lux). IS reflects 
the stability of the rhythm over the full time span of interest, ranging from 0 to 1, where 1 
represents perfect stability over the entire period. A low IS value indicates greater day-to-
day variation. IV indicates the degree to which the rhythm is fragmented. This also ranges 
from 0 to 1, with higher values indicating a more disrupted sleep–wake rhythm (e.g., 
frequent naps, frequent night-time sleep disruptions). RA expresses the ratio between the 
most active 10 h period and the least active 5 h period in each 24 hour period. As with the 
other measures, it ranges from 0 to 1. In this case, higher values indicate better-regulated 
sleep–wake rhythms. 
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1.6.2.4. Circadian phase marker- Dim light melatonin 
onset  
Perhaps the important hormone for synchronizing sleep patterns with night and day is 
melatonin. It is produced by the pineal gland, with the suprachiasmatic nuclei controlling 
its daily cycle of synthesis and excretion [25]. Light absorbed through the retina inhibits its 
production, while darkness permits production. Under normal conditions, melatonin levels 
rise during the night and decline at dawn [131] (Figure 6). The increase in melatonin 
secretion in the evening correlates with an increase in sleep propensity [132]. Melatonin 
affects the circadian rhythm by initiating a nightly thermoregulatory cascade which 
decreases heat production and vasodilatation of distal skin regions, leading to heat loss, 
which in turn induces increased sleepiness and a decrease in core body temperature 
preparatory for sleep [133].  
Figure 6: Example of an individual saliva melatonin profile 
 
Image credit: H. Burkhalter - Saliva melatonin profile of one subject that participated in the bright light intervention study (Chapter /) 
Melatonin begins to rise an hour or two before sleepiness begins, peaks in the 
middle of the night, and falls until about the time of awakening [134]. As Melatonin onset 
each evening results in a clear change from the low levels throughout the day, it is useful 
as a circadian marker when the entire nocturnal rhythm cannot be measured. Levels can 
be measured in the blood, saliva [135] and urine (melatonin metabolite 6-
sulphatoxymelatonin (aMT6S)) [136]. Dim-Light Melatonin Onset (DLMO) is a standardized 
physiological estimate of circadian phase when samples are collected under dim light 
conditions [137].  
Adding to its diagnostic value, empirical evidence indicates that saliva melatonin 
can reliably be self-collected and stored at home. For a study including 1848 patients with 
possible delayed sleep phase disorder, participants self-collected late afternoon and 
evening saliva melatonin samples at 5 consecutive one-hour intervals at home: dim-light 
02  04   06   08 
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melatonin onset could be determined in 76.2% (n=1408) of cases [138]. To check the 
reliability of patient self-collection, a recent study compared 24 individuals' home-
collected saliva melatonin samples with laboratory-collected samples from the same 
subjects the following night. Analyses indicated a significant correlation between the at-
home and in-lab dim-light melatonin onset assessments [139], and dim-light melatonin 
onset could be determined in 80% of the self-collected sample [139]. The reasons for the 
unsuccessful dim-Light melatonin onset measurement included very low values (<3 pg/mL), 
profiles where initial melatonin levels were already above the threshold of 4 pg/mL, 
fluctuating curves, bleeding gums or mislabeling of tubes [139]. 
For persons whose sleep onset is not aligned with melatonin increases, dim-light 
melatonin onset time is a useful measure to determine internal phase, as onset timing 
varies according to individual chronotype. Phase advance or phase delay with respect to 
normal dim-light melatonin onset times (around 9 pm) can easily be recognized through a 
pre-bedtime evening melatonin saliva profile. If dim-light melatonin onset is delayed, 
morning light exposure will normally advance it [140]. Figure 6 indicates that bright light 
therapy can correct problems in either direction: If dim-light melatonin onset is poorly 
synchronized (i.e., delayed or advanced), appropriately timed light exposure therapy can 
be used to correct it (Figure 7). 
Figure 7: Highly simplified diagram of phase shifts of the circadian system 
 
 
 
 
 
24        02                04           06 
Delayed 
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Early morning bright light 
treatment to advance the clock 
or melatonin supplementation 
treatment in the early evening 
Bright light in the evening or 
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treatment to delay the clock  
Biological night 
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Dim-Light Melatonin Onset is the most reliable marker for human circadian phase position, 
and is optimally obtained via evening blood or saliva sampling [141]. Unfortunately, the 
cost of assaying samples is relatively high. Dim-light melatonin onset can be calculated 
from hourly or half-hourly sampling. Thresholds either of 3 pg/mL or of a "3k" 
concentration (equal to the mean plus two standard deviations of the first three low 
daytime points) are commonly used [142]. Related calculations can easily be performed 
using the "hockey-stick" method recently developed by Danilenko et al. (2013) [143]. 
Figure 6 shows a saliva melatonin profile of an individual who participated in the bright 
light intervention study and figure 8 shows the calculated Dim-Light Melatonin Onset based 
on these data using the software developed by Danilenko et al. (2013). 
Figure 8: Example of a calculated Dim-Light Melatonin Onset time based on saliva 
melatonin samples collected in the evening  
 
Image credit: C. Danilenko - Hockey-stick method to estimate evening dim light melatonin onset (DLMO) [143] 
 
1.6.2.5. Other measurement tools 
In patients with symptoms suggestive of both a circadian rhythm sleep disorder and 
another primary sleep disorder, polysomnography (see section 1.5.1.3) is indicated to rule 
out numerous conditions; however, for reasons summarized above (see section 1.5.2.3), it 
is not indicated for the diagnosis of circadian rhythm sleep disorders. 
Hockey-stick 
DLMO=21:55 
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1.7. Treatments for sleep-wake disturbances 
The following section describes the main treatment for insomnia and circadian rhythm 
sleep disorders. 
1.7.1. Insomnia treatment 
The two main treatment classes for insomnia [113] are behavioral (e.g., cognitive 
behavioral therapy) [144, 145] and pharmacological (e.g., hypnotics, sedating 
antidepressants and antipsychotics)[146]. Buysse et al. (2013) wrote in a short report for 
the journal of the American medical association in his summary findings that: “Behavioral 
treatments should be used whenever possible, and medications should be limited to the 
lowest necessary dose and shortest necessary duration” [113]. Sleep medications are often 
used to diminish patients' worries, as most are extremely distressed about their poor sleep. 
Many individuals spend considerable time in bed trying to “catch up” on sleep; in this 
situation, a sleep drug is only helpful if administered with sleep (and eventually sleep 
restriction) schedules. Using the 3P model [83] as an underlying framework for insomnia, 
the main treatment objective is to prevent a transient insomnia from evolving into a 
persistent insomnia. Therefore, the vanguard of sleep intervention studies currently 
involve cognitive and/or behavioral treatments (sleep restriction, stimulus control therapy, 
relaxation based interventions, cognitive therapy and sleep hygiene education)[113]. 
1.7.2. Circadian rhythm sleep disorder treatment 
Circadian phase adjustments demand appropriate treatment timing. Before embarking on 
any course of treatment, a questionnaire estimating the patient’s chronotype is essential 
[147]. The most common treatment for sleep disorders is quick pharmacological relief; 
however, while behavioral interventions are slower, it has been suggested that they are 
more durable [148-150]. Especially in shift workers or frequent travelers with time zone 
changes, timed melatonin supplementation and /or light can speed up the phase change 
[151]. Behavioral therapy, such as improved sleep hygiene (See Table 1) (especially 
enforcement of stable sleep and wake times, together with exposure to light at the correct 
time of the day and avoidance of exposure at counterproductive times) is the basic 
approach for all patients diagnosed with circadian rhythm sleep disturbances [144]. There 
are hundreds of sleep hygiene rules, all of which include behavioral, environmental, 
dietary and exercise components. 
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Table 1: Sleep hygiene rules derived from the U.S. Department of Health and Human 
Services - National Institute of Health [152]:  
 
Nr. Sleep hygiene rule 
1 Keep your internal clock set with a consistent sleep schedule  
2 Exercise early during the day 
3 Avoid caffeine, alcohol, nicotine, and other chemicals that Interfere with sleep 
4 Avoid alcoholic drinks before bed.  
5 Avoid large meals and beverages late at night.  
6 Don’t take naps after 3 p.m.  
7 Relax before bed.  
8 Take a hot bath before bed.  
9 Have a good sleeping environment. 
10 Have the right sunlight exposure.  
11 Don’t lie in bed awake. Go to bed when you are truly tired 
 
1.7.2.1. Intervention with Zeitgebers – 
Chronotherapeutics to normalize the 
circadian process 
Chronotherapeutics involve controlled exposure to environmental stimuli (e.g., food 
intake, exercise, social cues, auditory stimuli and light [153, 154]) that influence biological 
rhythms and help synchronize the homeostatic and circadian processes both with one 
another and with the external day-night cycle. As light is the main Zeitgeber for the 
suprachiasmatic nucleus, bright light therapy is the main intervention against circadian 
imbalances [155]. When exposed to light, receptors in the retina transmit neural impulses 
to the suprachiasmatic nuclei–the body's master clock–and to a number of other centers 
responsible for sleep and wakefulness (cellular, physiological, and behavioral patterns) 
(figure 9). 
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Figure 9: Neurological structures, including the suprachiasmatic nuclei, which are involved 
in human circadian rhythm control.  
 
Image credit: http://thebrain.mcgill.ca (Copyleft) 
Further interventions include dawn and dusk simulation therapies [130, 156], dark 
therapy or blue light blocking therapy [157, 158] and wake therapy (sleep deprivation as a 
rapid antidepressant) [159, 160]. Dawn and dusk simulation therapy is used while in bed, 
during normal sleep hours. The simulator gradually alters light levels to mimic outdoor 
dawn and dusk transitions. As this treatment requires minimal attention from the patient, 
and most of the signal is presented while the user is asleep, it is considered automatic 
[161]. Blue light blocking therapy in the evening can involve the patient either wearing 
amber colored glasses or simply avoiding blue light. (In nature, blue light is normally a 
characteristic of morning light. However, computer screens and televisions equipped with 
short wavelength (blue range) light-emitting diodes (LED) have been shown to suppress the 
evening rise in endogenous melatonin [162]). Finally, wake therapy uses sleep deprivation 
to treat patients with affective disorders. In depressed patients, the combination of light 
and wake therapy elicits a rapid and sustained antidepressant response [163]. 
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1.7.2.2. Background and effect of bright light therapy  
Bright light therapy consists of exposure to specific very bright (typically 10,000 lux), full-
spectrum UV-filtered light from a light box for a beginning dose of 30 minutes [140]. When 
this light reaches the retina, it triggers signals to the suprachiasmatic nuclei to shift or 
stabilize circadian rhythms (Figure 10). As light suppresses melatonin secretion [164], 
night-time darkness is essential for normal melatonin production. Bright light therapy aims 
to stabilize the sleep phase [165] by resynchronizing a misaligned rhythm or by correcting 
for a lack of environmental light stimulation (e.g., for people living at higher latitudes in 
winter or who are housebound). Since 2005, light therapy has been indicated as the first-
line treatment in seasonal and non-seasonal depression in [155, 166], i.e., in depressed 
patients, it is considered a viable alternative or adjunct to antidepressive medication [167, 
168].  
 
Figure 10: Light influence cyclic human behavior 
 
Image credit: http://thebrain.mcgill.ca (Copyleft) 
In addition to the external influence of light, cyclical genes regulate the biological 
clock mechanism endogenously. When light reaches the retina, sensors activate the 
suprachiasmatic nuclei, which signal the pineal gland to regulate physiological and 
behavioral functions and cycles. The timing of light treatment must match the patient's 
chronotype [169] and other sleep pattern details. For example, advancing a patient’s sleep 
phase requires bright light early in the day. To increase the positive effect for people 
having trouble falling asleep and getting up on time each morning, light intervention 
should be even earlier. Terman and Terman (2005) recommend beginning morning light 
treatment about 7½ hours after dim light melatonin onset [170].  
In contrast to pharmacological agents, non-pharmacological interventions have 
little or no risk of adverse side effects [171, 172]. Side effects of light therapy overdose 
may include agitation, headache, or nausea. Side effects can be lessened by reducing the 
light dosage (intensity, duration, or both), increasing the distance between the patient and 
the light source (i.e., lowering the intensity), or by moving morning therapy sessions to a 
later time when ambient light levels are higher [173].  
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Apart from the circadian sleep disorders noted above, bright light therapy is useful 
against disturbances arising from shift work and jet–lag [174]. For shift workers [175, 176] 
it has demonstrated subjective improvements in work time performance tasks [144]. Some 
studies have even shown melatonin shifts and improvements in daytime sleep [177]. 
Regarding jet lag, bright light therapy can accelerate circadian synchronisation following 
transmeridian travel [178]. Preflight treatment with bright light therapy prior to eastward 
travel can be used to produce phase advances and potentially eliminate jet lag altogether 
[179].  
Morning bright light therapy has also proved useful against a growing range of 
neuropsychiatric disorders. For example, it is the treatment of choice for seasonal 
affective disorder (SAD) [155] and has shown promising results versus non-seasonal 
depressive syndromes [155, 180], in major depression [181, 182] , antepartum depression 
[183], eating disorders [184], attention deficit/ hyperactivity disorder [185], borderline 
personality disorder [186], Parkinson’s disease [187] and Alzheimer’s dementia [188]. 
1.7.3. Drug treatments for sleep disorders 
Sleep drugs can provide effective symptomatic relief of sleeplessness resulting from travel 
across time zones or to deal with acute stress (e.g., a medical procedure, loss of a loved 
one, mental trauma). However, where sleep disorders are deep-rooted, medication does 
nothing to treat the underlying causes. Persistent sleep disorders require in-depth 
assessment, with the diagnosis leading the treatment approach [189]. 
One commonly prescribed sleep medication group is the benzodiazepines. These 
drugs are well-suited for anxiety disorders [190], and include 3 classes: long-, 
intermediate- and short- acting (time to peak action) [191]. Short-acting 
benzodiazepines are considered safe for the short-term management of insomnia in the 
elderly [192]. However, the elimination half-life can last up to 100 hours [191, 193], 
leaving the patient with a “hangover”.  
Benzodiazepine and psychopharmacological treatment aiming to interrupt acute 
sleeplessness following a traumatic event (e.g., surgery, transplantation) are 
recommended primarily to stop the progress of molecular mischief associated with the 
brain’s reaction to traumatic stress [194]. Sleep disturbances lasting beyond this period 
require more comprehensive diagnostic criteria.  
After the diagnosis of an anxiety disorder, a long-term low-dose benzodiazepine 
treatment is not considered abusive or addictive [195] as this drug was designed especially 
to combat this disorder. Still, the side-effects can be significant. Studies have reported 
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ataxia, psychomotor impairments (leading to increased incidences of falls and fractures in 
the elderly), cognitive impairment, withdrawal, addiction, and renal bio-accumulation 
[196]. In fact, many prescribers dread benzodiazepines for their adverse daytime effect 
(daytime sleepiness and slowdown) [197] and their risk of addiction and abuse [198]. 
Additionally, benzodiazepine use can lead to tolerance [198], craving (if abruptly 
discontinued), and strain on hepatic and renal degradation processes [199]. Finally, even 
after a single dose [200], benzodiazepines reduce both the nocturnal secretion of 
melatonin [201] and inhibit cortisol secretion [202]. 
Non-benzodiazepine psychoactive drugs resemble the benzodiazepines regarding 
effects and risks, but different chemical structures. They are mainly used to treat sleep 
disorders and are known to reduce sleep onset latency [203]. Some also help the user to 
stay asleep (e.g., Zolpidem, Estazolam). However there is a debate about the safety of 
these drugs, as they may increase cancer risk, especially skin cancer [204].  This detail is 
very important for immunosuppressed patients as immunosuppression increases the risk of 
actinic keratosis progression to skin cancer [205]. As solid organ transplant recipients are 
normally immunosuppressed, their incidence and risk of malignancy is elevated [206]. A 
further problem is that patients often remain on sleep drugs for months or years, 
increasing the risk of dependence, accidents and other adverse health effects [207]. 
1.7.4. Melatonin supplementation for sleep disorders 
The circadian cycle-regulating hormone melatonin is secreted by the pineal gland in 
response to darkness. It is also available as a medication or dietary supplement. Clear 
evidence of benefits exists regarding its use against insomnia [208], the effects of jet lag 
[209], shiftwork-related difficulties [210], delayed sleep phase syndrome [211-213]. It also 
strengthens the immune system [214, 215], reduces free radicals in the body, functions as 
an anti-oxidant, may curtail metabolic syndrome [216-219] and has immunomodulation 
effects beneficial in cancer patients [220-224]. Melatonin or melatonin agonist medication 
doses are timed to increase melatonin levels 2-3 hours before bedtime [168], as this 
induces sleepiness [225]. 
Melatonin levels differ considerably between individuals [226-228]. Some studies 
report no gender-based differences in adult melatonin levels [226] and some do [229]; 
however, in children, girls' levels are significantly higher [230]. Melatonin secretion 
declines with age [231] and growth [226, 228]. However, the decrease between childhood 
and adulthood serum melatonin levels is related mainly to an increase in body size rather 
than to decreasing pineal secretion [228]. At every age, melatonin deficiency or disruption 
of its rhythm is associated with an increased prevalence of sleep disorders [232] and 
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sleep/wake cycles disturbances [233]. People with hormone cycle dysfunction, damaged 
melatonin receptors (fragile X syndrome) or disease-induced night-day rhythm reversal 
(Smith-Magenis Syndrome, a developmental disorder), require up to 100% melatonin 
supplementation [234]. 
In Switzerland melatonin is available only as a slow release drug of 2 mg (Circadin 
Retard®) [235] for the treatment of insomnia in people aged 55 and older [208]. In April 
2007, Circadin was approved by the European Medicines Agency as a monotherapy for the 
short-term treatment of primary insomnia in patients aged 55 or older. The recommended 
dosage is 2mg daily, 30 minutes before bedtime for 3 months [208]. This prescription is 
well tolerated, with no hangover and no observed safety issues regarding concomitant 
therapy with antihypertensive, antidiabetic, lipid-lowering or anti-inflammatory drugs 
[208]. Interestingly, a 2 mg dose is roughly 80 times higher than the amount of melatonin 
secreted nightly by healthy adults (5 to 25 micrograms). Further, the effect of melatonin 
supplementation seems to persist for at least 3 months after stopping exogenous treatment 
[236]. Keijzer et al. (2011) wrote in the discussion section that this might be caused by 
tissue storage of exogenous melatonin [138].  
Before a supplementation of melatonin is scheduled, the effect of evening bright 
light use has to be quantified and all substances and medications having interactive 
potential should be accounted for. Substances such as caffeine, tobacco, and alcohol can 
inhibit melatonin secretion [237]. Caffeine, for example, inhibits its metabolism via 
CYP1A2 [238]. A more complex challenge is checking all medications taken and their 
interaction potential. Medications known to interact with melatonin are Beta blockers and 
nonsteroidal anti-inflammatory drugs. Single studies have reported that melatonin may 
also change the efficacy of anti-coagulants (Warfarin® [239]), diabetes medications [240] 
and oral contraceptives [241]. Melatonin suppression by light or beta-blockers can be 
treated by melatonin supplementation [242, 243]. Beta blockers are known to suppress 
melatonin [244-246] by blocking sympathetic signaling to the pineal gland. Non-steroidal 
anti-inflammatory (NSAID) drugs providing analgesic, antipyretic and anti-inflammatory 
effects are known to inhibit the prostaglandin synthesis and suppress melatonin [247]. 
Further, melatonin decreases the effect of α1-adrenergic receptor agonists (methoxamine) 
and α2-adrenergic agonists (e.g., clonidine) by decreasing presynaptic calcium levels and 
inhibiting norepinephrine. Calcium channel blockers may lower melatonin levels via the 
activation of the voltage-dependent L-type channel (which mediates the entry of calcium 
ions into excitable cells) [248]. No results were found for the interaction with 
immunosuppresiva and steroids, however we assume a lower suppression of the immune 
system. 
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1.8. Sleep disturbances in solid organ transplant recipients  
Firstly, this section will describe the solid organ transplantation procedure and its 
prevalence. It will then deal with common outcomes and the need for immunosuppressive 
medication. In addition it will explain the importance of considering transplant recipients 
as chronically ill. Then the focus will shift to sleep disorders in solid organ transplant 
recipients, their prevalence, associated factors and treatment options.  
1.8.1. Introduction and prevalence of solid organ transplantation 
In 2012 35 hearts, 52 lungs, 92 livers, 96 living donor kidneys and 155 cadaveric donor 
kidneys have been transplanted in Switzerland alone, leaving 102 heart, 122 lung, 282 liver 
and 1207 renal failure patients on waiting lists [249]. Transplantation involves explanting a 
functioning organ from a donor and implanting it in a recipient. Recipients of solid organs 
(i.e., heart, lung, liver and kidney) are the focus of this dissertation.  
As a therapy for end-stage kidney disease, kidney transplantation surpasses dialysis 
treatment in the quality and length of life that it provides and in its cost-effectiveness 
[250]. Patients suffering from heart failure have only three treatment options: heart 
transplantation, heart-lung transplantation or implantation of a mechanical circulatory 
support device. For heart transplantation, no cost-effectiveness analysis can be applied 
due to the shortage of organs, and the devices available are mostly intended for temporary 
support only [251]. With lung transplantation, factors to be considered include the 
underlying disease, other therapies which alleviate the disease, life expectancy and quality 
of life with or without transplantation. For some diseases, lung transplantation shows a net 
benefit; careful decision making is necessary [252]. Liver transplantation is similar to 
kidney transplantation in that donors can be live or cadaveric, but the economics are very 
difficult to estimate, as liver allocations are based on the severity of the prospective 
recipient's illness (Model for End-Stage Liver Disease)[253]. In some cases, then, liver 
transplantation is clearly indicated; in others it is not. 
For those patients who receive organs, the risks of complication from the 
transplantation procedure itself are very small compared to that of rejection and the side 
effects of the anti-rejection therapy [254], particularly immunosuppressive medications. 
As their name implies, these functionally suppress the immune system and therefore 
increase susceptibility to infectious diseases. Without them, due to differences in human 
leucocyte antigen haplotypes, the recipient's immune system would attack the 
transplanted organ, leading to rejection (tissue death) [255, 256]. 
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The pharmacological treatment of solid organ transplant recipients is very complex. 
Immunosuppressive drugs are considered high-risk for the many possible pharmacokinetic 
and pharmacodynamic drug-drug interactions. Imprudent prescription or even over-the-
counter drugs can cause acute graft rejection. Also, as most solid organ transplant 
recipients are taking a calcineurin inhibitor (cyclosporine, tacrolimus), which are 
nephrotoxic, these patients are at risk of developing renal dysfunction [257]. Standard 
protocols in use for renal transplant recipients typically involve three drug groups, each 
directed to a site in the T-cell activation or proliferation cascade which are central to the 
rejection process: calcineurin inhibitors (e.g., cyclosporin, tacrolimus), anti-proliferative 
agents (e.g., azathioprine, mycophenolate mofetil) and steroids (prednisolone) [258].  
Chronic calcineurin inhibitor nephrotoxicity is associated with irreversible 
histological damage to the glomeruli, arterioles and tubulointerstitium [259]. Calcineurin 
inhibitor metabolism occurs mainly in the liver and gastrointestinal tract through the 
hydroxylating and demethylating actions of CYP3A4 and CYP3A5 isozymes [259]. 
Immunosuppressants act on the cytochrome P450 (CYP-450) system and P-glycoprotein 
protein transport, both of which which play significant roles in the absorption, distribution 
and metabolism of immunosuppressants [260]. Although a broad range of variables (age, 
hepatic function, multiple metabolic pathways) influence patient outcomes, substrates, 
inhibitors, and inducers of CYP-450 isoenzymes are the main drug interaction risk for 
immunosuppressed recipients, [261]. The best known interactions with immunosuppressive 
drugs such as calcineurin-inhibitor (cyclosporine and tacrolimus) are azole antifungals, 
macrolide antibacterials, rifampicin, calcium channel antagonists, grapefruit juice, St 
John's wort and protease inhibitors [262]. Interaction with mycophenolic acids occurs via 
interference with the intestinal flora or by limiting drug absorption [262]. Clinically 
relevant immunosuppressive drug interactions require prompt identification [263]. 
1.8.1.1. Monitoring of acute rejection 
While solid organ transplant groups have numerous organ-specific reasons for failure, the 
similarity of dissociation between short and long-term attrition suggests some similarities 
[264]. The recent decrease in acute rejection is the result of improved induction therapies 
and more potent immunosuppressive drugs. However, these result in more infections and 
elevate cancer risks. All solid organ transplant recipients treated with calcineurin 
inhibitors suffer from nephrotoxicity [265]–the dominant factor for chronic kidney disease– 
with increased morbidity and premature mortality [266]. Chronic kidney disease is highly 
prevalent, affecting 30% to 50% of the non-renal organ transplant population, with an 
annual end-stage renal disease risk of 1.5% to 2% [267]. In liver transplant recipients, 
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improved immunosuppression increases the risk of hepatitis C recurrence [268]. In heart 
transplantation, higher immunosuppression will decrease acute rejection but increase 
other side effects [269], though the cumulative number of moderate/severe rejections was 
found to have accelerate cardiac allograft vasculopathy onset [270].  
At 3 and at 6 months post-transplantation, a biopsy is standard procedure in 
Switzerland for renal transplant recipients, to balance the immunosuppressive medication 
dosage against the risk of opportunistic infections. In renal transplant recipients, the Banff 
classification of rejection is used on graft biopsies (normal, antibody-mediated rejection, 
borderline changes, T-cell mediated rejection, interstitial fibrosis and tubular atrophy and 
other) [271]. The Banff criteria are sometimes also used for liver [272] and pancreas 
transplant recipients [273]. If rejection is underway, a biopsy is necessary to determine 
the therapy required. The classification of heart [274] and lung allograft rejection [275] is 
described in a consensus paper of the International Society for Heart and Lung 
Transplantation (ISHLT). The categories are acute rejection, chronic rejection, chronic 
vascular rejection and airway inflammation (for lung transplant recipients) and cellular 
rejection and acute antibody mediated rejection (for heart transplant recipients). 
1.8.2. Outcome (survival) for solid organ transplant recipients 
The one-year survival rate after renal transplantation is 95% and roughly 90% at 3–5 years, 
with bacterial and invasive fungal infections being the primary causes of mortality in this 
population [276]. In the U.S., the expected one-year survival rate after liver 
transplantation approached 90% in 2012 [277]. This represents an astonishing improvement 
since 2000, when one study of a large U.S. cohort of liver transplant recipients reported an 
overall one-year patient survival rate of 59% [278].  
As with renal transplant recipients, infections are the most common multifactorial 
problem for liver transplant groups [279]. In Spain's heart transplant program database, the 
2012 figures for survival after heart transplantation were 77.8% at one year, 64.4% at five 
years, 48.9% at ten years, 35.6% at fifteen years, and 24.2% at twenty years [280]. In 2011 
the Registry of the International Society for Heart and Lung Transplantation reported that, 
for patients surviving one year post-transplantation, the median survival period had 
reached 14 years [281]. Lung transplant recipients' graft survival depends strongly on 
avoiding infections associated with bronchiolitis obliterans syndrome (chronic allograft 
rejection) [282]. Based on registry data, current survival rates are 87% at 3 months, 78% at 
1 year, 62% at 3 years, 50% at 5 years (the survival half-life), and 26% at 10 years. While 
the mortality rate is highest in the first year [283], the rates for wait-listed lung transplant 
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candidates has declined with the development of techniques to temporarily support 
acutely decompensating patients (extracorporeal membrane oxygenation)[284].  
1.8.3. Outcome (quality of life) for solid organ transplant 
recipients 
In addition to survival rates, there is considerable interest in examining patient-reported 
outcomes of solid organ transplantation, such as symptom experience and distress, and 
quality of life. Symptoms are very important both to transplant recipients and to pre- 
transplant patients, partly because they may signal significant changes in their health 
[285], but also because of symptoms' impacts on overall comfort. Studies have confirmed 
an overall improvement in health confirmed by studies describing symptoms improvement 
from pre- to post-solid organ transplantation; more details are provided in the following 
five studies. 
Approaching quality of life as a specific outcome, a cross-sectional case-control study 
by Reimer et al. (2002) compared 149 renal transplant recipients with 149 hemodialysis 
patients and 149 healthy controls. Members of the three groups were strictly matched by 
age and gender. Quality of life was measured with a global inventory, the Munich Quality 
of Life Dimension List. The analysis showed that transplant recipients and healthy controls 
experienced similar quality of life (6.55 respectively 6.52), and that both groups' ratings 
were significantly higher than those of the dialysis patients (5.63) (p < 0.0001) [286].  
In a more recent cross-sectional study, Kovacs, A.Z., et al. (2011) compared 888 
renal transplant recipients with 149 hemodialysis patients regarding health related quality 
of life using the Kidney Disease Quality of Life Questionnaire. This study's findings were 
similar to those of Reimer et al.: the transplant recipients had significantly better health 
related quality of life scores (median 50, IQR 40) compared to the hemodialysis group 
(median: 35, IQR: 30) [287].  
The same has been shown for liver transplant recipients. Measuring quality of life 
pre- and post-transplantation, Russell, et al. (2008) found that their group of 107 liver 
transplant recipients transplanted 1 to 39 months previously had a significant overall 
improvement in health related quality of life compared to pre-transplantation [288]. Their 
mean Short Form 36 Health Survey physical component score improved significantly from 
27±8 to 35±11 and the mean Short Form 36 Health Survey mental component score 
improved from 40±11 to 49±12 [288].  
Finally, one study compared sleep quality and quality of life at 6 and 12 months post-
transplantation. Silva et al (2012) reported that, evaluated with the Short-Form Health 
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Survey, post-transplant quality of life was 47.8±17.6 at 6 months and 46.3±16.8 at 12 
months for the physical component and 72.8±20.6 at 6 months and 71.2±18 at 12 months 
for the mental component [289]. For heart-lung and lung transplant recipients only post-
transplant numbers are available, but indicate that both groups' health related quality of 
life is similar to the general population [290]. 
1.8.3.1. Side effects of immunosuppressive drugs and 
symptom experience  
Studies have shown that frequently occurring and distressing symptoms negatively affect 
organ transplant recipients’ quality of life [291-294]. The post-transplant therapy regimen 
is very demanding, considering the risks of symptoms [295] and new comorbidities, which 
can include cardiovascular diseases [296], malignancies (especially skin cancer [297]) and 
infections [298]. Effective treatment must balance rejection prevention or control with 
loss of protection against an array of infectious agents and mutant cells [299]. The most 
common side effects of immunosuppressives are hypercholesterolemia, diabetes and 
nephrotoxicity. Others vary according to the immunosuppressive regimen and its dosage. 
High dosages of mycophenolate mofetil (MMF) and mucous membrane pemphigoid (MMP) 
are known to cause leukopenia and diarrhea; cyclosporine is nephrotoxic (constriction of 
pre-glomerular arterioles, causing hypertension), causes hyperlipidemia, hirsutism, fine 
tremor, increased appetite and gingival hyperplasia; tacrolimus can cause tremor and 
(when used in high doses) induce diabetes; Rapamune® (sirolimus) and everolimus are 
known to cause thrombocytopenia and hyperlipidemia. Most regimens include steroids, 
which are known for their side effects of nephrotoxicity, accelerated vascular disease, 
osteonecrosis, osteoporosis, and new-onset diabetes mellitus [299]. The one advantage of 
immunosuppression is a greatly decreased risk of rejection. The disadvantage is the greatly 
elevated risk of malignancies (especially neoplasm, the oncogenic potential of Epstein-Barr 
virus and human herpes virus) and infectious diseases (especially urinary tract infections) 
[299]. 
A number of studies have assessed symptom occurrence and patient distress. Since as 
early as 1987, research has shown that sleep-related symptoms are prevalent and/or 
distressing in solid organ transplant recipients. Below is a summary of the available data 
for symptom occurrence and distress, starting with renal, then lung, heart and finally liver 
transplant recipients. Unless otherwise noted, the studies were cross-sectional. 
Using the Adapted Transplant Symptom Frequency and Symptom Distress Scale to 
gather data from renal transplant recipients, De Barros and Cabrita (1999) reported that 
the most distressing symptoms for women were painful menstruation and insomnia [300]. 
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In that case, fatigue was ranked as the 7th most common and 9th most distressing symptom 
of 27 symptoms [300]. Using the Modified Transplant Symptom Occurrence and Symptom 
Distress Scale (45 symptoms) on a sample of 356 renal transplant patients, Koller et al. 
(2010) found that both sexes considered “tiredness” and “joint pain” the two most 
distressing and most frequently occurring symptoms [301]. Assessing symptom experience 
in renal transplant patients on tacrolimus-based therapy, Moons, et al. (2003) ranked 
sleeplessness 6th for occurrence and 10th for distress [302] out of 45 symptoms. And, 
Rosenberger, et al.(2005), assessing adverse symptoms of immunosuppressive medication 
in renal transplant recipients, ranked sleep disorders 8th for the most distressing symptom 
[303].  
Two studies assessed symptom occurrence in heart transplant recipients. One placed 
fatigue 2nd for occurrence and 4th for distress (Lough, et al.,1987) [304]; the other 
accorded sleeplessness rank 5 for distress and fatigue rank 7 for occurrence (Moons et al., 
1998)out of 27 symptoms [305]. Finally, a huge study including 722 solid organ transplant 
recipients ranked difficulty staying asleep 7th for occurrence (Hathaway et al., 2003) out of 
46 symptoms [306]. 
Symptom occurrence in lung transplant recipients has twice been assessed by a 
research group around D.M. Lanuza. In the first study she reported fatigue as the 3rd most 
occurring symptom (Lanuza et al., 1999) [307]. The second study reported that, prior to 
lung transplantation; sleepiness was ranked 8th for symptom frequency and 9th for distress. 
Not feeling rested after sleep was ranked 10th for frequency, but was not considered 
distressing. Fatigue was ranked 3rd for both frequency and distress (Lanuza et al., 2012) 
[308]. After transplantation, at 9 months, sleepiness decreased significantly. Problems 
falling asleep significantly increased at one month post-transplantation, and not feeling 
rested after sleep was significantly reduced after 12 months (Lanuza et al., 2012)[308]. 
In a study by Drent et al. (2008) of 123 liver transplant patients, symptom experience 
was assessed using the "Modified Transplant Symptom Occurrence and Symptom Distress 
Scale" (29-item version). Of the symptoms associated with immunosuppression, fatigue was 
ranked 5th and sleeplessness was ranked 9th for women. Eighty-five percent of the women 
sample (n=75) reported that the fatigue occurred frequently and 89% reported that it is 
distressing and 69% reported that the sleeplessness occurred frequently and 92% that it is 
distressing. Men ranked fatigue 6th and 72% of the men sample (n=47) reported that fatigue 
is frequent and 76% reported that it is distressing [309]. 
 
 
Chapter 1 
 
50 
1.8.4. Factors associated with sleep in chronically ill patients 
The previous section (1.7.3) described symptoms as useful for monitoring changes in 
health, and cited associated studies confirming sleep-related symptoms high rankings for 
frequency and distress. However, sleep disorders’ effects may go beyond psychological 
distress. In a cross sectional study by Riegel et al (2007 & 2009) including heart failure 
patients, daytime sleepiness has been associated with poor self-care [310, 311], and in a 
study by Elder et al. (2008) using data from the Dialysis Outcome and Practice Pattern 
Study, poor sleep quality in dialysis patients was associated with an increased risk for 
mortality [312].  
Also, immunosuppressant drugs are not the only cause of sleep disorders in 
transplant recipients. Various chronic medical conditions and comorbidities have also been 
found to reduce sleep quality [313]. Depression, heart disease, corporal pain and memory 
problems have all been linked to insomnia [314], while obesity, arthritis, diabetes, lung 
disease, stroke and osteoporosis are associated with other sleep-related problems such as 
breathing pauses, snoring, daytime sleepiness, restless legs or insufficient sleep [314]. 
Further sleep disturbances are correlated with pain [315] and depressive symptomatology 
[316]. It is also known that beta-blockers [244], non-steroidal anti-inflammatory drugs 
[247], bronchodilators [317], corticosteroids [318], decongestants [319], neurological [320] 
and psychiatric medication can all cause sleep disturbances. 
1.8.5. Transplant patients needs to be regarded as a chronically ill 
persons 
Chronic diseases persist over long periods with several symptoms and of generally slow 
progression [321]. Chronically ill patients need ongoing medical supervision and guidance 
in their self-management. Transplant recipients can be regarded as chronically ill as they 
require a complex lifelong therapeutic regimen, have to engage in regular medication 
intake and need regular medical follow-up [322]. Further, a study assessing chronic kidney 
disease according to the guidelines set out in the National Kidney Foundation's Kidney 
Disease Outcomes Quality Initiative reported that 90% of renal transplant recipients have a 
chronic kidney disease [323]. In addition, many have chronic kidney disease-related 
complications and the treatment fall below targets established for non-transplant chronic 
kidney disease patients [324].  
Current care in Switzerland is usually delivered as part of an acute-care treatment 
model. Transplant patients are often cared for by multiple surgical and medical specialists 
(physician, nurses, dieticians…) and may suffer from a lack of consistent care [325] (i.e., 
lack of care coordination, lack of active follow-up to ensure optimal outcomes, failure to 
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follow established practice guidelines or to adequately train patients to manage their 
illness)[326]. A disease management approach such as a multidisciplinary clinic may be an 
appropriate model for the future [327]. This emphasizes the need to implement chronic 
illness management principles into post-transplantation follow-up care [322, 328]. The 
chronic care model entails more than a multidisciplinary team: indeed, the focus is not on 
immediate acute problems but on professional long-term tracking, treatment and follow up 
programs. Emerging socio-demographic, psychosocial [329], behavioral [330] and system 
factors in tracking and follow-up care [331] indicate important associations between these 
factors and transplant outcomes [264, 332-337]. 
One aspect of chronic illness management absent from acute care models is a regular 
follow-up of self-management adherence issues (e.g., dealing with symptoms, emotional 
impact, complex medication regimens, difficult lifestyle adjustments…). Poor self-
management leads to poor healthcare outcomes, i.e., higher morbidity and mortality and 
further increased overall healthcare costs due to avoidable complications, hospitalizations 
and procedures [338]. In renal transplant recipients, 36% of graft failures are associated 
with medication non-adherence [339]. For this non-adherent group, immunosuppressive 
drugs are very unforgiving: missing more than 5% of doses significantly increases the risk of 
acute rejection [340]. Urquhart et al. (1998) defined forgiveness as: “the ability of a 
pharmaceutical to maintain therapeutic drug action in the face of occasional, variably long 
lapses in dosing” [341], pg.215. Forgiveness is dose-dependent, so one method of 
extending a pharmaceutical’s forgiveness is to increase the dose [342]. However, this 
would entail more side-effects, thereby damaging long-term outcomes. The clinical 
meaning of non-adherence is similar to that for HIV drugs [343], heart failure drugs [344] 
and oral anticancer drugs[345]. To summarize, it is crucial to keep the patient on track 
with his prescribed regimen. To emphasize the importance of long term follow-up tracking 
factors, a study including 249 renal transplant recipients reported that electronically 
monitored non-adherence was correlated with lower self-efficacy, higher self-reported 
non-adherence, no pillbox usage, and male gender [346]. A literature review further 
revealed that non-adherence resulted from the interplay of numerous influential factors 
(the most studied of these were socio-economic, patient-related and condition- or disease-
related factors)[347]. Schmid-Mohler et al. (2010) explored non-adherence to 
immunosuppressive drugs based on the Integrative Model of Behavioral Prediction: in this 
study, including 114 renal transplant recipients, forgetfulness was the most powerful 
barrier against adherence [348]. Intention to adhere plays a minor role in non-adherence in 
renal transplant recipients. As described in subsection 1.3.1, sleep deficit is associated 
with daytime sleepiness and cognitive impairments, including forgetfulness. As sleep 
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deficiency is associated with cognitive slowing [349], it has been hypothesized that 
forgetfulness is one of the consequences of sleep-wake deregulation[350]. Riegel et al. 
(2011) reported that excessive daytime sleepiness in heart failure patients was 
significantly associated with poorer medication adherence [51]. However, in 
transplantation medicine, evidence supporting a link between non-adherence and daytime 
sleepiness is very limited.  
1.8.6. Prevalence of sleep disorders in solid organ transplant 
recipients 
Another important aspect of chronic illness management is a regular follow-up of sleep 
[67, 351]. A small number of studies in solid organ transplant recipients focus on sleep-
related symptoms, characteristics, or diagnoses (e.g., sleep quality, insomnia, sleep 
apnea). There is, however, considerable variability in measurement tools and methods, 
leading to broad differences in the reported prevalence of sleep disorders pre- and post-
transplantation. One common point is that certain underlying medical diagnoses correlate 
strongly with higher risks of certain sleep disorders (e.g., adiposity with sleep apnea 
[352]). We therefore divided the description of sleep disorders by organ. Table 1 shows 
various aspects of sleep as measured or assessed with a number of measurement tools. A 
summary of the studied sleep diagnoses follows, starting with poor sleep quality, insomnia, 
fatigue, sleepiness, daytime functioning, sleep-disordered breathing, and finally sleep-
related movement disorders. 
Table 2: Summary of the literature of sleep measurement in solid organ transplant 
recipients (excluding case studies and reviews). 
Study Design  Sample Measurement Results Comment 
Kidney   Self-report   
Sabbatini, 
M., et al., 
2005 [353] 
Cross-
sectional  
N = 301 renal transplant 
recipient 
N = 245 hemodialysis 
patients 
N = 169 normal control 
subjects  
Sleep Quality: 
Pittsburgh sleep 
quality index (PSQI) 
PSQI mean  
 of renal transplant patients = 6.46±3.71 
 of hemodialysis patients = 8.52±3.81 
 of control subjects = 3.54±1.61 
 
With bivariate analysis, a significant correlation was 
detected between total PSQI score in renal transplant 
recipients and their age (r=0.2, P<0.002), but no further 
relationship existed with cumulative time on dialysis, time 
after transplantation, hemoglobin, C-reactive protein, or 
calculated creatinine clearance; nor with doses or blood 
levels of cyclosporin, tacrolimus and steroids 
No prevalence of 
sleep quality is 
reported 
Eryilmaz, 
M.M., et 
al., 2005 
[354] 
Cross-
sectional  
N = 100 renal transplant 
recipients 
Sleep quality: 
Pittsburgh sleep 
quality index  
Depression: Beck 
Depression Inventory  
Education: Self-
report questionnaire 
Prevalence of poor sleepers = 30%. 
 
Poor sleepers were younger (mean age: 31 vs 37), less 
educated (mean years of education: 7.80 vs 9.55), and 
more depressed (mean BDI scores 13.63 vs 7.18).  
Small and very 
young sample 
(mean age 36.1 
±11.3) 
Kachuee, 
H., et al., 
2007 [355] 
Cross-
sectional  
N = 125 renal transplant 
recipients 
Sleep Quality: 
Pittsburgh sleep 
quality index (PSQI) 
Quality of life: Short-
Form Health Survey 
(SF-36) 
Anxiety and 
depression: 
Hospital Anxiety and 
Depression Scale 
Sexual relation: 
Relationship and 
Sexuality Scale 
Prevalence of poor sleepers = 62% 
PSQI mean of renal transplant patients = 6.45±2.59 
 
Poor sleepers had higher total medical comorbidity scores 
(P=.009), more bodily pain, poorer general mental health, 
and less physical function on SF- 36 (P=.02), less sexual 
function, and more severe anxiety (P=.02). 
Very young 
sample (mean age 
42±12 years). 
Mean PSQI score is 
similar to 
Sabbatini et al 
2005. 
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Study Design  Sample Measurement Results Comment 
Burkhalter
, H., et 
al., 2011 
[9] 
Cross-
sectional  
N = 135 renal transplant 
recipients; age: 
51.6±11.9 years 
Sleep Quality: 
Pittsburgh sleep 
quality index (PSQI) 
 
Sleep Quality and 
daytime functioning: 
Swiss Transplant 
Cohort Study sleep 
quality and daytime 
functioning item 
Prevalence  
 of poor sleepers (PSQI) = 47.4% 
 of poor sleepers (STCS-SQ) = 31%. 
 of poor daytime functioning = 34%. 
 
 
Ameli, J., 
et al., 
2007 [356] 
case 
control  
201 kidney transplant 
recipients ; 67.7% males 
 
Group 1= end stage 
renal disease secondary 
to hypertension (n=82; 
mean age: 43.83±12.05; 
67.1%males) 
 
Group 2 = end stage 
renal disease secondary 
to other causes (n=119; 
mean age: 41.32±12.31; 
68.1% males). 
Sleep quality: 
Pittsburgh Sleep 
Quality Index (PSQI) 
 
Anxiety and 
depression : Hospital 
Anxiety Depression 
Scale (HADS)  
 
The groups were 
matched for medical 
comorbidities, 
demographic and 
clinical data, and 
symptoms of anxiety 
and depression 
Mean of the Pittsburgh sleep quality index for renal 
transplant recipients with end stage renal disease 
 secondary to hypertension = 7.42±2.36 
 secondary to other causes = 6.60±3.07 (sig. 
difference p=.042) 
 
Mean of sleep duration scores for renal transplant 
recipients with end stage renal disease 
 secondary to hypertension = 1.22±1.12 
 secondary to other causes = 0.86±1.12 (sig. 
difference p=.026) 
 
Mean of depression for renal transplant recipients with 
end stage renal disease 
 secondary to hypertension = 8.67±2.06 
 secondary to other causes = 9.30±2.32 (p= ns) 
 
Mean of anxiety for renal transplant recipients with end 
stage renal disease 
 secondary to hypertension = 8.74±3.27 
 secondary to other causes = 8.61±2.96 (p= ns) 
Pittsburgh sleep 
quality index 
score is 
significantly 
higher in renal 
transplant 
recipients with 
end stage renal 
disease secondary 
to hypertension 
compared to the 
other studies 
including all renal 
transplant 
recipients 
(6.46±3.71 [353] 
and 6.45±2.59 
[355]) 
Rodrigue, 
J.R., et 
al., 2011 
[357] 
cross-
sectional  
N = 100 renal transplant 
recipients; age:  
53.1±11.3, 54% males 
 
N = 100 hemodialysis 
patients; age: 52.1 ± 
12.2, 62% males 
 
Sleep quality : 
Pittsburgh Sleep 
Quality Index (PSQI) 
 
Fatigue: Profile of 
Mood States Fatigue 
subscale 
 
Mean of the PSQI  
 for hemodialysis patients = 9.55±4.8 
 for renal transplant patients =6.84±4.0 (p< 
0.001) 
 
Mean of the sum score of the fatigue scale 
 for hemodialysis patients = 8.99±5.5 
 for transplant recipients = 6.81±5.5 (p=0.02). 
 
Hemodialysis patients had worse physical functioning (p = 
0.008), role-physical (p =0.003), bodily pain (p = 0.05), 
general health (p < 0.001), vitality (p = 0.003), and social 
functioning (p = 0.05). 
Multiple testing 
Silva, D.S., 
et al., 
2012 [289] 
Longitud
inal 
design (6 
and 12 
months 
post-
transpla
ntation) 
N = 76 renal transplant 
recipients;  60% white; 
mean age 
42±12 years and similar 
proportions of male and 
female subjects. 
Sleep Quality: 
Pittsburgh sleep 
quality index (PSQI)  
 
Quality of life: Short-
Form Health Survey 
(SF-36) 
 
 
Prevalence of poor sleepers 
 at 6 months =  36.7%  
 at 12 months = 38.3% (p: ns) 
Quality of life physical component 
 at 6 months =  47.8±17.6 
 at 12 months = 46.3±16.8 (p: ns) 
Quality of life mental component. 
 at 6 months =  72.8±20.6 
 at 12 months = 71.2±18 (p: ns) 
Very small sample 
size 
Kovacs, 
A.Z., et 
al., 2011 
[287] 
Observat
ional 
cross-
sectional  
 
N = 888 renal transplant 
recipients; 58% males; 
age: 49±13 
 
N = 187 hemodialysis 
patients; 60% males; 
age: 49±12 
Insomnia: Athens 
Insomnia Scale 
 
Sleep apnea:  Berlin 
Sleep Apnoea 
Questionnaire 
 
Restless legs 
syndrome: Restless 
legs syndrome 
questionnaire 
 
Quality of life: 
HRQoL was assessed 
via the Kidney 
Disease Quality of 
Life Questionnaire  
 
Depression: Center 
for Epidemiologic 
Studies Depression 
(CES-D) questionnaire 
Prevalence of insomnia   
 in hemodialysis patients = 15% 
 in renal transplant recipients = 8% 
 
Prevalence of obstructive sleep apnea 
 in hemodialysis patients = 33% 
 in renal transplant recipients = 27% 
 
Prevalence of restless legs syndrome 
 in hemodialysis patients = 11% 
 in renal transplant recipients = 5% 
 
Prevalence of depression 
 in hemodialysis patients = 15% 
 in renal transplant recipients = 11% 
 
General health scores for quality of life 
 in hemodialysis patients = median 50, IQR 40  
 in renal transplant recipients = median 35, 
IQR 30 (low score = better quality of life) 
(sig. difference p< 0.001) 
Multiple testing 
Novak, M., 
et al., 
2006 [358] 
Observat
ional 
cross-
sectional  
N = 884 renal transplant 
recipients; age: 49 ± 13 
 
N = 183 Hemodialysis 
patients; age: 49±13 
 
N= 1996 general 
population; age: 49±12 
Insomnia: Athens 
Insomnia Scale 
 
Sleep apnea:  Berlin 
Sleep Apnoea 
Questionnaire 
 
Restless legs 
syndrome: Restless 
legs syndrome 
questionnaire 
 
Prevalence of insomnia 
 in hemodialysis patients = 15% 
 in renal transplant recipients = 8% 
 in general population = 8% 
 
Prevalence of at least 1 reported insomnia symptom 
 in hemodialysis patients = 83% 
 in renal transplant recipients = 70% 
 in general population = 50% 
 
Prevalence of restless legs syndrome 
  in renal transplant recipients  = 4.4% 
 
Prevalence of obstructive sleep apnea 
 in renal transplant recipients = 8.9% 
 
The prevalence of insomnia was higher for female vs. male 
transplant recipients (10% versus 6%; P = 0.014) and AIS 
scores (median, 3 [IQR: 5] versus median, 2 [IQR: 4]; p= 
0.05) . 
 
Renal transplant recipients with insomnia were 
Multiple testing 
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Study Design  Sample Measurement Results Comment 
significantly older than non-insomnia recipients (53±10 vs 
48±13 p<0.001) 
 
In the transplant population, the presence of restless legs 
syndrome and high risk for obstructive sleep apnea were 
associated with significantly higher AIS scores than the 
absence of these conditions (10% vs 4% p<0.001 
respectively 54% vs 25% p<0.001) 
Molnar, 
M.Z., et 
al., 2007 
[359] 
cross-
sectional  
N = 785 renal transplant 
recipients; mean age: 
49±13; 59% males 
Restless legs 
syndrome:  
Restless legs 
questionnaire 
 
Quality of life: 
HRQoL was assessed 
by the Kidney Disease 
Quality of Life 
Questionnaire  
 
Insomnia: Athens 
Insomnia Scale 
 
Prevalence of Restless legs syndrome = 4.46%  
 
Patients with Restless legs syndrome were more than 
three times more likely to have insomnia than patients 
without RLS (29% vs. 9%, p=.001). 
 
Almost 23% of patients with RLS reported moderate or 
severe problems with sleep initiation, whereas only 10% of 
the patients without RLS had a similar complaint (p<.05). 
Similarly, almost 20% of the patients with RLS versus 7–9% 
of those without it reported moderate or severe problems 
with sleep fragmentation and early awakening (P <.05). 
Daytime consequences of poor sleep (impaired well-being 
or functioning capacity, sleepiness) were also significantly 
more frequently reported in patients with restless legs 
syndrome versus those without restless legs syndrome 
(p<.05) 
In a multivariate negative binomial regression model, the 
presence of restless legs syndrome was the strongest 
significant predictor of insomnia (odds ratio=2.858, 95% 
CI=1.196–6.830; P=.018) after controlling for multiple 
sociodemographic and clinical variables 
 
Molnar, 
M.Z., et 
al., 2007 
[360] 
Prospect
ive study 
over 4 
years 
N= 804 renal transplant 
recipients; Mean age: 
49±13 and median time 
after transplantation 
was 54 months 
 
N= 38 renal transplant 
recipients with restless 
leg syndrome; age: 
51±11, 61% men 
 
N= 766 renal transplant 
recipients without 
restless leg syndrome; 
age: 48±13, 59% men 
Restless legs 
syndrome:  
Restless legs 
questionnaire 
 
Mortaliy over 4 years  
Prevalence of Restless legs syndrome in renal transplant 
recipients = 4.5%  
 
Mortality prevalence in renal transplant recipients  
 with restless legs syndrome = 26% 
 without restless legs syndrome = 11% (sig. 
difference p< 0.01) 
 
Mortality at 4 years was significantly greater in patients 
who had restless leg syndrome at baseline: univariate 
hazard ratio for the presence of restless leg syndrome was 
2.53 (95% confidence interval, 1.31 to 4.87). In 
multivariate Cox proportional hazard analysis, the 
presence of restless leg syndrome significantly predicted 
mortality (hazard ratio, 2.02; 95% confidence interval, 
1.03 to 3.95) after adjustment for several covariables. 
 
   Polysomnography   
Rodrigues, 
C.J.O., et 
al., 2010 
[361] 
Prospect
ive study 
N = 34 patients with end 
stage renal disease 
assessed pre- and post- 
transplantation, (age: 
35±10.4 years, 58% 
male) 
Sleep disordered 
breathing:  
Polysomnography  
Prevalence of sleep disordered breathing   
 in patients with end stage renal disease = 
26.5%  
 in renal transplant recipients = 21%  
 
Mild cases were predominant in both phases of the study, 
where only 3 patients before and 2 after transplantation 
had an apnea hypopnea index ≥15 (severe). 
Patients with apnea hypopnea index ≥5 prior to 
transplantation had a significant reduction in apnea 
hypopnea index (15.4±7.8 vs 4.4±4.4; p = 0.008). 
Considering only patients with apnea hypopnea index <5 
prior to transplantation, the difference was not significant 
(1.6±1.3 vs 2.7±4.5, p = 0.21). 
 
Molnar, 
M.Z., et 
al., 2010 
[362] 
Observat
ional 
cross-
sectional 
study 
N = 100 renal transplant 
recipients; age: 51±13 
 
N = 50 dialysis patients 
who were on the 
transplant waiting list; 
age: 50±13 
 
Sleep disordered 
breathing:  
Polysomnography  
 
 
Prevalence of obstructive sleep apnea   
 in hemodialysis patients = 26%  
 in renal transplant recipients = 25%  
 
Prevalence of mild apnea-hypopnea  
(apnea-hypopnea index [AHI] > or =5/h and <15/h) 
 in hemodialysis patients = 18% 
 in renal transplant recipients = 28% 
 
Prevalence of moderate apnea-hypopnea (AHI > or =15/h 
and <30/h) 
 in hemodialysis patients = 11% 
 in renal transplant recipients = 16% 
 
Prevalence of severe apnea-hypopnea (AHI > or =30/h) 
 in hemodialysis patients = 14% 
 in renal transplant recipients = 10% 
 
Of renal transplant recipients with obstructive sleep apnea 
more were males, compared to non-obstructive sleep 
apnea recipients (80% vs. 49% p= 0.006). Further BMI (29±5 
vs. 26±5 p= 0.005), neck circumference (40±3 vs. 37±4 p= 
0.002) and abdominal circumference (107±12 vs. 95±15 p= 
0.001) were significantly greater and average oxygen 
saturation during sleep (91.8±1.6 vs. 94±2.0 p= 0.001) was 
significantly lower. 
Multiple testing 
Jurado-
Gamez, 
B., et al., 
2008 [363] 
Prospect
ive study  
N= 9 hemodialysis 
patients who received 
transplantation (7 men 
and 2 women, age: 
42±16.2 years, BMI 
26±3.7) 
Sleep disordered 
breathing and sleep 
related moving 
disorders:  
Polysomnography  
Incidence of periodic limb movement per hour: 
 at pre-transplantation  = 36±34 
 at post–transplantation = 24±20.8 (p= 0.041) 
Incidence of apnea and hypopnea episodes 
 at pre-transplantation  = 10±10.7  
 at post-–transplantation =  4.9±6.1 (p= 0.029) 
Incidence of dips in SaO2 ≥3% per hour of sleep 
 at pre-transplantation  = 25±26 
 at post-–transplantation =  12±11.2 (p= 0.010) 
Incidence of sleep apnea/hypopnea (%): 
Small sample size 
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 at pre-transplantation  = 5±6.8 
 at post-–transplantation = 0.7±1.1 (p= 0.008). 
 
Three of the 9 patients had sleep apnea/hypopnea 
syndrome while on hemodialysis. The sleep 
apnea/hypopnea syndrome disappeared in 2 cases after 
kidney transplantation, with an overall improvement in 
the number of respiratory events and nocturnal SaO2. 
Beecroft, 
J.M., et 
al., 2007 
[364] 
Prospect
ive study 
N= 18 renal transplant 
recipients (11 men, 7 
women), age: 27-65,  
Sleep disordered 
breathing:  
Polysomnography 
Prevalence of sleep apnea 
 at pre-transplantation = 61% 
 at post-transplantation = 44% 
 
In three of the 11 patients (27%) with sleep apnea at pre-
transplantation, their apnea hypopnea index fell from 
20.4±15.4 to 7.2±6.8 events/h 
 
Following successful kidney transplantation, obstructive 
sleep apnea improved in fewer than 30% of patients with 
end stage renal disease. Persistent sleep apnea may 
contribute both to sleep-related symptoms and the risk of 
cardiovascular disease in this patient population. 
Very small sample 
size 
Beecroft, 
J.M., et 
al., 2008 
[365] 
Prospect
ive study 
N= 18 renal transplant 
recipients (11 men, 7 
women), age: 27-65, 
Sleep related 
movment disorders:  
Polysomnography 
Prevalence of periodic limb movement:   
 at pre-transplantation = 39% 
 at post-transplantation = 16% 
 
Prevalence of restless leg syndrome  
 at pre-transplantation = 47% 
 at post-transplantation = 5% 
 
Pre-transplant patients with periodic limb movement were 
significantly older than those without (median age 54 (38–
65) vs. 36 (27–57) p < 0.05. 
 
Transplantation was associated with a significant 
reduction in periodic limb movement index in all patients 
(8 (0-110) events/h vs. 2 (0-80) events/h); further sleep 
efficiency and sleep architecture were significantly 
improved. 
 
Patients with periodic limb movement at pre-
transplantation improved significantly at post-
transplantation for periodic limb movement index, 
events/ hour (40 (24–110) vs. 14 (1–80) p < 0.001); Periodic 
limb movement index arousals, events/ hour (13 (1–37) vs. 
3 (0–12); p < 0.05)); total sleep time (5.1 (3.3–6.2) vs. 5.5 
(4.2–6.0); p < 0.05) and Stage 1, % total sleep time (8.1 
(1.5–21.6) vs. 6.9 (2.4–20.2); p < 0.05). 
Very small sample 
size 
Fornadi, 
K., et al., 
2012 [366] 
Cross-
sectional 
study 
100 randomly selected 
kidney transplant 
patients; mean age: 
51±13 years, 43% were 
women. 
Sleep disordered 
breathing and sleep 
related moving 
disorders:  
Polysomnography  
 
Insomnia: Athens 
Insomnia Scale  
Prevalence of obstructive sleep apnea = 25% 
The percentage of men was significantly higher in the 
obstructive sleep apnea -positive group. Patients with 
obstructive sleep apnea had significantly higher BMI and 
hemoglobin level. 
 
Prevalence of periodic limb movements = 27% 
The percentage of diabetic patients was significantly 
higher among patients with periodic limb movements 
versus without. 
 
Prevalence of Insomnia =16% 
The serum interleukin-6 level was significantly higher in 
patients with insomnia. Insomniacs were older and had 
significantly higher Charlson Comorbidity Index compared 
with patients without insomnia. 
The usage of sleeping pills was significantly higher in 
insomniacs than in patients without insomnia. 
 
No significant difference was found in the levels of 
inflammatory markers between patients with versus 
without obstructive sleep apnea and periodic limb 
movements. Apnea-hypopnea index showed a significant 
association with white blood cell count (rho = 0.23), and 
weak, non-significant correlation (rho < |0.15|) with the 
other inflammatory markers. Periodic Limb Movement 
index showed weak (rho < |0.15|), non-significant 
correlation (rho < |0.15|) with all markers of 
inflammation. The serum interleukin-6 level was 
significantly higher in patients with insomnia (AIS >/= 10) 
than in non-insomniacs [median (IQR): 3.2(2.6-5.1) vs. 
1.7(1.2-2.9) ng/l; P = 0.009]. The levels of other 
inflammatory markers were similar between insomniacs 
and non-insomniacs. 
Multiple testing 
Lung   Polysomnography   
Malouf, 
M.A., et 
al., 2008 
[367] 
Prospect
ive study 
N = 25 lung patients 
assessed pre-and post-
transplantation 
 
 
Sleep disordered 
breathing:  
polysomnography 
Prevalence of sleep disordered breathing: 
 at pre-transplantation = 44% 
 at post-transplantation = 36% 
 
Eleven of the 25 patients (44%) had sleep disordered 
breathing prior to their lung transplantation. After lung 
transplantation, 5 of these 11 continued to have sleep 
disordered breathing, 4 of whom had respiratory 
disturbance index scores of >20 events/hour. Four of 14 
patients who previously had normal polysomnography 
developed new sleep disordered breathing post- lung 
transplantation. 
 
Improvement from pre-to post-transplantation: 
 awake SaO2: 91.5±4.7% vs. 96.0±1.85%, p < 
0.001 
Lung 
transplantation 
improves 
oxygenation, but 
new-onset sleep 
disordered 
breathing may 
occur after the 
procedure. 
 
No BMI and no 
percent total 
sleep time with 
SaO2 ≤90% data 
reported, only p 
value. 
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Study Design  Sample Measurement Results Comment 
 minimum sleep oxygen saturation (p < 0.004)  
 percent total sleep time with SaO2 ≤90% (p 
<0.001) 
 increase in BMI post- lung transplantation to 
24.3±4.7 (p < 0.02) 
 
There were no differences between pre- and post-
transplantation: 
 in total sleep time, 333.7±7 vs 349. ±5 
minutes (p< 0.9) 
 sleep efficiency, 76.9±27 vs 77.1±10.4 (p < 
0.96 
 arousal index, 19.9±11.6 vs 19.9±13.7 (p < 
0.98) 
 overall respiratory disturbance index 
8.48±10.8 vs 11.9±18.5 (p < 0.3),  
Small sample size 
Naraine, 
V.S., T.D. 
Bradley, 
and L.G. 
Singer, 
2009 [368] 
cross-
sectional 
N = 24 lung transplant 
recipients 
 
N = 9 non-sleep 
disordered breathing; 
age: 43.8±12.6; 56% 
males; time since 
transplantation: 
37.8±17.6 months 
N= 9 obstructive sleep 
apnea; age: 56.7±11.0; 
89% males; time since 
transplantation: 
24.3±12.7 months 
N = 6 central sleep 
apnea; age: 52.0±8.1; 
50% males; time since 
transplantation 19.8±5.0 
months 
Sleep disordered 
breathing:  
polysomnography 
 
Prevalence of sleep disordered breathing was 63% one 
year post-lung transplantation (obstructive sleep apnea 
was observed in 38% and 25% had central sleep apnea 
 
Apnea-hypopnea index, event/ hour in transplant 
recipients 
 With obstructive sleep apnea (1) = 20.1±14.2 
 With central sleep apnea (2) = 41.1±38.1 
 Without sleep-disordered breathing (3) = 
4.9±2.6 (1.2 vs. 3 p < 0.05) 
Obstructive event index/ hour in transplant recipients 
 With  obstructive sleep apnea (1) = 17.8±13.9 
 Without sleep-disordered breathing (3) = 
3.8±2.7 (1 vs. 3 p < 0.05) 
 
Hypopnea index/ hour in transplant recipients 
 With  obstructive sleep apnea (1) = 15.0±5.3 
 Without sleep disordered breathing (3) = 
4.5±2.6 (1 vs. 3 p < 0.05) 
 
Obstructive sleep apnea patient were significantly more 
emphysema patients (44% vs. 0% p < 0.05), more snoring 
(78% vs. 33% p < 0.05); higher systolic blood pressure 
(137.3±9.9 vs. 123.6±12.9 p < 0.05), higher body mass 
index (28.8±4.2 vs. 24.0±4.0 p < 0.05) compared to non-
sleep disordered breathing transplant recipients. 
 
Central sleep apnea patient were significantly treated 
more with Cyclosporine (100% vs. 22% p < 0.05) and had a 
higher body mass index (27.2±2.7 vs. 24.0±4.0 p < 0.05) 
compared to non-sleep disordered breathing transplant 
recipients. 
Small sample size 
 
Polysomnography 
should be 
considered in lung 
transplant 
recipients if they 
have gained 
weight 
Heart   Subjective 
measurement 
  
van de 
Beek, D., 
et al. 2008 
[369] 
retrospe
ctive 
cohort 
study 
N = 313 heart transplant 
recipients (transplanted 
between 1 to 10 years 
ago) 
Sleeping disorders: 
Data were extracted 
on patients „history” 
Prevalence of sleeping disorders = 32%  
 
sleeping disorders were related to baseline body mass 
index, with a mean body mass index of 26.8 for patients 
with sleeping disorders vs 24.5 for those without sleeping 
disorders 
Unclear which 
measurement 
tools were used to 
assess sleep. 
   Polysomnography   
Brilakis, 
E.S., et 
al., 2000 
[370] 
Retrospe
ctive 
study 
 
N = 147 heart transplant 
recipients 
 
17 heart transplant 
recipients mean interval 
of 17.5 months after 
transplantation. Age: 
50.8 years (range, 24-67 
years). 
Clinical assessment 
 
 
Sleep disordered 
breathing:  
polysomnography 
Prevalence of sleep apnea = 11.6% (13 had obstructive 
sleep apnea and 4 had mixed sleep apnea) 
 
 
The patients presented with snoring (100%), excessive 
daytime somnolence (65%), witnessed apneas (53%), and 
morning fatigue (53%). Sixteen (94%) had a mean weight 
gain of 10.4 kg after transplantation, although 1 lost 14.6 
kg. Of the 11 patients with obstructive sleep apnea who 
underwent nasal continuous positive airway pressure 
titration, significant improvements occurred in the apnea-
hypopnea index (decreased from 37.6 to 10.4; p = 0.01) 
and mean arousal index (decreased from 44.5 to 19.4; p = 
0.01). Only 2 of the 8 patients with sleep apnea for whom 
nasal continuous positive airway pressure was 
recommended were still using it at the time of telephone 
follow-up.  
Screening 
instrument for 
apnea is unclear 
Mansfield, 
D.R., et 
al. 2003 
[371]. 
Prospect
ive and 
observat
ional 
cross-
sectional 
study 
N = 37 heart failure 
patients pre-
transplantation: 
 
N = 16 patients with 
central sleep apnea 
N = 6 patients with 
obstructive sleep apnea 
N = 15 patients with no 
sleep-disordered 
breathing 
 
N = 22 (6 months post-
heart transplantation): 
 
N = 13 patients with 
central sleep apnea; 
age: 54±9, 100% males, 
post-transplantation 
time 13.2±8.3 months 
N = 9 patients with no 
sleep-disordered 
breathing; age: 44±10, 
80% males, post-
Sleep disordered 
breathing:  
polysomnograpy  
Apnea hypopnea index in heart transplant recipients 
 without central sleep apnea = 2±1 
 with central sleep apnea = 28±15 (p=< 0.01). 
 
Significant improvement from pre- to post- heart 
transplantation in the central sleep apnea group: 
 Heart rate, beats/min: 28±15 vs. 7±6, p < 
0.01, 
 mean Spo2, %: 94.7±1.8 vs. 96.3±1.6, p < 
0.01 
 
In the pre-transplant patients with no sleep-disordered 
breathing, all patients remained free of it after 
transplantation. 
Four patients from the central sleep apnea pre-transplant 
group acquired post-transplant obstructive sleep apnea. 
No prevalences 
are reported. The 
sampling strategy 
is not completely 
clear 
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Study Design  Sample Measurement Results Comment 
transplantation time 
20.6±10.7 months  
Javaheri, 
S., et al., 
2004 [372] 
cross-
sectional 
study 
N=45 heart transplant 
recipients: 
 
N = 15 no sleep 
disorders; age: 58±14, 
87% males; time post-
transplantation 25±14 
 
N= 14 with periodic limb 
movement, aged 
55±11,84% males, time 
post-transplantation 
26±14 
 
N = 16 with sleep-
related breathing 
disorders; age: 58±10, 
94% males, time post-
transplantation 30±15 
Sleep disordered 
breathing  and sleep 
movement disorders:  
polysomnograpy 
 
Quality of life: Short-
Form Health Survey 
(SF-36) 
Prevalence of obstructive sleep apnea = 36%  
Prevalence of periodic limb movement = 33% (45% of 
whom had restless leg syndrome) 
 
Body mass index was significantly higher in recipients with 
sleep-related breathing disorders (33±5 vs 28±3 recipients 
with no sleep disorders and 28±4 recipients with periodic 
limb movement p= 0.0008).  
Hypertension (prevalence in %) and systolic blood pressure 
(in mmHg) were also significant higher in these three 
groups (88% vs 27% and 50% p= 0.002) respectively (147±18 
vs 122±14 and 130±14). 
 
The physical component of the SF-36 health survey, a 
scale of physical morbidity, was significantly lower in 
cardiac transplant recipients with obstructive sleep apnea 
than in those without it. 
 
 
Ayik, S., et 
al. 2013 
[373] 
cross-
sectional 
study 
N=43 heart transplant 
recipients 
 
N = 18 recipients 
without obstructive 
sleep apnea; age: 
34.8±10.1, 77.8% males, 
time after 
transplantation 
32.6±20.9 
 
N = 25 recipients with 
obstructive sleep apnea; 
age: 49.0±12.1, 84% 
males, time after 
transplantation 
48.2±33.2 
Sleep disordered 
breathing: 
Polysomnography  
 
Daytime sleepiness: 
Epworth Sleepiness 
scale 
 
Prevalence of obstructive sleep apnea 58%  
 
Obstructive sleep apnea patients were significantly older 
(34.8±10.1 vs. 49.0±12.1) and showed a greater value of 
body mass index (23.4±2.7 vs. 26.8±4.1) and waist 
circumference (88.5±13.6 vs. 102.3±13.5); further, they 
had higher sleepiness scores 5.5±2.6 vs. 2.6±2.8. 
 
Obstructive sleep apnea patients had significantly more 
apnea hypopnea events/ hour (1.8±1.5 vs. 28.2±22.3) and 
more time with SaO2 under 90% (min) (4.3±12.6 vs. 
29.3±54.2). 
 
The apnea-hypopnea index showed significant correlation 
with age, BMI, waist circumference, neck circumference, 
time of oxygen saturation under 90% and systolic arterial 
pressure 
 
The multivariate analysis revealed obesity as a risk factor 
that, along with waist circumference, was an independent 
predictor for obstructive sleep apnea 
Only 50% agreed 
to participate in 
the study. 
Liver      
Rodrigue, 
J.R., et 
al., 2010 
[374] 
Observat
ional 
cross-
sectional 
study 
N= 95 liver transplant 
recipients 
 
N = 110 pre-transplant 
patients 
Sleep quality: 
Pittsburgh Sleep 
Quality Index 
 
Fatigue : Fatigue 
Symptom Inventory 
Prevalence of poor sleep quality 
 In pre-transplant patients = 73%  
 In liver transplanted recipients = 7/%  
Prevalence of fatigue 
 In pre-transplant patients = 86%  
 In liver transplanted recipients = 76%  
 
Correlates of pre-transplant fatigue severity were female 
gender (odds ratio [OR]=0.22, P=.04), higher body mass 
index (OR=1.07, P=.04), higher mood disturbance (OR = 
1.05, P= .02), and poor sleep quality (OR = 0.26, P= .02). 
 
Correlates of post-transplant fatigue severity were use of 
sleep medications in the past month (OR = 0.51, P= .02) 
and higher mood disturbance (OR = 1.06, P= .004). 
 
Higher body mass index (OR=1.06, P=.05), sleep 
medications (OR = 0.43, P= .03), and more mood 
disturbance (OR = 1.04, P= .007) were predictive of poor 
sleep quality in pre-transplant patients, whereas higher 
body mass index (OR = 1.07, P= .04) and more anxious 
mood (OR = 1.28, P= .03) were predictive of poor sleep 
quality in post-transplant patients. 
 
van 
Ginneken, 
B.T., et 
al., 2010 
[375] 
Prospect
ive study 
70 liver transplant 
recipients assessed pre- 
and 2 years post-
transplantation; age: 
52.5±12.3, 44% males; 
time since 
transplantation: 6.7 ± 
3.8 years 
Sleep quality: 
Pittsburgh Sleep 
Quality Index  
 
Fatigue: Severity of 
fatigue scale 
Health-related daily 
functioning: self-
assessment version of 
the Sickness Impact 
Profile- 68 (SIP-68). 
 
Health-related 
quality of life: 
Medical 
Outcomes Study Short 
Form-36 (SF-36) 
 
Anxiety and 
depression: Hospital 
Anxiety and 
Depression Scale 
Prevalence of poor SQ 
 post-transplantation = 51% (mean score 6.6 ± 
4.2) 
Prevalence of fatigue  
 pre-transplantation = 60% 
 post-transplantation = 62% 
Prevalence of depression 
 post-transplantation = 27% (mean score 
5.1±4.6) 
Prevalence of anxiety  
 post-transplantation = 26% (mean score 
4.8±4.2) 
 
Health-related quality of life [48.4±21.7 to 52.3±21.1 (p= 
ns)], fatigue [4.45±1.63 to 4.47±1.79 p=ns)] improved from 
pre- to post-transplantation. 
 
In the mixed model, fatigue was a significant predictor of 
daily functioning and all health-related quality of life 
domains (p < 0.01). Anxiety, depression, and sleep quality 
were significantly associated with severity of fatigue when 
controlled for age and sex (r = 0.30 to r = 0.60, p < 0.05. 
No pre-transplant 
prevalence for 
sleep quality 
Fredericks, 
E.M., et 
al., 2012 
[376] 
cross-
sectional 
study 
N = 47 pediatric liver 
transplant recipients; 
age: 10.9 ±4.6; time 
since transplantation: 
6.2±3.9, 45 % males 
Pediatric Quality of 
Life Generic Core 
Scales 
Prevalence of: 
 Sleep-disordered breathing = 23% 
 Restless legs syndrome = 30% 
 Snorers = 17% 
 Excessive daytime sleepiness= 40% 
 Symptoms of inattention and hyperactivity = 
45%  
 Low health related quality of life = 43% 
Pediatric 
recipients 
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A systematic PubMed search was performed for publications on sleep in solid organ 
transplant recipients (1966-2013), including only English, German, French and Italian 
articles. We included studies if they were retrospective, prospective or cross-sectional, 
and reported at least a prevalence for sleep and specified the measurement tool used. Out 
of 737 hits, we selected 27 studies for inclusion in the summary table. The following 
section provides first an overview of the sleep symptom or disturbance (poor sleep quality, 
insomnia, fatigue, sleepiness, sleep disordered breathing, sleep related movement 
disorder), followed by a summary categorized by organ (kidney, lung, heart, or liver). 
Poor sleep quality in renal transplant recipients has mainly been measured via self-
report (Pittsburgh sleep quality index) (7 Studies), with prevalence ranging from 30% - 62% 
[9, 289, 353-357]. In heart transplant recipients, van de Beek et al. (2008) reported a 
prevalence of 32% for sleep disturbances assessed by chart review [369]; and two studies 
assessed poor sleep quality in liver transplant recipients (via the Pittsburgh Sleep Quality 
Index, a valid and reliable questionnaire[107]) with prevalence ranging from 51% to 77% 
[374, 375]. All of these studies had relatively large sample sizes, ranging from 95 to 313 
transplant recipients. Poor sleep quality was associated with greater age [353], higher 
total medical comorbidity scores [355], more bodily pain [355], poorer general mental 
health [355], less physical function [355], less sexual function [355], and more severe 
anxiety [355]. 
Insomnia was measured in three cross-sectional studies using the Athens insomnia 
scale (a scale with diagnostic validity for insomnia [377]) in renal transplant recipients, 
revealing a prevalence of 15% [287, 358] in a sample of renal failure patients, 8% [287, 
358] – 16% [366] in renal transplant recipients and 8% in the general population [358]. A 
higher prevalence of insomnia has been found in female than male transplant recipients 
[358], and renal transplant recipients with insomnia are significantly older than non-
insomnia recipients (53±10 vs. 48±13y) [358]. 
Fatigue is not a sleep parameter [378]. Cella D. et al (1998) defined: “Fatigue is a 
subjective state of overwhelming, sustained exhaustion and decreased capacity for 
physical and mental work that is not relieved by rest”. However fatigue is often associated 
with insomnia [113]. Fatigue was measured in an observational cross-sectional study with 
the Profile of Mood States Fatigue subscale (a uni-dimensional scale that measures fatigue 
severity) [379]. Higher scores indicate more fatigue. Rodrigue et al. (2011) reported that 
the mean fatigue scale sum score was 8.99 ± 5.5, significantly higher for hemodialysis 
patients than for transplant recipients (6.81 ± 5.5; p= 0.02) [357]. Brilakis et al. (2000) in a 
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retrospective chart review study of heart transplant recipients reported a prevalence of 
53% for fatigue at a mean interval of 17.5 months after transplantation [370]. Regarding 
liver patients, two studies used the Fatigue Symptom Inventory (the psychometric 
proprieties of which have been determined useful and valid [380]) to measure fatigue. The 
first, by Rodrigue et al. (2010), showed a fatigue prevalence of 86% in liver-insufficient 
patients and 76% in liver transplant recipients [374]. The other, a prospective study by van 
Ginneken et al. (2010), reported fatigue prevalence of 60% pre-and 62% post-liver 
transplantation [375]. Correlates of pre-transplant fatigue severity were female gender 
(OR=0.22, p=.04), higher body mass index (OR=1.07, p=.04), elevated mood disturbance 
levels (OR = 1.05, p= .02), and poor sleep quality (OR = 0.26, p= .02) [374]. Correlates of 
post-transplant fatigue severity were use of sleep medications in the past month (OR = 
0.51, p= .02) and elevated mood disturbance (OR = 1.06, p= .004) [374]. In the mixed 
model, fatigue was a significant predictor of daily functioning and all health-related 
quality of life domains (p < 0.01). Anxiety, depression, and sleep quality were significantly 
associated with severity of fatigue when controlled for age and sex (r = 0.30 to r = 0.60, p 
< 0.05 [375]. As no fatigue prevalence has been reported in renal transplant recipients, no 
comparison is possible with this group; and no measurement tool was specified for the 
heart transplant study, preventing comparison with it as well. However, fatigue appears to 
be a highly relevant symptom in liver transplant recipients. 
Sleepiness, measured with the Epworth Sleepiness scale (a validated questionnaire 
that measures a subject’s expectation of dozing in eight hypothetical situations [105, 106]) 
showed in the study of Ayik et al. (2013) scores of 5.5±2.6 in heart transplant recipients 
with obstructive sleep apnea, and of 2.6±2.8 in those without it [373]. In the only other 
cross-sectional sleepiness study of transplantation recipients, Fredericks et al. (2012) used 
the Pediatric Quality of Life Generic Core Scales to gather data from pediatric liver 
recipients, reporting a sleepiness prevalence of 40%. The related topic of daytime 
functioning has been measured in just one study of renal transplant recipients. Using a 
developed item showing low content validity, the authors reported a 34% prevalence of 
poor daytime functioning (Burkhalter et al., 2012)[9]. 
Sleep disordered breathing is assessed with polysomnographic measurements of 
respiratory airflow, respiratory effort and peripheral pulse oximetry. Five studies have 
assessed sleep disordered breathing in renal transplant recipients. Unfortunately, as they 
used different inclusion and exclusion criteria, the only comparable prevalence is the 25% 
of obstructive sleep apnea reported by Molnar et al. (2010) and Fornadi et al. (2012) [362, 
366]. Molnar et al. (2010) also reported a slightly higher prevalence (26%) in hemodialysis 
patients [362]. And Beecroft et al. (2007) measured the prevalence of sleep apneas 
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(including obstructive and central sleep apnea) at 61% pre-renal transplantation and 44% 
post- transplantation [364]. Including all sleep breathing disorders, Rodrigues et al. (2010) 
reported prevalence of 26.5% in patients with end stage renal disease and 21% in renal 
transplant recipients [361]. Further, a prospective study by Jurado-Gamez (2008) reported 
no prevalence, but presented objective parameters from pre-to post-transplantation: 
significant reductions in the number and duration of apnea and hypopnea episodes, in the 
number of dips in SaO2 ≥3% per hour of sleep, and in the percentage of time spent in 
apnea/hypopnea [363]. Only two studies including lung transplant recipients both 
measured sleep parameters and assessed sleep disordered breathing. Both used small 
sample sizes–one 25 and the other 24 participants. In the first, a prospective study, Malouf 
et al. (2008) reported prevalence of 44% pre-transplantation and 36% post-transplantation 
[367]. In the other, a cross-sectional study conducted one year post-transplantation, 
Naraine, Bradley and Singer reported nearly double that prevalence (63%, i.e., obstructive 
sleep apnea was observed in 38%, while 25% had central sleep apnea) [368]. The same 
study showed that obstructive sleep apnea patients were significantly more likely to be 
emphysema patients (44% vs. 0%), to snore more (78% vs. 33%), to have higher systolic 
blood pressure (137.3±9.9 vs. 123.6±12.9), and to have higher body mass indexes (28.8±4.2 
vs. 24.0±4.0) compared to non-sleep disordered breathing transplant recipients [368]. 
Central sleep apnea patients were significantly more often treated with Cyclosporine (100% 
vs. 22%) and had a higher mean body mass index (27.2±2.7 vs. 24.0±4.0) compared to non-
sleep disordered breathing transplant recipients [368]. Malouf et al. (2008) reported that 
11 of their 25 patients had sleep disordered breathing prior to the lung transplantation. Of 
these, 5 (4 of whom had respiratory disturbance indexes >20 events/hour) continued to 
have sleep disordered breathing post-transplantation. Of the other 14, all of whom had 
previously received normal polysomnography reports, four developed new sleep disordered 
breathing post-transplantation [367]. Interestingly, the mean body mass index increased 
post-lung transplantation for the entire group to 24.3±4.7 [367].In Brilakis et al.'s (2000) 
retrospective study of 147 heart transplant recipients, the 17 with sleep apnea showed 
prevalence of 100% for snoring, 65% for excessive daytime somnolence, 53% for witnessed 
apneas and 53% for morning fatigue. Following transplantation, sixteen of these 17 
experienced a mean weight gain of 10.4 kg [370]. In the total sample of 147, the 
retrospectively assessed apnea prevalence was 11.6% (13 with obstructive sleep apnea and 
4 with mixed sleep apnea) [370]. Another prospective study including 22 heart transplant 
recipients assessed pre-and post-transplantation reported a significant improvement in the 
central sleep apnea patients regarding apnea hypopnea index (events/ hour: 28±15 vs. 7±6) 
and mean Spo2 (percentage: 94.7±1.8 vs. 96.3±1.6) Mansfield et al.(2003) [371]. The post-
transplant prevalence of obstructive sleep apnea in heart transplant recipients ranges from 
Chapter 1 
 
 
61 
36% [372] to 58% [371, 373], while a 13% prevalence is reported for central sleep apnea 
[371]. Pre-transplantation, the prevalence of obstructive sleep apnea is 16% [371] and of 
central sleep apnea, 43% [371]. In one cross-sectional study, body mass index was 
significantly higher in transplanted patients with sleep-related breathing disorders than in 
those with none (Javaheri et al., 2004) [372]. A more recent study by Ayik et al. (2013) 
reported that obstructive sleep apnea patients were significantly older, with a greater 
mean body mass index, waist circumference and higher sleepiness scores [373]. In lung 
[367] and in heart transplant recipients [370, 372], the weight gain reported could be 
associated with the increase of sleep disordered breathing prevalence [367, 370, 372, 373]. 
Abundant evidence links increased body mass index with increased obstructive sleep apnea 
[381]. 
Sleep related movement disorders were assessed with polysomnography (muscle 
activity or skeletal muscle activation) in 3 studies in renal and in 1 study in heart 
transplant recipients. Restless leg syndrome was assessed in 4 studies of renal transplant 
recipients via the Restless Legs Syndrome Questionnaire (a validated questionnaire that is 
updated yearly [382]). Jurado-Gamez et al. (2008) reported in a prospective study (N= 9) 
that the pre-transplantation prevalence of periodic limb movement per hour was 36±34 
and post-transplantation 24±20.8 (p= 0.041) [363]. The prevalence of periodic limb 
movements in renal transplant recipients ranges from 16% (Beecroft et al., 2008) [365] to 
27% (Fornadi et al., 2012) [366].In a study including 18 patients at pre-transplantation, 
reported a prevalence for periodic limb movements of 39% (Beecroft et al., 2008) [365]. 
Polysomnographic data of these 18 patients showed a prevalence of 47% pre-
transplantation and 5% post-transplantation for restless leg syndrome [365]. The research 
group of the Institute of Behavioral Sciences at Semmelweis University in Budapest 
published four studies reporting the prevalence of restless legs syndrome (assessed with 
the Restless legs syndrome questionnaire) in renal transplant recipients. The pre-
transplantation prevalence was 11% [287] and 4% to 5% post-transplantation [287, 358-
360], however these prevalence appear to be based on the same sample. The mortality 
rate at 4 years in renal transplant recipients with restless legs syndrome is reported to be 
26%; without restless leg syndrome, it is 11% (sig. difference p< 0.01) [360]. Periodic limb 
movements are experienced by 33% of heart transplant recipients, 45% of whom have 
restless legs syndrome (Javaheri et al. 2004) [372]. 
The literature includes only one intervention study for sleep in solid organ 
transplant recipients. Gross et al. (2010) assessed the efficacy of mindfulness-based stress 
reduction on anxiety, depression and sleep quality. This intervention (eight weekly 2.5-
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hour classes) reduced anxiety and sleep symptoms (P < .02), with medium treatment 
effects (.51 and .56). Benefits were sustained over one year [383]. 
The following section supplies a more general discussion of sleep symptoms and 
sleep disturbances, classified by transplanted organ. While our literature review revealed 
different priorities across the solid organ transplant groups, it is clear that poor sleep 
quality is prevalent (30-62%) after renal transplantation. Some of the poor sleepers have 
insomnia (8%), some sleep disordered breathing (18%), some sleep movement disorders 
(5%) and some a combination or a less prevalent sleep disturbance. Concerning the 
prevalence of obstructive apnea after kidney transplantation, Sim et al. (2010) report an 
association with the side effects of steroid regimens, which include weight gain, obesity, 
abnormal fat distribution and development of metabolic syndrome [384]. 
As described in section 1.3.2, sleep is associated with the immune system. 
However, Fornadi et al. (2012) reported a lack of significant association between sleep and 
inflammatory markers in renal transplant recipients [366]. They found that the apnea-
hypopnea index was associated with white blood cell count but had only a weak correlation 
with the other inflammatory markers; their Periodic Limb Movement index data showed 
weak correlations with all markers of inflammation; and, while the serum IL-6 level was 
significantly higher in patients with insomnia, the levels of other inflammatory markers 
were similar for both insomniacs and non-insomniacs [366]. 
Chronic lung allograft dysfunction, mostly manifested as bronchiolitis obliterans 
syndrome, is the single most severe limitation to lung recipients' long-term survival [385]. 
The main symptoms are airway obstruction, shortness of breath, wheezing and dry cough. 
These symptoms can start gradually and trigger sleep disordered breathing. In lung 
transplant recipients, the post-transplantation prevalence of sleep disordered breathing 
ranged from 15% to 63%, the prevalence of obstructive sleep apnea was 38% and that of 
central sleep apnea was 25%. Lung transplantation improves sleep disordered breathing 
and oxygenation. However, Malouf et al. (2008) reported that new-onset sleep disordered 
breathing occurred later in the post-transplant phase [367]. In addition, lung transplant 
recipients with sleep disordered breathing (prevalence 63%) had a higher systolic blood 
pressure, higher body mass index and higher arousal index compared with those who had 
no sleep disordered breathing condition [368]. Further, Naraine et al. (2009) reported that 
cyclosporine use was associated with central sleep apnea, and lung transplant recipients 
with obstructive sleep apnea had a greater change (pre- to post- transplant) in body mass 
index compared with non-sleep disordered breathing subjects [368].  
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Sleep disturbances are also very prevalent (32%) after heart transplantation. The 
most common diagnoses are obstructive sleep apnea (36-58%), followed by restless legs 
syndrome (45%) and periodic limb movement (33%). Obstructive sleep apnea adversely 
affects cardiac function in heart transplant recipients [386]. Weight gain since 
transplantation was significantly greater in recipients with obstructive sleep apnea than in 
those without [372]. Van de Beek et al. (2008) in a retrospective cohort study of 313 heart 
transplant recipients linked sleeping disorders to baseline body mass index: the mean body 
mass index was 26.8 for patients with sleeping disorders vs 24.5 for the patients with none 
[369]. Ayik et al. (2013) found that elevated body mass index is a risk factor and waist 
circumference an independent predictor for obstructive sleep apnea [373]. Mansfield et al. 
(2003) reported that central sleep apnea persist despite normalization of heart function 
and sympathetic nerve activity [371] and Javaheri et al (2004) found additionally that 
quality of life was significantly worse in heart transplant recipients with obstructive sleep 
apnoea [372]. 
To sum up, poor sleep quality and fatigue are highly prevalent after liver 
transplantation, when poor sleep quality is associated with higher body mass index and 
more anxious mood, and fatigue is a significant predictor of daily functioning and health 
related quality of life [375]. Sleep quality, anxiety, depression [375], use of sleep 
medications in the past month, and higher mood disturbance [374] are associated with 
fatigue severity [375]. In pre-transplant recipients, higher body mass index, sleep 
medication use and increased mood disturbance are all associated with poor sleep quality 
[374]. However, pre-transplantation fatigue is also associated with female gender, a higher 
body mass index, higher mood disturbance and poor sleep quality [374].  
1.8.7. Sleep treatment in solid organ transplant recipients 
1.8.7.1. Pharmacological sleep treatment  
While sleep drugs provide safe, effective treatment for many acute sleep disorders, 
transplant recipients require special consideration. Particularly sleep drugs acting on the 
cytochrome P450 and cytochrome 3A4 enzymes (see section 1.7.1.) have the potential to 
inhibit, induce, or compete for available sites in both systems, potentially altering the 
efficacy of immunosuppressives [260]. Sleep drugs might have an additive effect when 
adverse effect profiles are shared with other medications, but the effects vary widely 
between users. Therefore, each new drug has to be evaluated for the individual recipient 
as to whether its benefit outweighs its potential damage to the kidney or liver. A gap 
remains in the literature regarding recommendations for the use of sleep aids in solid 
organ transplant recipients. Regarding non-prescription cough suppressants, Gabardi et al. 
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(2011) have performed a review and provided recommendations for solid organ transplant 
recipients [387]. The main issues addressed involve interaction with calcineurin inhibitors 
(e.g., diphenhydramine). 
Melatonin supplementation might be indicated for solid organ transplant recipients 
when treated with bisoprolol, which suppresses melatonin, and no option is available to 
change to nebivolol or carvedilol (which do not)[388]. (See section 1.6.4 for further details 
of melatonin and interactions).  
1.8.7.2. Non-pharmacological sleep treatment  
For the reasons outlined above, physicians are understandably reluctant to 
prescribe sleep drugs to solid organ transplant recipients. Possible alternatives include the 
implementation of sleep hygiene rules (see section 1.6.2 [152] and chronotherapeutics 
((bright light or melatonin [389]), see 1.6.3.1 for details). At present, though, 
understanding is limited regarding the management of sleep disorders in transplant 
recipients. To our knowledge, only one pilot study has assessed the efficacy of 
mindfulness-based stress reduction in solid organ transplant recipients. The intervention 
consisted of a training program of eight weekly 2.5-hour classes; after its completion, the 
researchers reported reduction of distressing symptoms including anxiety, depression and 
poor sleep, along with improved quality of life [383]. To our knowledge no other 
intervention studies to improve sleep disturbances in this population have been published. 
Therefore, bright light intervention should be tested as an alternative to sleep drugs for 
sleep-wake disturbances in the renal transplant population. 
1.9. Identified gaps in the state of science of sleep-wake 
disorders in solid organ transplant recipients  
In summary, the following gaps in the literature on “sleep-wake disturbances in solid organ 
transplant recipients” guided the proposal of this research project. Given the knowledge 
gaps remaining to be filled, the following rationales guided this research project regarding 
study design and sample selection. 
Firstly, as described above (in sections 1.5.1 and 1.5.2 of the literature review), 
valid instruments are available to measure some aspects of sleep; however, these are 
extensive questionnaires. The time investment they demand entails a high risk of low 
response rates and missing data, making them impractical for the screening and long-term 
follow-up of sleep-wake disorders in clinical practice.  
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Although several instruments have been developed to measure sleep and related factors, a 
need remains for a short, easy screening tool for sleep quality and daytime sleepiness. 
Such a tool is already available for sleep quality [9]. For daytime sleepiness, however, 
content validity and validity in relation to other variables have yet to be established. 
Further, an assessment instrument validated for use in different organ transplant recipient 
groups will enable inter-group comparison. 
Secondly, sleep disorders and sleep deprivation are causing an increasing public 
health burden (see sections 1.3.1 and 1.3.2). Sleep deprivation impairs the entire 
spectrum of mental abilities, ranging from simple psychomotor performance to executive 
mental functions [45], neurocognitive functions [46] and decision making [47]. The most 
obvious consequence of sleep deprivation is daytime sleepiness [36]. According to Naraine 
et al. (2009) [368], studies are needed to determine whether sleep is a risk factor and, if 
so, how it–or the lack of it–influences clinical outcomes [368]. As described in section 
1.7.4, poor sleep quality is linked to immunosuppressive non-adherence, which directly 
impacts graft rejection rates [390].  
As immunosuppressive non-adherence is a preventable factor of graft rejection, then, a 
daytime sleepiness component would be a valuable addition to the current battery of 
therapeutic tools. More precisely, it is necessary to establish the odds for taking and timing 
non-adherence in transplant recipients reporting daytime sleepiness. Based on this 
information, practice guidelines and an improved sleep assessment for transplant 
recipients can then be established in clinical practice to reduce the high prevalence of 
non-adherence. Also, Riegel et al. (2011) found that daytime sleepiness has proven 
associations with reduced medication adherence in patients with heart failure [51]. Renal 
transplant recipients have similarly high rates both of medication non-adherence and of 
daytime sleepiness, although no association has been established between these two 
variables. 
Thirdly, in spite of a small number of sleep studies performed in solid organ 
transplant recipients, a strong need remains for studies that include sleep assessment 
interviews that go beyond a screening questionnaire. In particular, there is a need for 
studies focusing on the diagnosis of insomnia and circadian rhythm sleep disorders that 
cannot be assessed via one-night polysomnography (see Subchapter 1.5.1). According to 
Javaheri et al. (2003) [372] and to Eryilmaz et al (2005)[354], more sleep study variables 
should be chosen with a focus on improving health-related quality of life [354, 372]. Sleep 
is a vital parameter, impacting daily life in countless ways. In collaboration with patients, 
studies are therefore needed to explore ways of improving and reacting to related 
diagnoses.  
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This means that sleep assessment interview studies following the International 
Classification of Sleep Disorders will require a clear knowledge of the symptoms of poor 
sleep quality and daytime sleepiness identified in post-transplantation follow-up care. 
Renal transplant recipients have a high prevalence of sleep-wake disturbances [9, 391, 
392] although it is not known to which sleep disturbance poor sleep quality and daytime 
sleepiness symptoms belong. Via a structured interview, it will be necessary to assess the 
prevalence of sleep disturbances in renal transplant recipients screened positive for poor 
sleep quality and / or daytime sleepiness. 
Fourthly, according to Naraine et al. (2009) [368] and Eryilmaz et al (2005)[354], 
longitudinal studies including the assessment of the presence of sleep disturbance pre- and 
(up to several years) post-transplantation are needed to determine the effect of sleep 
diagnoses / interventions on clinical outcomes [368]. This will require researchers to 
ascertain whether and how sleep-related complaints persist after transplantation and how 
other relevant variables interact [354].  
In addition, longitudinal studies such as the ongoing Swiss Transplant Cohort Study have to 
be improved by including not only a sleep quality item, but also a daytime variable such as 
daytime sleepiness. The sleep quality item has already been validated [9] and satisfactorily 
integrated into the Swiss Transplant Cohort Study's psychosocial questionnaire, which also 
assesses health related quality of life. For the first time, a single assessment tool will 
enable researchers to determine the impact of poor sleep quality on health related quality 
of life, and to examine prevalence data on the long-term pre- to post-transplantation 
development of sleep quality variables across all four solid organ transplant groups.  
Fifthly, according to Rodrigue et al (2011), improving sleep disturbance 
interventions and testing their effectiveness in transplant recipients will require more 
research and development on both pharmacological and non-pharmacological interventions  
[357]. The testing component will require randomized controlled trials (Novak et al 2006) 
[358]. And Van de Beek et al. (2008) recommend longitudinal sleep studies with objective 
measurement tools [369]. As described in section 1.6.2 above, considerable knowledge has 
been established on chronotherapeutics and non-pharmacological interventions; however, 
none have been tested on solid organ transplant recipients.  
In renal transplant recipients, whose daily medication regimens commonly balance twelve 
separate drugs, the high prevalence of sleep-wake disturbances makes them particularly 
vulnerable to accidental non-adherence. However, safe interventions, where no 
interaction occurs (especially with the immunosuppressive medications) are difficult to 
determine. As described in section 1.6.2, this makes physicians justifiably reluctant to 
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prescribe sleep drugs. Still, the comparative benefits of chronotherapeutics have never 
been assessed in transplant recipients. In particular, bright light therapy has yielded 
promising results against insomnia and circadian rhythm sleep disorders. A randomized 
controlled pilot trial is needed to establish the benefits of such therapy in renal transplant 
recipients diagnosed with post-transplantation sleep-wake disturbances, and to estimate 
the effect size for a full-powered study. 
Thus far, the proposed dissertation and the included research program will 
contribute in multiple ways to the international scientific literature, as well as expanding 
the existing knowledge of sleep-wake disturbances in solid organ transplant recipients in 
Switzerland. 
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CHAPTER 2 
AIMS OF THIS RESEARCH PROGRAM 
Given the identified gaps in the literature regarding a short validated item to measure 
daytime sleepiness and a safe intervention to treat sleep-wake disturbances, this research 
projects included the following aims: 
1) a) to evaluate the validity of a single item DS measure integrated in the Swiss 
Transplant Cohort Study (Chapter 3). 
b) to describe the prevalence of immunosuppressive non-adherence in renal 
transplant patients (Chapter 4). 
c) to assess the association between daytime sleepiness, depressive 
symptomatology and non-adherence to the immunosuppressive regimen (Chapter 4). 
2)  to categorize patients with sleep disorders following the International Classification 
of Sleep Diagnoses (ICSD-2 classification) (Chapter 5). 
3)  a) to compare by type of organ transplant the prevalence and evolution of sleep 
quality from pre to post transplantation in kidney, liver, lung and heart recipients 
included in the Swiss Transplant Cohort study (a prospective nation-wide cohort 
study) from pre- to 2 years post-transplantation. (Chapter 6). 
b) to assess the impact of sleep quality on perceived health status from pre- to 2 
years post-transplantation (Chapter 6). 
4)  to assess the feasibility and effect size of bright light therapy in home dwelling 
renal transplant patients with sleep-wake disturbances (Chapter 7) on bedtime. 
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3.1. Abstract 
Context: Daytime Sleepiness (DS) in renal transplant (RTx) recipients has emerged as a 
potential predictor of impaired adherence to the immunosuppressive medication regimen. 
Thus there is a need to assess DS in clinical practice and transplant registries. 
Objective: To evaluate the validity of a single item DS measure integrated in the Swiss 
Transplant Cohort Study (STCS), using the American Educational Research Association 
(AERA) framework.  
Methods: Using a cross-sectional design, we enrolled a convenience sample of 926 home-
dwelling RTx patients [median age 59.69 years (Q25-Q75: 50.27-59.69), 63% men; median 
time since Tx 9.42 years (Q25-Q75: 4.93-15.85) DS was assessed using a single item from 
the STCS and the 8 items of the validated Epworth Sleepiness Scale (ESS). ROC curve 
analysis was used to determine the cut-off for the STCS-DS item against the ESS score.  
Results: Based on the ROC curve analysis, a score > 4 on the STCS-DS is recommended to 
detect DS. Content validity was high as all expert reviews were unanimous. Concurrent 
validity was moderate (Spearman’s rho, rs: 0.531 p < .001) and convergent validity with 
depression and poor sleep quality although low, was significant (rs: 0.235 p < .001 and rs: 
0.318 p = .002, respectively). For the group difference validity: RTx recipients with 
moderate, severe and extremely severe depressive symptomatology scores showed 3.4, 4.3 
and 5.9 higher odds of having DS, respectively, as compared with recipients without 
depressive symptoms. 
Conclusion: The accumulated evidence provided evidence for the validity of this simple 
screening scale for DS: the STCS-DS. 
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3.2. Introduction 
The Swiss Transplant Cohort Study is a nationwide prospective multicenter interdisciplinary 
cohort study including all patients receiving organ transplants in Switzerland in one of the 
6 transplant centers (Lausanne, Geneva, Basel, Zürich, Bern, St. Gallen) [1, 2]. The STCS 
began patient enrollment and data collection on May 2nd 2008. In this study only one item 
assessing sleep quality was integrated. In view of the evidence described below we 
developed a daytime sleepiness item to be included, after validation, into the STCS and 
used for this same format as the 1-item sleep quality measure already included in this 
nation-wide cohort study  
It is commonly recognized that lack of nocturnal sleep increases the tendency to 
fall asleep during the day. Daytime sleepiness (DS) is the subjective report of an increased 
desire to fall asleep and lack of energy during the day even after an adequate night’s 
sleep.[3] DS is not a disorder in and of itself, yet it is an important symptom of many other 
sleep disorders. DS is associated with poor performance [4], cognitive slowing, attention 
failures, errors, [5] and accidents.[6] It is also a known a predictor of increased morbidity 
and mortality in patients with cardiovascular disease [7, 8] and diabetes.[9] 
So far, there is limited evidence for the presence and impact of DS in the renal 
transplant (RTx) literature. In a previous study, we found that 34.1% of RTx recipients 
suffered from poor daytime functioning, a measure similar to DS, although DS was not 
directly assessed as functioning was more related to performance.[10] The prevalence of 
DS in the general population ranges from 2.5% [11] to 25.7% [12] and in hemodialysis 
patients from 15% [13] to 27.3%. [14] 
Because of its impact on clinical outcome, DS is emerging as a relevant parameter 
to assess in research and clinical practice. We therefore decided to integrate the 
assessment of DS in the Swiss Transplant Cohort Study (STCS) [2]. Many instruments exist 
to measure DS objectively such as the Multiple Sleep Latency Test [15], Maintenance of 
Wakefulness Test [16], and Psychomotor Vigilance Task,[17, 18] or subjectively, using self-
report, such as the Epworth Sleepiness Scale (ESS).[19, 20] The commonality among these 
instruments is that they are time consuming and labor-intensive, and some are in a 
laboratory situation not reflecting daily life. Whereas the ESS is easy to administer, 
clinicians do not commonly use it outside the field of sleep medicine. This may be due to 
both a lack of awareness of the importance of DS problems or a reluctance to add 8 
questions to an already lengthy medical assessment. Taking this into account, a simpler 
more direct question about DS might better serve as a screening tool. A single item 
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questionnaire has been previously published asking “Please measure your sleepiness on a 
typical day” (0 = none, 10 is highest; cutoff ≥7), however, this item is only validated in 
patients having a diagnosis of a sleep disorder and no specific recall period is used, making 
it unclear to patients which time frame to take into consideration when completing this 
item.[21] 
DS, sleep quality and depression are interrelated and have been explored and 
explained in different models and approaches.[22-24] Poor sleep quality and DS are 
included in the criteria for the diagnosis of depression. The Diagnostic and Statistical 
Manual of Mental Disorders [25] define criteria for a Major Depressive Disorder: “Difficulty 
falling or staying asleep (insomnia), or sleeping more than usual (hypersomnia)” (criterion 
1d) and feeling tired or having little energy (1e). For Dysthymic Disorder criterion 2 is set 
as “Sleeping too much or having difficulty sleeping” and criteria 3: “Low energy or 
fatigue”. Depression is common among RTx recipients; reported cumulative incidences 
were 5.05%, 7.29%, and 9.10% at 1, 2, and 3 years post-Tx.[26] The prevalence of poor 
sleep quality in RTx recipients ranges from 30% to 62%.[27-29] 
Patients suspected to suffer from obstructive sleep apnea and a high score on the 
ESS also had a significantly higher score on the Center for Epidemiological Studies 
Depression Scale[30]. In a cross-sectional study with 3045 community-dwelling women aged 
70 and older depression was associated with poorer sleep quality and DS.[31] Another 
cross- sectional study including 67 patients diagnosed with a depressive episode showed 
that DS measured with the ESS correlated highly with the Hamilton Depression Rating Scale 
(r = 0.69, p <0.001).[32] 
Given that transplant registries do not allow the use of lengthy measures because of 
subject burden, we developed a single item to measure DS prospectively as part of the 
STCS.[2] It needs to be determined, however, which cut-off with respect to other existing 
measures is appropriate to identify DS by a single item (i.e. cross-validation). Moreover, 
the validity of this single item STCS-DS instrument needs to be demonstrated before 
analyses on Tx outcomes can be performed.  
Theoretical Background: Validity 
Assessing the validity of an instrument implies gathering as much evidence as possible to 
support validity related to test content, response processes, internal structure, relation to 
other variables, and consequences of testing, as outlined by the American Educational 
Research Association (AERA) framework.[33, 34] For the purpose of our study, we 
focused on evidence related to test content and relationships to other variables. In order 
to guide our validation process we developed four hypotheses based on empirical evidence 
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that outlines the relationships between DS, sleep quality, and depression to be tested as 
part of the validation process (Table 1) [33].  
In absence of an established validated cut-off of the STCS-DS item, the first aim of 
this study was to identify the optimal cut-off point for classifying patients as having DS 
using the ESS as reference. However the main aim of this study was to assess the validity 
of the STCS-DS item using the American Education Research Association framework to 
assess evidence based on content and evidence based on relationship to other variables.  
3.3. Methods 
Design, Setting and Sample 
This study used a cross-sectional multicenter correlational design. A convenience sample of 
926 home dwelling RTx patients transplanted at 3 Swiss renal transplant centers 
participated in the study. Patients were included when they were at least 6 months post-
transplant, had the ability to understand and read German, were 18 years of age or older, 
and provided written informed consent. Individuals were excluded if they were unable to 
complete the study questionnaire by themselves for any reason. 
Variables and Measurements  
Age (in years), gender, and time since transplantation (in years) were retrieved from the 
hospital charts. Daytime sleepiness was assessed by 2 measures, the Swiss Transplant 
Cohort Study Daytime Sleepiness (STCS-DS) item [2] and the Epworth Sleepiness Scale (ESS) 
[19]. The STCS-DS item asks subjects to rate their overall DS in the past four weeks on a 
scale of 0 (no sleepiness) to 10 (extreme sleepiness). This item is similar to a widely used 
but not validated item in sleep diaries carried out with actigraphy measurements.[21] The 
layout was made congruent with the STCS sleep quality item [10] derived from the Kidney 
Disease Quality of Life Short Form.[35] Receiver operating characteristic (ROC) curve 
analysis [36] has been utilized to establish an appropriate cutoff for the STCS-DS item.  
The ESS is a validated questionnaire containing eight items that measure a subject’s 
expectation of dozing in eight hypothetical situations. Dozing is defined as falling into a 
light sleep[37]. Dozing probability ratings range from 0 (no probability) to 3 (high 
probability). Scores on the eight items are summed, yielding a total dozing score between 
0 and 24. An ESS sum score ≥6 indicates DS.[19] A score of ≥10 indicates that the subject is 
very sleepy and should seek medical advice.[19] Total ESS scores show high test-retest 
reliability (rho = 0.82, , p < 0.001)[38] and a high level of internal consistency (Cronbach’s 
alpha = 0.74-0.88 in 4 different groups of chronically ill).[39] A single factor emerged when 
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performing factor analyses on ESS item scores of 150 patients and 104 students.[38] The 
ESS has been validated for application in German-speaking populations.[20]  
Sleep quality 
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a self-rated 
questionnaire consisting of 19 items, assessing a wide variety of factors related to sleep 
quality over a 1 month time interval, including estimates of sleep duration and latency, 
and of the frequency and severity of specific sleep-related problems. These 19 items are 
grouped into seven component scores, each weighted equally on a 0-3 scale. The seven 
component scores are then summed to yield a global PSQI score, which has a range of 0-21; 
higher scores indicate worse sleep quality. 
A cut-off of > 5 points is used to classify patients as having poor sleep quality.[40] A 
PSQI global score > 5 resulted in a sensitivity of 98.7 and specificity of 84.4 as a marker for 
sleep disturbances in insomnia patients versus healthy controls.[41] Backhaus et al. 
translated the PSQI into German using the back-translation method.[41] Item analysis 
confirmed internal consistency of the German version of the PSQI scale (Cronbach’s alpha 
of 0.85).[41] The test–retest reliability for the short interval (2 days) was high for the 
global as well as for subscale scores (0.76 to 0.92). For the longer interval (45.6 ± 18 days), 
the test–retest reliability was low for the subscores “sleep quality” (r = 0.23) and “sleep 
disturbance” (r = 0.84) whereas it remained moderate to high for the global score (r = 
0.86) and four of seven subscores, ranging from 0.59 to 0.83 [41]. Sleep diaries show a high 
correlation to the PSQI[41] indicating good validity based on relation to other relevant 
variables.[41] 
Depression 
Depression was measured with the Depression, Anxiety, and Stress Scale (DASS 21): a 21-
item self-report instrument, of which 7 items measure depressive symptoms (DASS-D) [42] 
on a ordinal 4 point Likert severity/frequency scale to rate the extent to which they have 
experienced each state over the past week: 0 = did not apply to me; 3 = applied to me 
very much over the last week. Scores are summed and multiplied by two resulting in a 
range of 0 to 42 for each subscale. The following cut-offs are used to evaluate severity of 
depressive symptomatology: 0-9 no depressive symptomatology, 10-13 mild, 14-20 
moderate, 21-27 severe and 28+ extremely severe symptomatology.[43] Cronbach’s alpha 
for the DASS-D scale is high (alpha= .88 (95% CI = .87-.89) and shows good concurrent 
validity with the Brief Symptom Inventory (r=0.70)[44], the Beck Depression inventory (r = 
0.74) [42], the Personal Disturbance scale depression scale (r=.78) and the Hospital Anxiety 
and Depression Scale (r=.66) [45].  
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Evidence based on content 
Content validity 
Evidence supporting test content includes logical or empirical analyses of how adequately 
that content represents the domain of interest and can include the judgment of content 
experts.[33] Validity-related data analysis procedures were guided by research questions 
and hypotheses formulated to test item validity (see Table 1).  
Table 1: Hypotheses and research questions guiding the validation process 
Evidence based on 
content 
Q 1 Does STCS-DS item reflect the concept of daytime 
sleepiness based on expert review? 
Evidence based on 
relation to other 
variables 
H 1 STCS-DS (low score means no DS) is positively correlated 
with ESS sum score (low score means no DS) [concurrent 
validity]. 
 H 2 There is a positive correlation between STCS-DS and the 
DASS depression score [convergent validity] 
 H 3 There is a positive correlation between STCS-DS and sleep 
quality measured by the PSQI score [convergent validity]. 
 H 4 Higher levels of depressive symptomatology are associated 
with higher degree of daytime sleepiness. [group 
difference validity]. 
Legend: STCS-DS: Swiss Transplant Cohort Study – Daytime Sleepiness; DS= Daytime 
Sleepiness; DASS =Depression, Anxiety and Stress Scale; PSQI = Pittsburgh Sleep Quality 
Index 
 
To test if the STCS-DS item indeed measures daytime sleepiness, we asked all members of 
the STCS Psychosocial Interest Group (transplant physicians, psychologists, nurses, 
physicians and epidemiologists) to evaluate whether the STCS-DS item captures DS, 
expressed as the percentage of agreement. First the item was evaluated and then voted at 
one of the in-person meetings of the STCS Psychosocial Interest Group.  
Evidence based on relationships with other variables 
Evidence of relationships to other variables is commonly evaluated by assessing 
associations among variables. If the observed relationships match the hypothesized 
relationships, then the evidence supports the validity of the interpretation.[33] 
Concurrent validity 
Concurrent validity (or criterion related validity) requires that both variables measuring 
the same concept are captured at one point in time. As the strength of the correlation 
increases, there is an increased probability that the variables measure the same 
concept.[46] DS is the subjective report of an increased desire to fall asleep and lack of 
energy during the day even after an adequate night’s sleep.[3] Excessive DS is sleepiness in 
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a situation when an individual would be expected to be awake and alert.[47] Following 
these two definitions the ESS asks about 8 very concrete situations when an individual 
would be expected to be awake and alert. In contrast the STCS-DS asks for sleepiness over 
the past 4 weeks unrelated to a specific situation. The ESS is more precise in asking for 
these situations whereas the STCS-DS asks for a metacognitive process transforming the 
concept of DS into a daily life situation. 
Therefore we expected a moderate to high correlation between the STCS-DS item 
and the ESS total score, given that STCS-DS asks for sleepiness in general in the past 4 
weeks, and the ESS asks the same, but in specific circumstances[46]. 
Convergent validity 
Convergent validity is when two measures of a construct that theoretically should be 
related to each other are, in fact, observed to be related to each other.[48] In order to 
provide evidence for convergent validity, we expect to observe [48] 1) a moderate to high 
correlation between the STSC-DS item and sleep quality, as measured by the PSQI; and 2) a 
low to moderate positive correlation between the STSC-DS item and depressive symptoms, 
measured by the DASS-D.  
Known group difference validity  
Known group difference validity is when data are collected from two groups that have 
expected differences on the measure of interest. If the measure is able to discriminate 
between the groups through statistically significant findings, this provides evidence for the 
validity of the measure.[49] The evidence states that depression is associated with poorer 
sleep quality and DS. [31] We hypothesize therefore that stratifying our sample on the 
DASS-D score will split the sample in a similar way for DS. If DASS-D scoring (normal, mild, 
moderate, severe, extremely severe) is able to discriminate between the groups through 
statistically significant findings, this provides evidence for the validity of the DS 
measure.[49] 
Data Collection 
Addresses of all patients who fulfilled the eligibility criteria were extracted from the 
centers’ transplantation databases by the responsible physician and the head outpatient 
nurse. Each potential participant received a package containing an information letter, the 
informed consent documents, pre-stamped envelopes, and the questionnaires. Participants 
who consented to participate completed the study questionnaires and returned them to 
the researcher by mail. Patients not responding were contacted once by telephone and 
invited to participate again. If they agreed a new package was sent. The study was 
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approved by the ethics committee of Basel, Bern, and Zürich. Data were de-identified and 
stored in an electronic databank. 
Statistical Analysis 
Data were entered once and randomly checked for discrepancies with original data (less 
than 1%). The Package IBM® SPSS® Statistics 19 (Version 19.0.0, IBM Corporation, Somers 
NY) was used for statistical analysis, setting 5% for all critical probability levels. 
Descriptive statistics included mean, standard deviation (SD), median and interquartile 
ranges (IQR), and frequencies as appropriate based on measurement levels and 
distributions of variables. The Mann-Whitney-U test and Chi-squared was used to explore 
whether gender, age and years since transplantation differed between those who 
responded and those who did not send back the questionnaires. 
Establishing the best cut-off for the STCS-DS 
Receiver operating characteristic (ROC) curve analysis was utilized to establish an 
appropriate cutoff for the STCS-DS item. We plotted the true positive rate (sensitivity) as a 
function of the false positive rate (1-specificity) for different cutoff values for the STCS-DS 
item, relative to the ESS sum score (i.e. cut-off ≥ 10 - where a score of 10 or more 
indicates very sleepy and should seek medical advice and a cut-off ≥ 6 - whereas a score of 
6-9 suggests DS [19]). 
Validity-related data analysis 
At an in-person meeting in January 2011, the DS concept was presented by the author in a 
10 minute power-point presentation, showing different arguments and perspectives. After 
the presentation the members (N = 20) of the PSIG of the STCS were invited to comment 
and vote. The percentage of agreement was assessed by counting the participating 
members present at the meeting and dividing the number of members agreeing to the 
statement: “the STCS-DS item reflects the concept of daytime sleepiness” by that total. 
Spearman’s rank-order correlation was used to examine the association between the STCS-
DS item and ESS sum score (H1), depressive symptomatology (H2) and poor sleep quality on 
the PSQI (H3). The group difference validity was done with a binary logistic regression with 
the DASS-D score (cut-off < 9 normal; cutoff ≥ 13 mild depression; cut-off ≥ 20 moderate; 
cut-off ≥ 27 severe; cut-off ≥ 28 extremely severe) as a predictor of STCS-DS (H4).  
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3.4. Results 
Out of 1788 renal transplant recipients, 1492 met the eligibility criteria and had a valid 
home address of which 926 returned a completed questionnaire (62% response rate) (See 
flow-diagram in Figure 1).  
Figure 1: Flow diagram of sample 
 
There were no differences between responders and non-responders apart from age: 
non responders (n = 509) were significantly younger than responders (t = 2.51, df = 1039, p 
= .012). The analyses were based on the 926 participants with complete data. The median 
age was 59.69 years (Q25-Q75: 50.27-59.69), 586 were men (63.3%) and the median time 
since transplantation was 9.42 years (Q25-Q75: 4.93-15.85) (Table 2). 
Table 2: Description of the sample 
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Cut-off Values for the STCS-DS item 
Based on ROC curve analyses, a cutoff value of 4.5 on the STCS-DS item yielded the highest 
levels of sensitivity and specificity in predicting the ESS cut-off ≥ 10 (= excessive DS) with a 
sensitivity of 67% and a specificity of 84%. A cut-off value of 3.5 for the STCS-DS item also 
had the highest sensitivity (57%) and specificity (77%) relative to the ESS cut-off ≥6 (= DS) 
(Table 3). 
Table 3: Receiver operating characteristic (ROC) curve for the single DS item 
 
Variable N (Percent)  Property STCS DS STCS DS 
Daytime 
Sleepiness £ 
469 (50.7%) AUC (95% CI) 0.75 (0.71-0.78) 0.75 (0.71-0.78) 
  Optimal cutoff 3.5 4.5 
  Sensitivity 58% 48% 
  Specificity 77% 84% 
Excessive 
daytime 
Sleepiness$  
197 (21.2%) AUC (95% CI) 0.80 (0.77-0.83) 0.80 (0.77-0.83) 
  Optimal cutoff 3.5 4.5 
  Sensitivity 75% 67% 
  Specificity 69% 87% 
 
Legend: AUC = Area under the curve; £= DS on the Epworth Sleepiness Scale ≥6; $= DS on 
the Epworth Sleepiness Scale ≥10 
 
Evidence based on content (Table 1, Q 1) 
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All experts (100%) agreed that the STCS-DS item reflects the concept of DS.  
Evidence based on relations to other variables (Table 1, H 1-4) 
The concurrent validity between STCS-DS item and the ESS Score [H1] showed a moderate 
but significant correlation (Spearman’s rho, rs: 0.531 p < .001). Convergent validity [H2] 
showed that the STCS-DS was correlated minimally but significantly with DASS-D score 
(Spearman’s rho, rs: 0.235 p < .001) and the [H3] STCS-DS ≥ 4 was correlated minimally but 
significantly with the PSQI score (Spearman’s rho, rs: 0.318 p = .002). Table 4 shows the 
group difference validity results. Higher levels of depressive symptomatology are 
associated with higher odds of DS. RTx recipients with moderate to extremely severe 
depressive symptomatology show 3.4, 4.3 and 5.9 higher odds to have DS, respectively as 
compared to those without depressive symptomatology. 
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Table 4: Predictors of STCS-DS in the simple logistic regression analysis 
DASS-D Odds( 95% CI) p 
Normal (reference)   
Mild 1.377 (0.91 – 2.09) 0.133  
Moderate 3.411 (2.25 – 5.165) P<.001 
Severe 4.260 (2.29 – 7.93) P<.001 
Extremely severe 5.990 (2.86– 12.54) P<.001 
 
Legend: STCS-DS= Swiss Transplant Cohort Study- Daytime Sleepiness; DASS-D= Depressions 
Anxiety and Stress Scale- Depression 
3.5. Discussion  
This study examined the validity of using one item to measure DS as incorporated in the 
STCS. The STCS is a nationwide prospective cohort study that uniquely also assesses 
selected psychosocial and behavioral variables from pre-Tx to life-long post-Tx including 
sleep quality and DS.[2] As the STCS does not allow extensive assessment of each variable 
to limit subject burden, DS is assessed with 1 item derived from previous research. Testing 
the validity of the STCS-DS item was performed using a large dataset of renal transplant 
patients participating in a research program on sleep research in RTx recipients, a study 
separate from the STCS. Validity was tested in view of evidence related to test content 
and evidence related to relationships with other variables.[33] 
Cut off score for STCS-DS item 
As a cut-off for the STCS-DS item has not yet been established we used the ROC curve 
analysis to determine it. This analysis showed useable results based on 2 cut offs of the 
ESS, a validated and established instrument to assess DS. We did this analysis for both of 
the cut-offs of the EES thus allowing two suggested cut offs for our STCS-DS item. The 
ideal cut-off for DS is 3.5 and the ideal cut-off for excessive DS is 4.5. To avoid screening 
for a diagnosis of a sleep disorder where one does not exist, we recommend restrictive 
positive screening using values higher than or equal 4 in the STCS-DS item. These findings 
support its use for a general screening tool followed by in depth sleep disorder 
assessments.  
Evidence based on test content 
The agreement of our experts showed that the STCS-DS measures the DS concept. For 
further studies we suggest assessing the content validity index for the validity based on 
test content.[50] 
 
Chapter 3 
 
 
109 
Evidence based on relationships with other variables 
We provided first evidence for validity of STCS-DS item. H1 showed a significant moderate 
correlation, demonstrating the similarity of the concepts. We had hoped to find a higher 
correlation, however this was unrealistic considering the aim of replacing 8 items with one 
is very ambitious. 
Depressive symptomatology (H2) and poor sleep quality (H3) were significantly correlated; 
this result may be, in part, due to the large sample. These results highlight the expected 
interaction of these variables with DS and demonstrate that they measure different things. 
The low correlation may indicate that other factors that we did not correct for and did not 
assess, affect the variability. For example we did not assess for past insomnia history; this 
factor is a predictor for future development of depression in older persons as well as young 
adults.[51] Further we had no polysomnography measurements to establish changes in 
sleep architecture. We will in future have actigraphy in a selected subgroup that may 
provide detailed information as to the nature of the diverse sleep disturbances in RTx. In 
addition, RTx recipients are subjected to other strong factors limiting the correlations and 
affecting sleep, for example the consequences of immunospressive drug therapy [52], 
impaired immune system [53] and high vulnerability for infections [54]. 
Group difference validity has been shown with the DASS-D scale. Higher levels of 
depressive symptomatology were significantly associated with a higher odds ratio of DS. 
These validities show that STCS-DS measures a similar concept to the ESS, that STCS-DS is 
related to but measures a different concept than depression and sleep quality; and that a 
positive score on the DASS-D scale is associated with an increased odds ratio for DS. This 
suggests that careful use of a simple screening is beneficial and - in case of a positive 
screening value - should be followed up by a thorough assessment for sleep disorder.  
We suggest for a further validity study to test all sources of validity [34, 48], especially 
evidence based on response processes and evidence based on consequences of testing. 
Evidence based on internal structure is in this case irrelevant, as there is only one item. 
Validity based on response processes should be assessed with more assessments (interview 
techniques, verbal protocol methods, think-aloud techniques) at different time points.[33] 
Validity based on consequences of testing could be assessed by assessing the alertness and 
performance (the impact of DS score results) of the RTx recipients and the consequences 
on the nurses in charge in view of higher services. For example a study could measure the 
difference in immunosuppressive medication adherence between RTx recipients screened 
with DS receiving no intervention and RTx recipients screened with DS receiving light 
therapy to improve DS. 
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Limitations of the study 
This study has several limitations: The questionnaire responders were significantly older 
compared to non-responders, perhaps because they are retired [55] and thus have more 
time to answer the questionnaires. Next, the study aimed to include a broad sample with 
low selection criteria and low questionnaire and measurement burden. Therefore we had a 
big sample, only one time point measure and few items included in the questionnaire, 
limiting the analysis for testing other validity dimensions. A further limitation is that the 
questionnaire did not permit investigation of self-rated DS as related to specific sleep 
disorders. Lastly testing validity and reliability of a 1-item scale is limited [e.g: reliability 
(internal consistency) is only possible with more than 1 item] and study design (e.g: for 
test-retest validity and criterion validity a longitudinal study is needed).[46] 
Conclusion  
The “Standards for Educational and Psychological Tests” proposed that validity is a unitary 
concept supported by theory and accumulating evidence provides a sound scientific basis 
for the proposed score interpretation. Our results support the importance of daytime 
sleepiness, sleep quality, and depressive symptomatology assessment in renal transplant 
patients. Our validity testing based on evidence “based on content” and “evidence based 
on relationship to other variables” provided supporting evidence for the validity of a single 
daytime sleepiness item in the STCS-DS.  
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4.1. Abstract  
Background 
The aims of this study were to determine the prevalence of immunosuppressive non-
adherence (NA) in renal transplant patients and describe whether the degree of daytime 
sleepiness (DS) and depressive symptomatology are associated with immunosuppressive NA. 
Methods 
Using a cross-sectional design, 926 home-dwelling renal transplant recipients who were 
transplanted at one of three Swiss transplant centers provided data by self-report. The 
Basel Assessment of Adherence Scale for immunosuppressive was used to measure the 
taking, timing and overall NA to immunosuppressive medication. DS was assessed with the 
Epworth Sleepiness Scale (cutoff≥6 for DS) and the Swiss Transplant Cohort Study DS item 
(cutoff≥4 for DS), and depressive symptomatology was assessed with the Depression, 
Anxiety and Stress Scale (cutoff>10). A ordinal logistical regression model was applied for 
statistical analysis. 
Results 
The prevalence of the Epworth Sleepiness Scale -DS was 51%. NA for taking timing and the 
median overall NA level assessed by 0 to 100% visual analogue scale was 16%, 42% and 0% 
respectively. Based on the multivariate analysis DS was a significantly associated (p < 
0.001) with taking (1.08 [1.04-1.13]), timing (1.07 [1.03-1.10]) and overall NA (1.09 [1.05-
1.13]). Very similar results were found for the Swiss Transplant Cohort Study DS item. 
Conclusion 
DS is associated with immunosuppressive medication NA in renal transplant recipients. 
Admittedly the association’s strength is limited.  
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4.2. Introduction  
Medication non-adherence (NA) is defined as a deviation from the prescribed medication 
regimen sufficient to impair the regimen’s intended effect [1]. Based on meta-analysis 
data, Butler et al. (2004) reported a median of 22% (IQR: 18%-26%) of immunosuppressive 
non-adherence in renal transplant recipients [2], and reported that non-adherence 
contributes substantially to graft loss; a median of 36% (interquartile range: 14%-65%) of 
graft losses were associated with prior non-adherence [2]. A preliminary analysis of an 
ongoing cohort study including kidney, liver, lung and heart Tx recipients showed a 28% 
prevalence of NA to immunosuppressive drugs in the past month pre-Tx, 8.2% at 6 months 
post-Tx, 11.6% at 1 year and 13.1% at 2 years, respectively [3]. 
Following transplantation, NA to immunosuppressive drug regimens is associated with an 
increased risk of graft loss [4] as well as negative economic outcomes [5]. Non-adherent 
patients have US $12 840 higher medical costs over a period of 3 years compared to 
adherent patients [5]. Reported reasons for intentional NA include high medication costs 
and beliefs that the medication is harmful and causes side effects. The Swiss health system 
is regulated by the health insurance act that gives everyone living in Switzerland access to 
good medical care. This compulsory insurance covers the cost of medical treatment in case 
of illness or accident if the victim has no accident insurance. The insured person is free to 
select a health insurance provider. Immunosuppressive drugs are often paid for initially by 
the transplant recipient, who is then reimbursed 90% of the cost. Therefore, costs might 
be a factor influencing NA. Regarding self-reported behavior such as immunosuppressive 
NA, the key items to measure are taking the medication (ingestion), regular intake (timing 
adherence), drug holidays (not taking consecutive doses) and dose reduction [6]. 
Daytime sleepiness (DS) is a term used to describe difficulty maintaining a desired level of 
wakefulness, and refers to the feeling of drowsiness with a tendency to doze [7]. The 
clinical measurement in use reflects the implications that this level of sleepiness has for 
the individual's ability to perform a relevant tasks [8]. Thus, DS is not a disorder, but a 
symptom [9]. DS is measured by electroencephalographic correlates of sleepiness and 
markers of sleep with objective tests, such as the Multiple Sleep Latency Test or the 
Maintenance of Wakefulness Test. However, the rather high costs of these diagnostic tools 
restrict their overall usefulness in clinical practice [10]. Alternatives to the objective tests, 
are self-report questionnaires such as the Epworth Sleepiness Scale [11]. There is ample 
evidence for correlation between subjective and objective sleepiness [12]. 
Chapter 4 
 
119 
Causes for DS vary: insufficient sleep duration, sleep apnea, narcolepsy, idiopathic 
hypersomnia, recurrent hypersomnia, circadian rhythm disorders, restless legs syndrome 
and periodic limb movement disorder, neurological conditions, somatic illness, psychiatric 
disorders and medication-induced somnolence [13]. It is known that DS diminishes 
cognitive and physical performance [14], with adverse impact on health [15], which 
include obesity and impaired glucose tolerance [16], cardiovascular disease and 
hypertension [17], mental distress, depressive symptoms, anxiety, and increased alcohol 
use [18]. DS is a public safety concern, particularly regarding the increased risk for 
workplace injuries and drowsy-driving accidents. 
The rate of DS are between 1.4% [19] and 8% [20] in the general population and as high as 
27.3% in hemodialysis patients [21]. The most common sleep disorders in hemodialysis 
patients are insomnia, restless legs syndrome, obstructive sleep apnea, and snoring [22]. In 
our RTx group, we found a 30.7% prevalence of poor sleep quality and a 34.1% prevalence 
of poor daytime functioning in the last 4 weeks [23]. RTx recipients commonly also suffer 
from other sleep disorders, such as chronic insomnia (8%), poor sleep quality (30% - 34%), 
obstructive sleep apnea (27%), restless legs syndrome (4.5%) [24], and periodic limb 
movement [25]. Sleep-wake disturbances in RTx recipients are multifactorial. 
Theoretical Framework 
DS and NA have been positively associated in heart failure patients [26]. In these patients 
obstructive sleep apnea, disturbed sleep, impaired cognition and failure stage are the main 
determinants[27]. In RTx recipients the main determinates are unknown. RTx recipients 
follow a lifelong immunosuppressive treatment, to inhibit or prevent activity of the 
immune system. NA to immunosuppressive has very little forgiveness (NA >5% of doses not 
taken, resulted in a higher risk of acute rejection rate) [28], therefore factors (i.e.: DS) 
hindering adherence  have to be quantified in RTx recipients as well as the impact on an 
important outcome variable: immunosuppressive non-adherence to plan targeted 
interventions. 
To consider DS as a factor for medication NA [29] we used our adaptation of the Integrated 
Model of Behavioral Prediction (IMBP) [30], based on our previous work employing the IMBP 
to assess NA-associated variables in RTx groups [31]. Previous research has suggested that 
most NA in RTx is accidental (non-intentional) [32, 33]. As a non-intentional risk factor for 
NA, however, DS was not examined in these studies. The IMBP model posits that 
medication non-adherence results from intentional and unintentional cognitive factors and 
barriers [30]. In our adapted model, DS (a non–intentional tendency to fall asleep) is seen 
as a behavioral (unintentional) barrier to adherence (see Figure 1).  
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Figure 1: Theoretical model adapted from the Integrative Model of Behavioral Prediction - 
Schmid-Mohler et al.[31]. 
 
Using the IMBP, our aims were: (1) to describe the prevalence of NA, DS and 
depression in a cohort of RTx recipients, (2) to describe whether medication NA dimensions 
differed between RTx recipients with and without DS, and (3) to describe whether the 
degree of DS is associated with NA (controlling for age, gender, years since Tx, depression, 
and comorbidities).  
4.3. Methods 
Design, Setting and Sample 
This study was a secondary data analysis using a cross-sectional multicenter design to 
gather data from a convenience sample of 926 home-dwelling RTx patients transplanted at 
three Swiss centers (parent study: Burkhalter et al.2013[34] ). For the parent study the 
ethic committee approved only the retrieval of the renal insufficiency cause, comorbid 
condition and immunosuppressive drugs. The inclusion criteria were: at least 6 months 
post-transplant with a functioning graft; ability to understand and read German; 18 years 
of age or older; and signed written informed consent. Individuals were excluded if: they 
were unable to complete the study questionnaires; participation was not approved based 
on a congruent evaluation (insufficient language proficiency, too ill to fill in a 
questionnaire or known cognitive impairments) by the responsible physician and the head 
nurse in charge of outpatient transplant follow-up care; or the patient was on dialysis. 
Variables and Measurements 
Sample characteristics: Age (in years), gender, years since transplantation and presence 
of comorbidities were retrieved from the participants' hospital charts. Comorbidities were 
assessed using the Charlson comorbidity index [35], which assigns weights to specific 
Non adherence 
Attitudes 
Norms  
Self-efficacy 
Depression 
Gender 
Years since Tx 
Comorbidities 
 
Age 
Daytime Sleepiness 
Barriers 
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diseases. The total score is calculated by adding the weights [35]. We examined every 
addressed patient's chart to determine whether any significant comorbidities were 
present. 
Immunosuppressive non-adherence  
Medication adherence was assessed with three items of the Basel Assessment of Adherence 
Scale for Immunosuppressives (BAASIS), a self-report questionnaire assessing general 
medication adherence over the preceding month [36]. It assessed: taking NA (omission of 
single doses) and timing NA (timing deviations >2 h). These 2 items are rated on a 6-point 
ordinal scale: never (0), once per month (1), every second week (2), every week (3), more 
than once per week (4), and every day (5). Finally, a visual analogue scale (VAS) was used 
to assess patients’ perception of their overall NA, ranging from 0% (never took medications 
as prescribed) to 100% (always took medications as prescribed). A prospective Italian study 
in liver Tx recipients (De Simone et al. University of Pisa, work in progress) supported the 
overall predictive validity of the BAASIS, while concurrent validity was demonstrated in 
Brazilian RTx recipients [37]. Dobbles et al (2010) compared the BAASIS with other 
adherence self-report instrument in Tx, showing positive results for this tool [36]. 
Daytime sleepiness 
Two measures were used to assess DS: the Swiss Transplant Cohort Study Daytime 
Sleepiness single-item scale (STCS-DS)[34]  and the Epworth Sleepiness Scale (ESS)[11]. On 
the STCS-DS, study participants rated their DS over the past four weeks on a scale of 0 (no 
sleepiness) to 10 (extreme sleepiness). Its item response format was made congruent with 
the STCS sleep quality item [23]. Primary evidence supporting the validity of the STCS-DS 
has been developed by our research group [34] . Based on receiver operating characteristic 
analysis (using the ESS as gold standard), the recommended cutoff is ≥ 4 (details are 
described in Burkhalter et al. 2013 [34]). 
The ESS is a validated eight-item questionnaire to measure a subject’s expectation 
of dozing (falling into a light sleep) in eight hypothetical situations. Dozing probability 
ratings range from 0 (no probability) to 3 (high probability). An ESS total score ≥ 6 
indicates DS [11]. A score ≥ 10 indicates that a person tends to become very sleepy and 
should seek medical advice [11]. Psychometric proprieties has been shown in English 
speaking populations: The ESS scores is reliable in a test-retest over a period of months (p 
< 0.001); internal consistency is adequate Cronbach’s α = 0.88 – 0.74 in 4 different groups 
of subjects and it has concurrent validity with self-rated problem sleepiness [38, 39]. In 
German-speaking populations [40] item analysis confirmed internal consistency of the scale 
(Cronbach’s α = 0.60 in healthy adults, 0.83 in patients with various sleep disorders). The 
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item-to-total correlation ranged from 0.41 to 0.70. Test-retest reliability measured in a 
sample of  19 healthy subjects' obtained 5 months apart was acceptable with a mean 
difference in the total score of 0.3 ± 2.5 (p: non-significant) [40]. 
Depression  
Depression was measured with the Depression, Anxiety and Stress Scale (DASS–21), a 21-
item self-report instrument. Each component is measured with seven items [41] on a 4-
point Likert-type severity/frequency scale rating the extent to which the patients have 
experienced each state over the past week (0 = did not apply to me; 3 = applied to me 
very much). Scores for depression, anxiety and stress are first summed, resulting in a range 
of 0 to 21 for each subscale. We evaluated results only for the DASS–depression (DASS–D) 
score (0-4 no depressive symptomatology; 5-6 mild, 7-10 moderate, 11-13 severe and 14 or 
more extremely severe symptomatology) [42]. The DASS-21 has strong construct validity, 
structure validity and concurrent validity [42]. To estimate a prevalence of depressive 
symptomatology we will adopt the cutoff >10. 
Data Collection 
Addresses of all eligible patients were extracted from the transplant centers’ databases. 
Each potential participant received a packet containing an information letter, consent 
form, pre-stamped, pre-addressed envelopes and the questionnaires. Participants returned 
the informed consent and the study questionnaires in separate envelopes to ensure 
anonymity.  
Data were collected from the three centers sequentially, between December 2010 
and September 2011 at the last center. Patients who had not responded within 2 months 
after their packets were sent, were called by a research associate to ask if they had 
received the materials and would still be willing to complete the questionnaire. Patients 
were called several times, after which they were categorized as not reachable. Packets 
that did not reach the patients, as they moved to another place, were sent to the new 
place if this was possible to track. If nobody knew where the patient moved to or if at this 
new place more than one had the same name, the packet was not sent. Ethics committees 
of the three transplant centers approved the study. Data were de-identified and stored in 
an electronic databank. 
Statistical Analysis 
The categories of taking and timing NA were collapsed from 6 into 4 categories: never (0), 
once per month (1), every second week (2) and ranging from every week to every day (3) 
to have a meaningful sample size in each category. Descriptive statistics (means, standard 
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deviations (SD), medians, quartiles, frequencies) were used as appropriate for the 
measurement characteristics. The Mann-Whitney U and chi-squared tests (for nominal or 
dichotomous variables) were used to explore differences between participants and non-
responders. 
An ordinal logistic regression model was used to assess a possible association between DS 
and each of the 3 NA components (taking, timing and overall NA on the VAS), controlling 
for depression, comorbidities, gender, age and years since Tx. SPSS® Statistics software 
(Version 19.0.0, IBM Corporation, Somers NY) was used for statistical analysis, with all 
critical probability levels set to 5%. 
4.4. Results 
Of the 1492 eligible patients, 926 returned completed questionnaires (response rate: 62%) 
(Figure 2). No significant differences on age, gender, year since transplantation and 
comorbidities were found between responders and non-responders. Analyses were based on 
926 participants Sample characteristics are displayed in Table 1.  
Figure 2: Flow diagram of the sample 
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Table 1: Description of the sample 
 
Mean ± SD; Median (Q25-Q75); 
Percentage 
Characteristics (N = 926)  
  Males 63% 
  Age [Median (Q25-Q75)] 59.7 (50.26 – 67.77) 
  Years Tx£ [Median (Q25-Q75)] 9.42 (4.93 – 15.85) 
  CCI >1* 52.9% 
Causes for renal insufficiency  
  Diabetic nephropathy 11.8% 
  Vascular nephropathy 9.4% 
  Chronic glomerulonephritis 24.0% 
  Interstitial nephropathy 12.1% 
  Cystic renal diseases 19.4% 
  System diseases 3.4% 
  Other causes 8.3% 
Most prevalent comorbid condition   
  Hypertention 85.6% 
  Acute myocardial infarction 4.8% 
  Congestive heart failure 33.2% 
  Peripheral vascular disease 9.5% 
  Liver disease 10.6% 
  Diabetes 17.9% 
  Diabetic complication 13.4% 
  Cancer 14.1% 
Immunosuppressive regimen  
  Cyclosporine 44.6% 
  Tacrolimus 40.5% 
  Sirolimus/Everolimus 8.8% 
  Mycophenolat mofetil 66.8 % 
  Azathioprine 15.8% 
  Corticosteroid 39.1% 
Daytime Sleepiness  
  ESS$ ≥ 6 50.9% 
  ESS$ ≥ 10 21.3% 
  STCS-DS+ 40.7% 
Taking adherence  
Never NAǂ 84% 
Once per month NAǂ 10.5% 
Every second week NAǂ 3.5% 
Every week to every day NAǂ 1.9% 
  Timing adherence  
Never NAǂ 57.9% 
Once per month NAǂ 14.4% 
Every second week NAǂ 20.4% 
Every week to every day NAǂ 7.3% 
  Overall adherence  
100% adherent 65% 
90-99% adherent 26.5% 
80-89% adherent 5.3% 
70-79% adherent 1.6% 
0-69% adherent 1.6% 
Depressive symptomatology& 33.7%  
 
Legend: £= Years since the transplantation took place; *= Charlson comorbidity index over 1 score 
point; $= Epworth Sleepiness Scale; += Swiss Transplant Cohort Study daytime sleepiness score; ǂ = 
Non-adherence; & = Depressive symptomatology based on the DASS-21 score  
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The prevalence of NA and ESS DS and STCS DS are displayed in Table 2. Both the ESS and 
the STCS–DS data indicated positive associations between DS and NA. Younger age was 
associated with timing and overall (VAS) NA and more years since transplantation was 
associated with higher NA and finally, the univariate analysis positively associated 
depression with timing NA (Table 2). 
Table 2: Predictors of non-adherence in the univariate analysis 
Univariate 
 
Taking  
OR (CI 95%) 
p Timing  
OR (CI 95%) 
p VAS  
OR (CI 95%) 
p 
Sex∆ 0.77 (0.53;1.11) 0.162 0.79 (0.61;1.03) 0.080 0.63 (0.47;0.84) <0.001 
Age/5$ 0.93 (0.87;1.00) 0.047  0.86 (0.82;0.91) <0.001 0.86 (0.82;0.91) <0.001 
Years Tx/5£ 1.18 (1.08;1.29) <0.001 1.14 (1.06;1.23) <0.001 1.10 (1.02;1.19) 0.010 
CCI*  0.97 (0.87;1.08) 0.625 0.94 (0.87;1.02) 0.129 1.02 (0.94;1.10) 0.628 
ESS#  1.08 (1.04;1.13) <0.001 1.08 (1.05;1.11) <0.001 1.09 (1.05;1.12) <0.001 
STCS-DS+ 1.13 (1.06;1.20) <0.001 1.06 (1.01;1.11) 0.027 1.06 (1.01;1.11) 0.030 
Depression& 1.15 (1.00;1.33) 0.058 1.15 (1.03;1.28) 0.010 1.04 (0.93;1.17) 0.515 
 
Legend: ∆= Reference category women =0; $ = Age per 5 years; £ = Years since the transplantation 
took place per 5 years; * = Charlson comorbidity index score; #= Epworth Sleepiness Scale score, += 
Swiss Transplant Cohort Study daytime sleepiness score, &= Depressive symptomatology based on 
the DASS-21 score  
 
In the multivariate model including the ESS score for DS (Table 3) controlling for 
age, gender, years since transplantation, comorbidities and depression, for each additional 
scale point on the ESS, the odds for taking NA increased by 8% (1.08 [1.04-1.13]), the odds 
for timing NA increased by 7% (1.07 [1.03-1.10]) and the odds for overall NA increased by 
9% (1.09 [1.05-1.13]). For each additional five years since the Tx took place, the odds for 
taking NA increased by 20% (1.20 [1.09-1.31]), the odds for timing NA increased by 19% 
(1.19 [1.10-1.29]) and the odds for overall NA increased by 16% (1.07 [1.07-1.25]). Older 
age was associated with a 7% higher chance for taking NA (0.93 [0.86-1.00]) and a 14% 
higher chance for timing NA and overall (VAS) NA (0.86 [0.82-0.91]). Male sex was 
associated with a 62% higher chance for overall (VAS) NA (1.62 [1.19-2.21]). 
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Table 3: Predictors (including DS measured with the ESS) of non-adherence in the 
multivariate analysis 
 
Multivariate 
 
Taking  
OR (CI 95%) 
p Timing  
OR (CI 95%) 
p VAS  
OR (CI 95%) 
p 
Sex∆ 1.23 (0.82;1.83) 0.313 1.25 (0.94;1.65) 0.129 1.62 (1.19;2.21) 0.002 
Age/5$ 0.93 (0.86;1.00) 0.044 0.86 (0.82;0.91) <0.001 0.86 (0.81;0.91) <0.001 
Years Tx/5£ 1.20 (1.09;1.31) <0.001 1.19 (1.10;1.29) <0.001 1.16 (1.07;1.25) <0.001 
CCI* 0.97 (0.87;1.08) 0.580 0.92 (0.85;1.00) 0.053 1.03 (0.95;1.12) 0.494 
ESS# 1.08 (1.04;1.13) <0.001 1.07 (1.03;1.10) <0.001 1.09 (1.05;1.13) <0.001 
Depression& 1.07 (0.91;1.25) 0.440 1.09 (0.96;1.23) 0.176 0.95 (0.83;1.08) 0.439 
 
Legend: ∆= Reference category women =0; $ = Age per 5 years; £ = Years since the transplantation 
took place per 5 years; * = Charlson comorbidity index score; #= Epworth Sleepiness Scale score, &= 
Depressive symptomatology based on the DASS-21 score 
 
In the multivariate model including the STCS-DS item for DS (Table 4) controlling for 
age, gender, years since transplantation, comorbidities and depression, for each additional 
scale point on the STCS-DS scale, the odds for taking NA increased by 13% (1.13 [1.05-
1.21)), the odds for timing NA increased by 5% (1.05 [0.99-1.10]) and the odds for overall 
(VAS) NA increased by 7% (1.07 [1.02-1.14]). For each additional five years since the Tx 
took place, the odds for taking NA increased by 18% (1.18 [1.08-1.30]) the odds for timing 
NA increased by 18% (1.18 [1.09-1.27]) and the odds for overall NA increased by 14% (1.14 
[1.06-1.23]). Older age was associated with a 14% higher chance for timing NA and 14% 
higher chance for overall (VAS) NA (0.86 [0.81-0.91]). A 1-point increase in the depression 
score was associated with a 13% higher chance of timing NA (1.13 [1.00-1.27]). Male sex 
was associated with a 68% higher chance for overall (VAS) NA (1.68 [1.23-2.28]).  
 
Table 4: Predictors (including DS measured with the STCS-DS) of non-adherence in the 
multivariate analysis 
Multivariate 
 
Taking  
OR (CI 95%) 
p Timing  
OR (CI 95%) 
p VAS  
OR (CI 95%) 
p 
Sex∆ 1.30 (0.88;1.94) 0.191 1.30 (0.98;1.73) 0.065 1.68 (1.23;2.28) <0.001 
Age/5$ 0.93 (0.86;1.00) 0.045 0.86 (0.82;0.91) <0.001 0.86 (0.81;0.91) <0.001 
Years Tx/5£ 1.18 (1.08;1.30) <0.001 1.18 (1.09;1.27) <0.001 1.14 (1.06;1.23) <0.001 
CCI* 0.96 (0.86;1.08) 0.497 0.92 (0.85;1.00) 0.052 1.03 (0.94;1.11) 0.557 
STCS-DS+ 1.13 (1.05;1.21) <0.001 1.05 (0.99;1.10) 0.102 1.07 (1.02;1.14) 0.013 
Depression& 1.08 (0.93;1.27) 0.315 1.13 (1.00;1.27) 0.052 0.99 (0.87;1.13) 0.871 
Legend: ∆= Reference category women =0; $ = Age per 5 years; £ = Years since the transplantation 
took place per 5 years; * = Charlson comorbidity index score; += Swiss Transplant Cohort Study 
daytime sleepiness score, &= Depressive symptomatology based on the DASS-21 score 
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4.5. Discussion 
The major finding of this study was that DS was significantly positively associated with 
taking, timing, and overall NA. With 926 patients from a multicenter setting, this is, to our 
knowledge, the largest sample in which DS in RTx recipients has ever been studied.  
 The prevalence of NA (Table 2) is comparable with data from other studies [30] 
confirming that the magnitude of NA is substantial (Table 1) in RTx recipients [31]. An 
estimate of 20% of late acute rejections and 16% of graft losses are associated with NA 
[28]. The current study's DS prevalence, as assessed with the ESS, was 50.8% using a cut-off 
of ≥ 6 and 21.3% with a cut-off of ≥ 10. This prevalence is higher than in the general 
population, which ranges from 1.4% [19] to 8% [20], yet lower than those reported (ESS 
cut-off ≥ 10) in other chronically ill populations, e.g., hemodialysis (27%) [21], heart 
failure (23.6%) [43], gastroesophageal reflux disease (48.8%) [44] and primary biliary 
cirrhosis (51%) [9]. Our multivariate model showed that higher DS scores were associated 
with more immunosuppressive NA. Based on our theoretical model [30] (Figure 2), these 
findings support the premise that DS is a non-intentional barrier to adherence.   
Table 4 showed 13% greater odds of being non-adherent in the drug taking, the statistical 
significance seems very small, though the clinical significance appears to be more 
impressive. A patient reporting a score of 4 on the STCS-DS (no daytime sleepiness), 
compared to a patient with a score of 8 has a 52% greater odds of being non-adherent (4 
times 13%).  
The time investment of screening a patient with a scale from 0 to 10 for DS is worth 
compared to the costs related to the consequences of NA [28]. The current literature 
highlights the importance of adherence to avoid graft rejection [2], therefore minimizing 
the risk for NA, will reduce the risk for acute rejection [45]. 
In the multivariate analysis, depressive symptomatology was associated with timing NA, 
showing independent predictability. In our data the prevalence for depressive 
symptomatology were higher (not significant) in the group of patients having DS. One 
criterion for major depressive disorder is “insomnia or hypersomnia nearly every day” [46]. 
Hypersomnia, a condition of DS, may appear before the patient meets the full diagnostic 
criteria for depression [47]. When it is a symptom of depression, DS creates distress and 
disrupts social functionality [48]. This is highlighted by an epidemiological study where 
sleep durations of less than 6 hours or more than 8 hours were associated with depression 
[49]. 
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Length post transplantation in years, was positively associated with taking, timing and 
overall NA, confirming published findings [50-52]. 
Limitations 
The primary limitation of this study was the cross-sectional design, which allows the 
identification of associations but does not infer causality. As cross sectional studies cannot 
differentiate cause and effects from simple associations, we base the interpretation of the 
results using the theoretical framework that guided our study as a basis. Further, it was a 
secondary data analysis not allowing including some relevant factors. There is a need for 
NA research including prospective longitudinal studies to assess the evolution of NA over 
time and causality among factors as well as research specifically developed to assess risk 
factors of NA thus including a comprehensive set of variables or combination of variables in 
the model to predict NA. Longitudinal prospective cohort studies especially would allow to 
study changes and trends of DS over time controlling for different characteristics. 
Additionally, this study was a secondary data analysis limiting the number and kind of 
variables we could include in our analysis such as medical conditions leading to fatigue, 
medication contributing to sleepiness, forgetfulness, symptoms and sleep diagnoses. 
A further limitation is the use of self-reported data on immunosuppressive 
medication non-adherence and DS. NA self-reports may be underestimated [53], DS may be 
overestimated, [54] and a social desirability bias is possible; however, self-reports are easy 
to complete, inexpensive, and feasible for large samples [36]  . 
Thirty eight percent were non-responders, this prevalence is considerably higher 
than the previous study on poor sleep quality done in one center [23]. Participation 
seemed to be influenced by familiarity with the investigator as patients that had to be 
called were irritated if they did not know the physician responsible for the study. To 
conclude, this study was useful in identifying associations that can be more rigorously 
studies using a cohort or a controlled study. 
Conclusion 
While DS, as the main factor in our analysis, showed associations with taking, timing and 
overall NA, it is a symptom for which treatment is available if its underlying cause is 
known. The high prevalence of DS in RTx recipients suggests a need to assess and treat DS 
as a means for reducing the likelihood of NA [55]. 
Very specific treatments are available for DS, and may consist of antidepressants, a 
diet to reduce weight and sleep apnea symptoms, short daytime naps to counteract 
drowsiness, or sunlight exposure (respectively light therapy) to increase alertness and 
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synchronize the subject's internal clock with the external day-night cycle [56]. Above all, 
the patient must be addressed as an individual, considering his predispositions and risk 
factors, to tailor an effective intervention. This means for the ambulatory follow-up care 
to inquire about sleep (i.e: using the STCS-DS screening tool) on a regular basis to detect 
sleep-wake problems. Interventions to prevent NA, focusing on DS as a non-intentional 
behavior, include implementing reminder systems, increasing social support, encouraging 
self-monitoring, and, if possible, simplifying the medication regimen's complexity [57]. 
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5.1. Abstract  
Background 
Poor sleep quality (SQ) and daytime sleepiness (DS) are common in renal transplant (RTx) 
recipients; however, related data are rare. This study describes the prevalence and 
frequency of self-reported sleep disturbances in RTx recipients. 
Methods 
This cross-sectional study included 249 RTx recipients transplanted at three Swiss 
transplant centers. All had reported poor SQ and / or DS in a previous study. With the 
Survey of Sleep (SOS) self-report questionnaire, we screened for sleep and health habits, 
sleep history, main sleep problems and sleep-related disturbances. To determine a basis 
for preliminary sleep diagnoses according to the International Classification of Sleep 
Disorders (ICSD), 164 subjects were interviewed (48 in person, 116 via telephone and 85 
refused). Descriptive statistics were used to analyze the data and to determine the 
frequencies and prevalences of specific sleep disorders. 
Results 
The sample had a mean age of 59.1 +/- 11.6 years (60.2% male); mean time since Tx was 
11.1 +/- 7.0 years. The most frequent sleep problem was difficulty staying asleep (49.4%), 
followed by problems falling asleep (32.1%). The most prevalent sleep disturbance was the 
need to urinate (62.9%), and 27% reported reduced daytime functionality. Interview data 
showed that most suffered from the first ICSD category: insomnias. 
Conclusion 
Though often disregarded in RTx recipients, sleep is an essential factor of wellbeing. Our 
findings show high prevalences and incidences of insomnias, with negative impacts on 
daytime functionality. This indicates a need for further research on the clinical 
consequences of sleep disturbances and the benefits of insomnia treatment in RTx 
recipients. 
 
 
Keywords: renal transplantation, sleep disturbances, sleep quality, daytime sleepiness 
Chapter 5 
 
138 
5.2. Background 
Poor sleep quality is common among renal transplant (RTx) recipients, with a prevalence 
ranging from 30% to 62% [1-4] as measured using the Pittsburgh Sleep Quality Index (PSQI). 
Subjective sleep quality (SQ) is an evaluation of sleep by the affected individual [5], 
covering elements such as total sleep time, sleep onset latency, total waking time, sleep 
efficiency and disruptive events. Daytime sleepiness (DS) involves difficulty maintaining a 
desired level of wakefulness, i.e., the feeling of drowsiness with a tendency to doze [6]. 
One cross-sectional study using the PSQI in a Swiss transplant center reported a poor SQ 
prevalence of 47.4% [7]. As measured using the Epworth Sleepiness Scale (ESS),[8] data 
from three Swiss transplant centers showed a prevalence of 52% for poor SQ [8] and 50.9% 
for daytime sleepiness (DS). Most cross-sectional studies suggest that poor SQ is higher pre-
RTx (49%-78% [3, 9, 10]) than post-RTx (30%-52% [1, 11]). Similarly, insomnia (difficulty 
falling asleep, staying asleep, waking up before the desired time and being left tired 
during the day) in RTx candidates [12] has a prevalence of 15% in patients on maintenance 
dialysis, compared to 8% post-RTx [13]. Post-RTx SQ remains constant [14]. Supporting 
these findings, Sabbatini et al. (2005) showed that sleep significantly improved from pre- 
(PSQI mean: 8.52±3.81, P<0.001) to post-RTx (PSQI mean: 6.46±3.71, P<0.001), although it 
remained higher than in control subjects (3.54±1.61, P<0.0001)[3]. Finally, poor SQ has 
been linked to pre-RTx impaired health status [14, 15], with post-RTx health status 
improving alongside SQ [13, 16]. 
The most frequent sleep disorders among hemodialysis patients are conditioned insomnia 
(unconscious association of bedtime with negative feelings), obstructive or central sleep 
apnea (repeated cessation of breathing during sleep), restless leg syndrome (an irresistible 
urge to move the legs) and periodic limb movement disorder (involuntarily limb 
movements) [17]. In patients with end-stage renal disease, several uremic and non-uremic 
factors are thought to contribute to the pathogenesis of sleep disorders [17]. Sleep apnea 
appears to be related to displacement of fluids which destabilize the control of breathing 
and narrow the upper airway [18]. Restless leg syndrome and periodic limb movement 
disorders are correlated with anemia, iron deficiency, and peripheral and central nervous 
system abnormalities. Therefore, most such disorders improve post-RTx [18]. Excessive 
daytime sleepiness occurs in approximately 50% of patients with end-stage renal disease 
[19], the etiology of which appears related to both uremia and sleep fragmentation [19]. 
Self-report screening questionnaires to assess sleep problems are an efficient preliminary 
step in a sleep diagnostic process before the first assessment interview. However, 
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screening survey data analyses cannot do more than generally categorize sleep complaints. 
A detailed diagnosis of a sleep disorder requires sleep experts and specific diagnostic tools. 
In sleep medicine, diagnosis follows the International Classification of Sleep Disorders 
(ICSD), which groups disorders into eight categories: (1) Insomnias; (2) Sleep Related 
Breathing Disorders; (3) Hypersomnias (excessive daytime sleepiness); (4) Circadian 
Rhythm Sleep Disorders; (5) Parasomnias (strange movements, behaviors, emotions, 
perceptions, and dreams during sleep); (6) Sleep Related Movement Disorders; (7) Isolated 
Symptoms, Apparent Normal Variants and Unresolved Issues; and (8) Other Sleep Disorders 
[20]. ICSD diagnosis guidelines require a clinical assessment interview and may specify 
diagnostic tools (e.g., polysomnography [21] or biophysiological measurement [22]) to 
differentiate sleep disorders from others with similar symptoms.  
In summary, sleep quality normally improves after RTx; [3] however, a high proportion of 
the current study's RTx recipients were still suffering from sleep disorders several years 
post-Tx[8]. Prior to this study, no self-reported data existed on sleep disturbances among 
(post-Tx) RTx recipients. Therefore, the aims of this study were: 
1. to describe the frequency of self-reported sleep disturbances in RTx recipients 
screened with the Survey of Sleep (SOS); and 
2. based on structured sleep assessment interviews, to measure the prevalence of 
sleep disorders in RTx recipients. 
5.3. Methods 
Design, Setting and Sample 
This study used a sequential cross-sectional multicenter design with a sample of 249 adult 
home-dwelling RTx patients, all of whom were participating in a larger study on sleep and 
daytime sleepiness. The inclusion criteria were: (1) RTx took place at one of the three 
participating Swiss transplant centers, (2) a functioning renal graft at least 6 months post-
Tx, (3) the ability to understand and read German, (4) 18 years of age or older, and (5) 
participation in the preceding study with poor SQ (PSQI >5 [23]) and / or DS (ESS > 6 for 
increased DS [24]) scores. Candidates were excluded if they were undergoing dialysis or 
had not signed the written informed consent form.  
The stage sampling approach used was based on candidates' PSQI and ESS scores, both of 
which were assessed as a part of the larger study [8]. The PSQI is a self-rated questionnaire 
consisting of 19 items, assessing a wide variety of factors related to sleep quality over a 1 
month period, including estimates of sleep duration and latency, and of the frequency and 
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severity of specific sleep-related problems. These 19 items are grouped into seven 
component scores, each weighted equally on a 0-3 scale. The seven component scores are 
then summed to yield a global PSQI score, which has a range of 0-21; higher scores indicate 
worse sleep quality. A cut-off of > 5 points is used to classify patients as having poor sleep 
quality [23]. The ESS is a validated eight-item questionnaire to measure a subject’s 
expectation of dozing (falling into a light sleep) in eight hypothetical situations. Dozing 
probability ratings range from 0 (no probability) to 3 (high probability). An ESS total score 
≥ 6 indicates DS [25]. A score ≥ 10 indicates that a person tends to become very sleepy and 
should seek medical advice [25]. All 249 provided self-reported Survey of Sleep (SOS) data; 
a sub-sample (n=164) additionally participated in a sleep assessment interview (83 
declined participation).   
Variables and Measurements 
Age (in years), gender, years since transplantation, body mass index (kg/m2), creatinine 
(μmol/l), hemoglobin (g/l) and drugs (including sleep drugs) were retrieved from the 
participants’ hospital medical charts. Comorbidity data were also extracted from patients’ 
charts and categorized using the Charlson comorbidity index [26], which assigns various 
weights to specific conditions. Each of the 19 noted conditions was assigned a score of 1, 
2, 3, or 6, depending on the associated mortality risk. For each patient the scores were 
summed to provide his or her overall comorbidity score [26]. Sleep quality and daytime 
sleepiness was extracted from the preceding study and categorized in three groups: 1) 
PSQI≤5 (good SQ) & ESS≥6 (DS); 2) PSQI>5 (poor SQ) & ESS<6 (no DS); 3) PSQI>5 (poor SQ)& 
ESS≥6 (DS). 
Survey of Sleep (SOS) 
The self-reported Survey of Sleep (SOS) questionnaire was developed at the University of 
Pittsburgh and translated into German by the second author. It is often used to report 
sleep symptoms in insomnia patients,[22] and studies often employ it as a preparatory step 
before carrying out sleep assessment interviews [27, 28]. The questionnaire consists of 7 
sections: (1) sleep overview (existence of problem(s) (yes/no), general sleep problem 
(main complaint); duration (less/more than 1 year), course (getting worse, same, better, 
irregular), and frequency of the sleep problem (once/month, several times/week, 
nightly)); (2) sleep habits (including bedtime, get-up time and sleep latency in hours and 
minutes, whether the subject sleeps better in another location (yes/no), regularity of 
bedtimes (yes/no); (3) sleep disturbances (sleep-related symptoms and a list of 45 
potential disturbances); (4) daytime function (typical feelings on getting up (energetic, 
optimistic, refreshed, low energy, irritable, depressed, confused, anxious); nap behavior 
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(intentional or unintentional naps, dreaming during the naps (yes/no), feeling more alert 
after the nap (yes/no), daytime function (sleepiness (not at all, slightly, moderately, 
extremely), accidents because of sleepiness (yes/no), fatigue (not at all, slightly, 
moderate, extremely), having to close eyes during the day to relax (yes/no), impaired 
daytime function (yes/no),  most functional period of the day (early or late morning, 
afternoon or evening; night; no particular time), (5) health habits (use of sleeping drugs 
(Yes /No), caffeine (amount in cups), nicotine (number of cigarettes per day), alcohol use 
(glass unit per day), (6) sleep history (select the main complaint); and (7) medical history 
(diagnoses, drugs) [29].  
The estimated time necessary to complete the SOS is 30 minutes. There is no sum scoring 
of the items and as of the time of writing no validity or reliability measures are available 
for it, as it was developed as a guide for an sleep assessment interview and not as a 
diagnostic tool [22]. The complete Survey of Sleep (SOS) questionnaire is available on 
request from the second author.  
Sleep assessment interview 
Data from the SOS were used to prepare and structure the sleep assessment interview. All 
responses indicating possible sleep disturbances were addressed and elaborated on in the 
interview, which was structured to follow the 7 SOS sections, and lasted approximately one 
hour. The information generated by the interview helped to exclude some sleep disorders; 
however, as no follow-up visits took place and no further sleep diagnostic measurements or 
tools were used, the given diagnoses according to the ICSD criteria [20] should be regarded 
as preliminary. 
The interviewer (first author) was trained to perform sleep assessment interviews by a 
certified sleep specialist and somnologist at the Hirslanden Sleep Disorders Center in 
Zollikon, Switzerland. This training included an overview of sleep disorders and of the 
techniques used to diagnose them. The second author checked a random sample of the 
completed interview transcripts and evaluated the comprehensive justification (to provide 
inter-rater reliability) of the preliminary sleep diagnoses. He also provided back-up 
assistance in view of resolving difficulties in assessment or categorization of sleep 
disorders.  
Data Collection 
Patients were informed at the start of the research project [8] that they might be invited 
for a further screening and assessment if their initial data indicated poor SQ and/or DS 
(see flowchart, figure 1). Each such patient received a package containing an information 
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letter, informed consent documents, a pre-stamped return envelope and the Survey of 
Sleep questionnaire (SOS). Candidates were included in the study if they signed the 
informed consent form, completed the SOS and returned the documents. 
Data collection started in June 2011 at the first transplant center and ended in June 2012 
at the third. Patients who had not responded within 2 months of the document mailings 
were contacted by phone to ask whether they had received the material and would still be 
willing to complete the questionnaire. Each eligible patient (N= 249) was contacted to set 
up a sleep assessment meeting, which could be conducted either in person or via 
telephone. Only 48 agreed to in-person interviews; 116 agreed to a phone interview. After 
10 unsuccessful call attempts, the patients were categorized as unreachable or it was 
noted that they had declined to participate (n=85). According to each participant's wishes, 
the first author either met him/her at a predetermined place or called at the 
predetermined time. 
The study was approved by the ethics committees of all three transplant centers 
(Ethikkommission beider Basel; Kantonale Ethikkommision Bern; Kantonale Ethikkommision 
Zürich). Data were anonymized following the interview and stored in an electronic 
databank. Participants given preliminary diagnoses were encouraged to consult their 
nephrologists regarding their sleep problems. Any patient who wished also received a list 
of certified sleep disorder centers in Switzerland for further examination and treatment. 
Statistical Analysis 
Descriptive statistics (means, standard deviations (SD), medians, quartiles, and 
frequencies) were used as appropriate, based on measurement levels and variable 
distributions. Likewise, comparisons between respondents and non-respondents were 
performed via t-test,  Goodman and Kruskal’s gamma test, or Mann–Whitney U test. 
Missing values were left blank and analysis was performed on the values given. SPSS® 
Statistics software (Version 19.0.0, IBM Corporation, Somers NY) was used for statistical 
analysis, with all critical probability levels set to 5%.  
5.4. Results 
Of 688 RTx recipients invited to participate in this study, 249 (36.2%) agreed. Of 145 RTx 
with PSQI≤5 (good SQ) & ESS ≥ 6 (excessive DS), 18 (12.41%) participated; of 218 with 
PSQI>5 & ESS < 6, 78 (35.78%) participated; and of 325 with PSQI>5 & ESS ≥ 6, 153 (47.08%) 
participated (Figure 1). Participants did not differ significantly from non-participants 
regarding age, gender, years since transplantation, comorbidities or daytime sleepiness. 
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However, poor SQ (PSQI score >5) was significantly more prevalent among participants 
(Gamma: 479, df: 48; p= 0.0001). Of the 249 participants who filled in the SOS 
questionnaire, 164 (65.8%) participated in the subsequent sleep interview (Figure 1). The 
patients with PSQI>5 (poor SQ) & ESS ≥ 6 (excessive DS) scores also had the highest 
participation rate in the assessment interview (65.8%). Most in-person sleep assessment 
interviews (n=43) were performed with patients from center 1 in connection with a 
nephrology follow-up visit, where the first author has a clinical position. Participation in 
the sleep interview was much lower for patients in centers 2 and 3, as each interview 
required 1-4 hours of travel either for the patient or for the interviewer, and no 
possibilities existed to connect the interviews with nephrology follow-ups. 
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Figure 1: Flowchart of the sample 
 
Legend: † = Pittsburgh Sleep Quality Index (cutoff for poor SQ >5); ‡ = Epworth Sleepiness 
Scale (cutoff for increased DS≥6 ); § = Center 1,2,3 = Numbering of the three partecipating 
swiss transplant centers; * = Burkhalter H., et al., Validity of a single item to assess 
daytime sleepiness for the Swiss Transplant Cohort Studys, Prog Transplant, 2012. in 
press. 
 
The participants had a mean age of 59.1±11.6y; 60.2% were male and the mean time since 
RTx was 11.1±7.0 years (Table 1). Immunosuppressive therapy, sleep drugs and co-
medications, health habits and sleep history data are listed in table 1. Sleep drug 
frequency, as noted in the nephrology charts, was 1.6% for benzodiazepines and 2.0 % for 
other sleep drugs. The prevalence of self-reported sleep medication in the SOS was 32.9%.   
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Table 1: Characteristics of the sample [chart review and SOS part 5 (health habits), 6 (past 
sleep history) & 7 (medical history)] 
All (N=249) Frequency Percentage 
  Male  151 60.2 
 Mean Std 
  Age in years  59.6 12.1 
  Years since RTx  11.1 7.0 
  Body Mass Index (kg/m²) 25.9 5.2 
  Creatinine (µmol/l) 125.0 81.6 
  Haemoglobin (g/l) 127.6 16.5 
 Median  (25Q-75Q) 
  Charlson Comorbidities Index 1 0-2 
Immunosuppressive drugs Frequency Percentage 
  Cyclosporin  103 41.4 
  Tacrolimus  93 37.3 
  Sirolimus, Everolimus  23 9.2 
  Mycophenolat 152 61.0 
  Azathioprine 38 15.3 
  Corticosteroids 78 31.3 
Co-medication chart review   
  Statin 97 39.0 
  ACE inhibitor 61 24.5 
  Angiotensin receptor blocker 68 27.3 
  Calcium channel blocker 43 17.3 
  Beta blocker 92 36.9 
  Anticoagulants 58 23.3 
  Antidepressants 14 5.6 
  Diuretics 42 16.9 
  Sleep drugs 9 3.6 
Self-reported sleep drug use 82 32.9 
Caffeine use (>2cups/d) 132 62.3 
Nicotine use 31 12.4 
Alcohol use (>1 glass/day) 64 25.8 
Past sleep history   
  Insomnia 24 9.6 
  Sleepwalking 16 6.4 
  Bed-wetting 24 9.6 
  Talking in your sleep 29 11.6 
  Nightmares 21 8.4 
  Night terrors (screaming in the middle of the night and being 
difficult to awaken) 6 
 
2.4 
  Head-banging or body rocking 8 3.2 
  Seizures during sleep, while falling asleep, or while waking up 
5 
 
2.0 
  Daytime sleepiness 12 4.8 
  Snoring 12 4.8 
  Breathing difficulties 5 2.0 
 
Frequencies and percentage of sleep problems and sleep habits [SOS part 1 & 2] 
The most frequent sleep problem was difficulty staying asleep (49.4%), followed by 
difficulty falling asleep (32.1%) (Table 2). Most RTx recipients (61.4%) had experienced 
their sleep problems longer than 2 years without change (45%) and for 43.8% the problems 
occurred every night. 
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Table 2: General description of the sleep problem [SOS part 1 (overview) & 2 (sleep 
habits)] 
General sleep problem Frequency Percentage 
Having an actual problem with sleep or wakefulness 179 69.1 
Main sleep problem   
Difficulty falling asleep 83 32.1 
Difficulty staying asleep 128 49.4 
Awakening early and being unable to fall back asleep 76 29.3 
Excessive long sleep at night 21 8.1 
Unusual behavior or experiences during sleep (e.g., nightmares, 
sleepwalking) 30 11.6 
Excessive sleepiness during waking hours 66 25.5 
Other problems 34 13.1 
Judgment of the sleep problem   
Intense severity of the sleep problem (or problems)  67 26.9 
Intense amount of interference with ability to function at home, at 
work, and with other people 48 19.3 
Fairly intense sleepiness before bedtime 127 51.0 
Better sleep outside compared to the sleep at home 11 4.4 
Having regular sleep times 192 74.1 
   
Times related to sleep Mean Std 
Bedtime during the week 22.6 0.9 
Bedtime at weekends 23.2 1.3 
Time of lights off during the week 22.9 1.1 
Sleep latency 28.1 32.1 
Frequencies of sleep interruptions 2.8 1.8 
Sleep latency after interruptions 21.9 27.3 
Wakeup time during the week 6.5 1.2 
Sleep duration 6.4 1.5 
Get up time during the week 6.9 1.1 
Get up time at weekends 8.0 1.1 
 Frequency Percentage 
How long having sleep problem   
  Between 6 months and 2 years 74 29.7 
  Between 2 and 5 years 60 24.1 
  >5years 93 37.3 
Course of the problem   
  Becoming worse 15 6.0 
  Same 112 45.0 
  Improving 17 6.8 
  Irregular 79 31.7 
  Recurring regularly 8 3.2 
Frequency   
  Every day/night 109 43.8 
  Sometimes in a week 24 9.6 
  Sometimes in a month 31 12.4 
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Frequencies and percentage of sleep symptoms [SOS part 3] 
Of 45 sleep-related symptoms, the most prevalent were the need to urinate (62.9%), leg 
cramps during sleep (37.8%), frequent tossing and turning in bed (37.1%), feeling too hot or 
too cold (33.2%) and awakening for no particular reason (29.7%) (Table 3).  
Table 3: The 32 most prevalent sleep disturbances out of 45 [SOS part 3 (sleep 
disturbances)] 
Sleep Disturbance of N=249 Frequency  Percentage 
Need to urinate 163 62.9 
Leg cramps during sleep 98 37.8 
Frequent tossing and turning 96 37.1 
Feeling too hot or too cold 86 33.2 
Awaken for no particular reason (spontaneous awakenings) 77 29.7 
Feeling anxious or emotionally tense, or worrying about things 
at bedtime 72 27.8 
Physical nervousness and agitation in the evening or at night 68 26.2 
Restless, uncomfortable, or "crawling" sensation in your legs 
during the evening or at night 62 23.9 
Awakened by dreams (not nightmares) 56 21.6 
Snoring 54 20.8 
Feeling physically tense at bedtime 42 16.2 
Awakening because of noise or light 38 14.7 
Jerking or twitching in feet, legs, or arms during sleep 34 13.1 
Large body jerks as you are falling asleep 33 12.7 
Awakened by noises 32 12.4 
Awakened by recurring dreams 31 12.0 
Other pain during sleep 31 12.0 
Muscle aches during or after sleep 30 11.6 
Grinding teeth 26 10.0 
Nightmares 26 10.0 
Heartburns or other burning in chest, stomach 24 9.3 
Headaches beginning during sleep 24 9.3 
Palpitations, heart racing, or irregular heart beat 23 8.9 
Other sleep disturbances 22 8.5 
Talking in your sleep 19 7.3 
Hallucinations as you are falling asleep or waking up, i.e., 
seeing or hearing things which turn out not to actually be real 15 5.8 
Frequent cough 15 5.8 
Episodes of confusion during sleep or upon awakening 14 5.4 
Awakening choking, smothering, or gasping for air 13 5.0 
Periods of not breathing during sleep 13 5.0 
Difficulty breathing (including wheezing) 11 4.3 
Difficulty swallowing 11 4.2 
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Frequencies and percentage of daytime function [SOS part 4] 
At wake-up time in the morning, 68 participants (26.2%) felt low energy, while an equal 
number felt optimistic. Only 16.9% napped unintentionally during the day; 47.2% napped 
intentionally. Half (49.8%) of all nappers felt more alert after a nap. During the day, 16.1% 
felt extreme sleepy, 16.9% intensely fatigued and 27.8% impaired in their daytime 
functions (Table 4). 
Table 4: Description of daytime function [SOS part 4 (daytime function)] 
 Frequency Percentage 
Typical feelings at awakening in the morning   
  Optimistic 68 26.2 
  Low energy 68 26.2 
  Energetic 44 17.0 
  Refreshed 28 10.8 
  Irritable 18 6.9 
  Other 17 6.6 
  Depressed 16 6.2 
  Anxious 14 5.4 
  Confused 4 1.5 
Nap behavior   
  Intentional napping 118 47.4 
  Unintentional napping 42 16.9 
  Falling 1-2 times a day asleep or nap during the day  62 24.9 
  Often dreaming when falling asleep or nap during the day 10 3.9 
  Feeling more alert and awake after falling asleep or nap 124 49.8 
Daytime function   
  Extreme amount of sleepiness during daytime  40 16.1 
  Had an accident because of sleepiness or falling asleep 11 4.4 
  Intense amount of fatigue during the day 42 16.9 
  Have to close eyes during the day to relax  78 31.3 
  Impaired daytime functioning because of nighttime sleep    
disturbances, daytime sleepiness or fatigue 72 27.8 
Best function during the day   
  Early morning 102 39.4 
  Late morning 83 32.0 
  Early afternoon 38 14.7 
  Late afternoon 41 15.8 
  Early evening 34 13.1 
  Late evening 18 6.9 
  During the night 4 1.5 
  No specific  time 35 13.5 
 
Frequencies and percentage of preliminary sleep diagnoses according to the ICSD 
The most prevalent preliminary sleep diagnosis was chronic insomnia (42.5%), followed by 
circadian sleep-wake disturbances. Table 5 presents the preliminary sleep diagnoses based 
on a single assessment interview. 
Chapter 5 
 
 
149 
Table 5: Frequency of preliminary sleep diagnosis based on the interview grouped 
into the international classification of sleep disorders categories. 
N= 164 Frequency  Percentage 
Insomnias     
  Psychophysiological insomnia or paradoxical insomnia 53 32.3 
  Adjustment insomnia  3 1.8 
  Inadequate sleep hygiene 5 3.0 
  Insomnia due to medical condition 9 5.5 
Sleep Related Breathing Disorders     
  Obstructive Sleep Apnea, Adult 8 4.9 
  Other Sleep Related Breathing Disorders 5 3.0 
Hypersomnias of Central Origin Not Due to a Circadian Rhythm 
Sleep Disorder, Sleep Related Breathing Disorder or Other Cause 
of Disturbed Nocturnal Sleep 
    
  Behaviorally induced insufficient sleep syndrome 11 6.7 
  Idiopathic hypersomnia with long sleep time 7 4.3 
  Hypersomnia due to drug or substance use 1 0.6 
Circadian Rhythm Sleep Disorders (CRSD)      
  CRSD delayed sleep phase type 22 13.4 
  CRSD advanced sleep phase type 3 1.8 
  CRSD irregular Sleep-Wake Type 8 4.9 
Parasomnias     
  Nightmare Disorder 4 2.4 
  Parasomnia due to drug or substances 4 2.4 
  Confusional Arousals 4 2.4 
  Parasomnia due to med conditions 2 1.2 
Sleep Related Movement Disorders  1 0.6 
Isolated Symptoms, Apparent Normal Variants, and Unresolved 
Issues 
0 0.0 
Other Sleep Disorders 0 0.0 
No presumed diagnosis 14 8.5 
5.5. Discussion 
To our knowledge, this is the first study to focus on sleep problems in RTx recipients by 
using a detailed sleep questionnaire (SOS) and subsequent sleep assessment interview. This 
study describes the frequency of self-reported sleep disturbances in RTx recipients 
screened with the Survey of Sleep questionnaire (SOS) and the frequency of presumed 
sleep diagnoses based on the sleep interview.   
As shown in table 1, of the 688 patients invited to participate, roughly 50% (n=325) 
registered poor SQ and DS. Figure 1 shows an increasing proportion of participants in the 
“poor SQ (PSQI>5) & and DS (ESS≥6)” group. Of these 325, 153 (47.1%) filled in the SOS and 
108 (70.6%) participated in the assessment interview. In addition, poor SQ was significantly 
more prevalent in participants compared to non-participants. This would support a 
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hypothesis that, even where no therapeutic benefit can be hoped for, patients are more 
likely to participate in studies directly relevant to their personal experience. 
Prevalence and percentages of sleep problems and sleep habits [SOS part 1]  
The most prevalent sleep problem was difficulty staying asleep, followed by problems 
falling asleep. Both are characteristic of insomnia [20]. Other characteristics of insomnia 
common in this group were the extended duration of the sleep problem (61.4% reported 
durations greater than 2 years), the severity of the sleep problem (26.9% called their 
problems severe), the high prevalence of nightly sleeping pill use (32.9%), sleep latency of 
28±19.3 minutes, a high number of awakenings (2.8±1.8) per night, long sleep latency after 
awakening (21.9±16.4 minutes), and high ratios of time in bed to hours of sleep (8.3±1.3 
hours) to hours of sleep 6.4±1.5. These results corroborate those of Moul et al. (2002),[30] 
who reported that 68% of insomnia patients exhibited long-term sleep problems (more than 
1 year), severe sleep problems (81%), high nightly use of sleeping pills (89%), long sleep 
latency (53.3±51.8 minutes), high numbers of awakenings (2.7±1.7) per night, long sleep 
latency after awakening (56.0±64.7 minutes), and high ratios of time in bed to hours of 
sleep (8.2±1.9 hours in bed: 5±1.7 hours of sleep). The average sleep duration of 6.4±1.5 is 
very low, as studies have shown that chronic restriction of sleep to 6 h or less per night 
produces cognitive performance deficits equivalent to up to 2 nights of total sleep 
deprivation [31]. Sleep deficits seriously impair waking neurobehavioral functions (lapses 
in behavioral alertness) in healthy adults [31]. 
Prevalence and percentages of sleep habits [SOS part 2]  
One third of participants (n= 82) reported using sleeping pills; however, the medical chart 
data showed that very few (n=9) had informed their nephrologists regarding their sleep 
problems or use of sleep medication. During their post-transplant hospitalization, all RTx 
recipients receive education regarding over-the-counter medication and medication 
prescriptions from other physicians, during which they are advised always to consult their 
nephrologist about possible interactions with their immunosuppressive drugs [32]. This 
discrepancy may indicate that patients are reluctant to bring up sleep problems, that they 
do not see sleep disorders as a topic that nephrologists can deal with, or that the 
nephrologists themselves simply consider sleep disorders a normal side effect of RTx 
immunosuppressive regimens. Compared to the general population, our prevalence of 
32.9% self-reported sleep medication use is very plausible: sleep medications are used 
regularly by 3.2% of subjects 44 or younger, 13.3% of subjects between 45 and 64, 22% of 
those between 65 and 74 and 32% of individuals 75 or older [33].  
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Prevalence and percentage of sleep symptoms [SOS part 3] 
The most prevalent night-time symptom was nocturia. The frequency of its occurrence is 
key to further diagnosis. Nocturnal polyuria (nocturnal urine overproduction) and 
diminished nocturnal bladder capacity [34] require further testing to exclude urinary tract 
infections and prostate hyperplasia [35]. Also very prevalent were leg cramps and frequent 
turning in bed, indicating muscle fatigue, nerve dysfunction or electrolytic imbalances 
[36]. However, these symptoms could also be indices of restless leg syndrome, periodic 
limb movements, myositis, or peripheral neuropathy [36]. Similarly, turning or rocking in 
bed could indicate parasomnia (undesirable physical or behavioral phenomena occurring 
during the sleep period) [37]. For the diagnosis of parasomnias a careful physical 
examination is crucial and often a polysomnogram, including an expanded 
electroencephalographic montage, is necessary to distinguish between parasomnias (non-
REM or REM) and nocturnal seizures [37].  
Leg cramps during sleep were the second most prevalent sleep symptom (37.8%), followed 
by frequent tossing and turning in bed (37.1%). These two symptoms could be related to 
restless leg syndrome and/or periodic limb movements. The prevalence of restless leg 
syndrome in RTx recipients overall is 4.5% [38]. For periodic limb movements the overall 
prevalence is unknown, although there is an improvement from pre- to post-Tx [39]. 
Nocturnal leg cramps are often associated with vascular disease, lumbar canal stenosis, 
cirrhosis and hemodialysis [36], however no prevalence is known for RTx recipients. The 
sensorimotor symptoms of restless leg syndrome and/or periodic limb movements can be 
treated with dopamine agonists, gabapentin and its derivatives, and opioids [40]. To 
summarize, in-depth assessment of all these listed symptoms is crucial for the right 
treatment choice. 
Prevalence and percentage of daytime function [SOS part 4] 
Table 4 shows the high prevalence of daytime sleepiness, tiredness and impaired daytime 
functioning, highlighting the importance for affected patients to use reminders (e.g., 
pillbox alarms, SMS reminder functions, or other cues) to ensure punctual intake of their 
immunosuppressive drugs. An earlier study showed correlations between DS and impaired 
immunosuppressive medication adherence [41]. However, it is possible that compensating 
behaviors such as increased use of mild stimulants (e.g., caffeine, nicotine) (table 1) 
account for the lower prevalence of non-adherence (16%) than of DS (52%)[42]. 
Napping behavior and sleep duration depends on cultural, environmental, occupational and 
health factors [43]. In this study, 47.4% of participants reported intentional napping, a 
behavior shown to be protective against mortality [43]. However, a nap lasting several 
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hours [44] might interfere with nighttime sleep–a point which would have to be borne in 
mind while counseling patients regarding sleep hygiene. The ideal nap duration for adults 
is about 10-20 minutes and the timing depends on the quality of sleep duration the 
preceding night, amount of prior wakefulness and morningness-eveningness tendencies 
[45]. 
Prevalence and percentages of preliminary sleep diagnoses  
This study's most prevalent sleep diagnosis was chronic insomnia, followed by circadian 
rhythm sleep disorders. The prevalence of insomnia in the general population is 15 -20% 
[46] and prevalence of circadian rhythm sleep disorders ranges from 3.1% in adults aged 
40-64 to 16% in adolescents [47]. Our prevalence of 42.6% insomnia and 20.1% CRSD is only 
partially comparable based on our group's pre-selection criteria (RTx recipients having poor 
SQ and /or DS). Various publications suggest RTx recipients’ sleep disorders are related to 
medications (e.g., β-blockers [48], nonsteroidal anti-inflammatory drugs [49], 
corticosteroids [50] and mycophenolic acid [51]) and other clinical conditions [52, 53]. 
Molnar et al. [54] list numerous potential causes of sleep disorders in this group, including 
pre-existing sleep disorders, transplant surgery, hospitalization, anxiety and uncertainty, 
fear of organ rejection, immunosuppressive medication, deteriorating kidney function and 
co-morbid medical conditions, psychosocial problems, psychiatric and neurological 
disturbances, lifestyle, diet, environmental factors and aging. With so many possible 
contributing factors, the most appropriate course of action might be a referral to a sleep 
expert, who could counsel the patient on the full range of behavioral and medical 
interventions available, and help them to choose those best suited to their needs [55]. 
Sleep interventions for RTx recipients are the same as for the general population, apart 
from the risk of interaction with immunosuppressive therapy and the need to consider the 
long-term side effects of their therapy (e.g., osteoporosis, new onset of diabetes, pain). 
Limitation of this Study 
Since only 249 RTx recipients filled in the questionnaire, of which only 164 (65.9%) gave 
interviews, the generalizability of this study's findings are limited. In addition, the high 
prevalence of RTx recipients in the “poor SQ (PSQI>5) & and excessive DS (ESS≥6)” group 
showing an increasing proportion along the study steps, limits the significance and 
comparability of the presumed sleep diagnoses. 
Suggested further research 
Further research will be necessary to develop safe interventions for RTx recipients with 
sleep-wake disturbances, taking into account their impaired renal function (limited organ 
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survival), high risk of skin cancer (a side-effect of immunosuppressive treatment) and need 
to adhere to their medication regimens (high risk of acute graft rejection). These 
interventions should include education [56] regarding sleep disorders and their negative 
health impacts. Apart from established cognitive and behavioral interventions for 
insomnia, new chronotherapeutics treatments, particularly bright light therapy and 
melatonin supplementation [57] should be investigated. For RTx recipients, who already 
have a high number of medications to ingest daily, light therapy might be a realistic 
intervention to stabilize sleep-wake rhythms compared to melatonin supplementation (one 
more drug to ingest). 
Conclusion 
Our findings show high prevalence of insomnia and of impaired daytime functionality. This 
indicates a need for further research on the clinical consequences of sleep-wake 
disturbances and the benefits of insomnia treatment in RTx recipients.  
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6.1. Abstract   
Background:  
Poor sleep quality (SQ) is a risk factor for poor clinical outcomes in solid organ transplant 
(Tx) recipients. The aim of this study was to describe the prevalence and variability of SQ 
from pre to post Tx simultaneously in kidney, liver, lung and heart recipients included in 
the Swiss Transplant Cohort study (a prospective nation-wide cohort study), and to test the 
predictability on health status.  
Methods:  
SQ was assessed at pre-Tx, 6, 12 and 24 months post-Tx using a single question ranging 
from 0 (very poor) to 10 (very good), where the cut-off for poor SQ was < 6. Health status 
was assessed with the visual analogue scale from 100 (best) to 0 (worst). Random intercept 
regression analysis was used to identify statistically significant associations. 
Results:  
1076 patients (age: 52.4±13.1 years; 65% males; 639 kidney, 215 liver, 126 lung, 96 heart) 
were included. Poor SQ decreased from pre-Tx (39.41%) to 12 months post Tx (24.75%) for 
all. Liver and heart recipients had the highest prevalence of poor SQ pre-Tx while all 
organs decreased to prevalence between 22-30% at 12 months and remained constant at 24 
months except for lung recipients (42%). SQ significantly predicted patient’s health status 
(p=<.0001).  
Conclusion:  
SQ improved from pre-to post-Tx and SQ predicted heath status.  
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6.2. Background 
Sleep in the general population is a critical determinant of health and poor sleep has been 
associated with a wide range of health consequences [58] such as higher risk for 
cardiovascular disease [59], diabetes [60], and an increased mortality [61-63]. Short sleep 
(<5 hours) is associated with coronary artery calcification [64], an increased risk of overall 
cardiovascular events and myocardial infarction [65]. In hemodialysis patients poor sleep 
quality  was a significant independent predictor for poor quality of life [66] and the 
relative risk of mortality was 16% higher for hemodialysis patients with poor sleep quality 
[9]. In solid organ transplant recipients only little is known. 
Sleep quality (SQ) is defined as the excellence in sleep evaluated by the individual [5], 
covering a number of elements such as total sleep time, sleep onset latency, total wake 
time, sleep efficiency and disruptive events. In the general population between 7% to 40% 
reported poor SQ [67]. In renal transplant (RTx) recipients the prevalence of poor SQ 
ranges from 30% - 62% [1-4, 11, 14, 68] and from 51% to 77% in liver Tx (LiTx) recipients 
[69, 70]. For lung (LuTX) recipients only prevalence on sleep disordered breathing are 
available (36% [71] and 63% [72]) and for heart transplant (HTx) recipients only prevalence 
on obstructive sleep apnea (36% [73, 74] and  58% [75]) and prevalence on periodic limb 
movements (33% [73]) are available. 
Further it is known that insomnia improves from pre to post RTx (15%-8%) [13] and fatigue 
decreases significantly from 8.99 ± 5.5 pre to 6.81 ± 5.5 post RTx [11]. There is a similar 
study in LiTx reporting an improvement of fatigue from 86 to 76% [70], however another 
prospective study reported a worsening from 60 to 62% [69]. Finally sleep disorder 
breathing in LuTx improved from 44% to 36% at post Tx [71]. Similarly, health status 
improved from pre to post renal [13, 14, 16] and liver [76] Tx. Health status is a generic 
measure of subjective perceived health [77]. For H-LuTx and LuTx recipients only post Tx 
numbers are available, indicating that health status is similar to the general population 
[52]. There is only one study that assessed SQ and health related quality of life at 6 and 12 
months post RTx, revealing that SQ worsened from 36.7% to 38.3% and that health related 
quality of life decreased especially in the vitality and role emotional domains [14]. In 
addition when they compared good and poor they found that the poor sleepers had lower 
health related quality of life scores [14]. 
Theoretical model 
The theoretical framework guiding our study (Figure 1) indicates that different factors 
influence clinical Tx outcomes. This study focused on SQ as potential predictor of Tx 
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outcome (i.e: health status), based on previous research that already found this relation in 
hemodialysis patients [66]. In addition selected socio-demographic (age, gender, time 
since Tx) and psychosocial factors (depression) were included as potential confounders 
while exploring the relations between SQ and health status. 
Figure 1: Theoretical model and design of the cohort study showing the evolution of sleep 
quality and depression as predictors for the outcome perceive health status. 
 
Legend:     =psychosocial questionnaire assessing sleep and depression;      psychosocial 
questionnaire assessing perceived health status 
 
Depression needs to be controlled for in SQ analysis, as poor SQ is a symptom belonging to 
the diagnosis of depression [20]. There is evidence of high prevalence of depression after 
Tx [9% at 3 years post RTx [78], 30% 2 years post LuTx [79] and 26% 2 years post HTx [79], 
29% 1-2 years post LiTx [80]] and higher depression levels were associated with a 3 to 4-
fold increased risk of graft failure and mortality 18-months post-RTx [81]. 
Yet, sleep quality, health status and depression in all these cited studies were measured in 
a different way and with other measurement tools making comparisons across studies 
difficult. Prevalence data from all solid organ Tx group at pre and post Tx, as well as 
evolution data of SQ at different time point after Tx would strengthen enormously the 
evidence base in view of SQ as a predictor for health status in solid organ Tx recipients. 
The gap in the literature is that there are no studies assessing sleep longitudinally and in 
all solid organs populations simultaneously using the same methodology. The data of the 
Swiss Transplant Cohort Study provide a unique possibility to fill this gap in the literature.  
Study Aims 
The aims of the study are therefore: 
(1) to describe the prevalence and evolution of SQ from pre Tx until 24 months post 
Tx in kidney, liver, lung and heart Tx recipients 
(2) to investigate differences in prevalence and evolution of SQ in kidney, liver, lung 
and heart Tx recipients groups within and across assessment times (pre Tx, 6, 12 
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and 24 months post Tx) controlling for age, gender, depressive symptomatology 
and the number of months between the pre Tx measurement and the Tx date, 
and  
(3) to determine if poor SQ is predictive with regard to health status across Tx groups 
and assessment times (pre Tx, 6, 12 and 24 months post Tx) controlling for age, 
gender, depressive symptomatology and the number of months between the pre 
Tx measurement and the Tx date. 
6.3. Material and methods 
This study used the data from the Swiss Transplant Cohort Study (STCS). The STCS is a 
prospective open cohort study including all patients transplanted in Switzerland in one of 
the 6 Tx centers (Lausanne, Geneva, Basel, Zürich, Bern, St. Gallen). The STCS started 
patient enrollment and data collection on May 2nd 2008. Because all subjects receiving an 
organ qualify for enrollment in the STCS, no patient selection process is involved in the 
design [82, 83]. The STCS is unique as it includes not only a comprehensive set of 
biomedical and genetic data yet also includes a psychosocial data collection from pre to 
lifelong post Tx. SQ, health status and depressive symptomatology are parameters assessed 
in this regard. We used therefore data already collected by the STCS. 
Sample and Setting 
For this analysis we included all single first kidney, liver, lung, and heart Tx recipients till 
a re-transplantation, death, graft loss or drop-out, aged 18 years or older; German, 
French, English or Italian speaking; able to self-complete the STCS Psychosocial 
Questionnaire. For the analysis, we included only the patients who had complete data on 
SQ for at least two of five measurement times (pre Tx, 6, 12, 24 and 36 months post Tx) 
(Figure 2). 
Figure 2: Design of Swiss Transplant Cohort Study in view of sleep quality 
 
Legend:       =psychosocial questionnaire assessing for example sleep and depression 
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Variables and Measurements 
As mentioned, the STCS collects biomedical and psychosocial variables [83]. The 
psychosocial questionnaire data collection points are: pre Tx at time of listing (or inclusion 
in STCS for patients already on the waiting list on May 2nd 2008); at 6 months post Tx, 1 
year post Tx and yearly thereafter.  
Socio-demographic variables 
Demographic characteristics as age (in years) and gender and clinical variables 
(transplanted organ type) were abstracted from the STCS database. Other socio-
demographic factors were assessed by the psychosocial questionnaire including educational 
level and living situation. 
Sleep quality 
Sleep quality (SQ) was assessed with one item derived from the ‘Kidney Disease 
Quality of Life-Short Form’ initially developed for patients with end stage renal disease 
[84]. Patients were asked, “On a scale of 0 to 10, how would you rate your sleep quality 
overall?”, where 0 represents ‘very bad’ and 10 represents ‘very good’. Values lower than 
6 were used in this study to define poor SQ. This SQ item has been validated in view of 
evidence based on content and evidence in view of relationships to other variables [85]. 
Content validity was assessed using the content validity index (CVI: .81); concurrent 
validity by comparing the scale to the Pittsburgh Sleep Quality Index (rs: -.737 p<.01) and 
discriminate validity by examining associations with depression and quality of life [85]. 
Predictive validity with regard to mortality in hemodialysis patients has been 
demonstrated with the Dialysis Outcome and Practice Pattern Study data assessing SQ at 4 
months intervals [9, 84].  
Health Status 
Health status is assessed with the visual analogue scale (VAS) [77]. This scale is part 
of the standardized measure of health related quality of life developed by the EuroQol 
Group [86], in order to provide a simple, generic measure of health status for clinical and 
economic appraisal. This item records the respondents self-rated health on a vertical 
drawn scale, whereby the endpoints are labeled ‘Best imaginable health state’ (value = 
100) and ‘Worst imaginable health state’ (value = 0). This item has shown validity for the 
measurement of health status in RTx patients [87]. 
Depressive symptomatology 
Depressive symptomatology was measured with the 7-item subscale of the Hospital 
Anxiety and Depression Scale (HADS), a self-reported non-diagnostic screening instrument 
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and developed to assess cognitive symptoms of anxiety and depression in medically ill 
patients. The HADS is widely used and well validated as a screening instrument for 
depression in the general medical population, and, to some extent, in the context of RTx 
[88]. Each item has 4 choice possibilities (i.e.: not at all, not often, sometimes, most of 
the times) that are transformed into values from 0 to 3. Total score is calculated by 
summarizing the items in a score ranging from 0 to 21. A score of 8 or more indicates 
presence of depressive symptomatology based on sensitivity and specificity [89]. It has 
been shown in clinical group comparisons and in studies with several aspects of disease and 
quality of life that the HADS gives clinically meaningful results as a psychological screening 
tool. It is sensitive to change both during the course of disease and in response to medical 
and psychological interventions [90]. 
Data collection 
Data collection follows the description of Koller et al [82] and De Geest et al [83]. 
Organ Tx candidates are invited to be part of the STCS, upon providing written informed 
consent [83]. Psychosocial questionnaire data collection started in May 2008. Data 
collection at follow-up, occur either at a scheduled appointment or at home after mailing 
patients the PSQ which they return in a pre-addressed, pre-stamped envelope. 
Completeness of the PSQ is checked by the local STCS data managers in the local Swiss Tx 
centers, where data are entered into a centrally managed database. Further details on 
data collection in the STCS have been published elsewhere [82, 83]. The STCS was 
approved by the ethical committees of the 6 participating Tx centers.  
Statistical analysis 
Descriptive analysis on sample characteristics included frequencies, proportions, measures 
of central tendency (mean, median) and of dispersion (standard deviation, interquartile 
range) as appropriate, based on measurement level and distribution.  
Modeling of SQ and health status across time and organs was performed using generalized 
linear mixed modeling. In both instances, ‘patient’ was added as random variable. Next to 
entering transplanted organ and time into the equation, we controlled for the following 
confounding variables: age, gender, depression and the number of months between the 
pre-Tx measurement and the Tx date. Changes over time were plotted for the different 
organs. We only included an interaction term between time and organ if observation of the 
data indicates that different organs showed different trajectories with regard to the 
outcome variable over time, in which case we used contrast statements to answer specific 
hypotheses e.g. differences between specific organs. Analyses were performed in SAS 9.1.3 
(SAS Institute Inc., Cary, NC, USA). The alpha level was set at 5%. 
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6.4. Results 
Sample characteristics 
A total of 2260 patients were included in the STCS by December 31st 2011 of which 
1686 patients were eligible for this study based on the inclusion criteria. At the pre-Tx 
assessment 1051 patients were waiting for a kidney, 317 for a liver, 188 for a lung and 130 
for a heart Tx. Over the course of the follow up period, the sample size decreased 
progressively as this is an open progressive cohort study which is enrolling new patients on 
a continuous basis (Figure 3) and has not yet reached steady state. A description of the 
sample can be found in Table 1. At enrollment, the mean age was 52.66 ± 13.00 years and 
64.53% were male. 
Figure 3: Flowchart showing the sample as selected from the STCS overall sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total Kidney Liver  Lung Heart 
Pre-Tx 1686 1051 317 188 130 
6 months post-Tx 1216 774 226 134 82 
12 months post-Tx 1050 673 187 115 75 
24 months post Tx 
36 months post Tx 
739 
452 
500 
295 
117 
84 
72 
44 
50 
29 
Patients in baseline 
data set N=2400 
N=2260 
No informed consent provided 
 
Below 18 years at time of pre-Tx assessment 
 N=2145 
Baseline PSQ available 
 N=1818 
Multiple transplants 
 N=1822 
N=1785 
Patients with kidney, heart, liver or lung 
transplants 
 
Sleep data present 
N=1686 
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Table 1: Sample characteristics at time of pre-transplantation and of six months post 
transplantation for all organs 
Variable   Pre-Tx  
Age  Mean (std) in years 52.66 
±13.00 
Gender  Male – N (%) 1088 (64.53) 
Marital status  Single – N (%) 287 (17.02) 
Married/living together – N (%) 1120 (66.43) 
 Widow/widower – N (%) 50 (2.97) 
 Divorced – N (%) 171 (10.14) 
 Separated – N (%) 42 (2.49) 
  Answer refused – N (%) 16 (0.95) 
Highest 
completed 
educational 
degree  
No completed school or professional education – N (%) 80 (4.74) 
Mandatory school (9 years in Switzerland) – N (%) 394 (23.37) 
Finished apprenticeship – N (%) 647 (38.37) 
Higher professional education – N (%) 95 (5.63) 
Higher technical or commercial school – N (%) 50 (4.69) 
 Bachelor – N (%) 149 (8.84) 
 University – N (%) 155 (9.19) 
 Other – N (%) 81 (4.80) 
Health-related 
Quality of Life  
Mean (std)  56.17 
(22.42) 
Depressive 
symptomatology  
Mean (std)  8.76 (1.79) 
Depressive symptomatology N (%) 1322 (79.35) 
Organ type  Kidney – N (%) 1051 (62.69) 
Liver – N (%) 317 (18.81) 
 Lung – N (%) 188 (10.06) 
  Heart – N (%) 130 (7.71) 
Time between 
inclusion in 
STCS and Tx  
Median (25th & 75th Percentile) in mo 4.23 (0.2-
12.4) 
 
Legend: Tx= transplantation; STCS (Swiss Transplant Cohort Study) 
 
Sleep quality  
Prevalence of overall poor SQ was 37.84% at pre Tx, 31.58% at 6 months post Tx, 
28.19% at 12 months, 27.20% at 24 months post Tx and 28.54% at 36 months post Tx (Table 
2).  
The slopes per organ are extremely different: LiTx recipients seems to profit most 
from transplantation until 2 years post Tx, however at the 3 year assessment poor SQ (38%) 
increases to the 6 months post Tx level (37%). Similar is the slope for HTx. An improvement 
after Tx followed by a steady state and a mayor improvement at 3 year. LuTx recipients 
are the only group that shows a slight increase of the poor SQ prevalence at 6 months post 
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Tx. At 1 year post Tx the prevalence decreases, followed by an impressive increase in 
recipients with poor SQ, with higher prevalence compared to pre and 6 months post Tx. 
RTx recipients showed a steady decreasing prevalence over time (Table 3). The 
improvement seen in Figure 4 until one year and subsequent leveling off is confirmed by 
the fact that the drop in occurrence of poor SQ pre Tx to 12 months is significant 
(p<.0001), whereas the differences month 12, 24 and 36 are not.  
Figure 3: Percentage of poor sleep quality at time of listing till 3 years post-Tx (overall & 
per Tx group) 
 
 
Table 2: Descriptive statistics of poor sleep quality over time by organ  
 
    
All 
organs Kidney  Liver  Lung  Heart  
At pre-Tx 
N total 1686 1051 317 188 130 
N poor SQ 638 362 162 57 57 
% poor SQ 37.84 34.44 51.1 30.32 43.85 
At 6 months post Tx 
N total 1216 774 226 134 82 
N poor SQ 384 230 84 43 27 
% poor SQ 31.58 29.72 37.17 32.09 32.93 
At 12 months post Tx 
N total 1050 673 187 115 75 
N poor SQ 296 186 60 26 24 
% poor SQ 28.19 27.64 32.09 22.61 32 
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At 24 months post Tx 
N total 739 500 117 72 50 
N poor SQ 201 134 28 23 16 
% poor SQ 27.2 26.8 23.93 31.94 32 
At 36 months post Tx 
N total 452 295 84 44 29 
N poor SQ 129 76 32 15 6 
% poor SQ 28.54 25.76 38.1 34.09 20.69 
       
Legend: SQ = Sleep quality; Poor SQ = Poor SQ (cut-off<6) 
 
Table 3: Modeling poor SQ: differences in SQ between measurement points and organs 
Parameters Contrast 
Odds ratio 
(95% confidence 
interval) 
Chi² 
value p-value| 
Intercept  -2.44 (-3.04;-1.84) 64.19 <.0001 
Age  0.99 (0.99-1.00) 0.06 0.8011 
Gender  1.31 (1.00-1.57) 9.01 0.0027 
Depressive symptoms  1.16 (1.11-1.22) 47.16 <.0001 
Number of months 
pre-transplant 
 
1.00 (0.99-1.00) 0.07 0.79 
Organ Kidney vs Liver 0.66 (0.53-0.81) 14.90 0.0001 
 Lung vs Liver 0.64 (0.46-0.89) 7.06 0.0079 
 Heart vs Liver 0.91 (0.62-1.33) 0.23 0.6319 
 Lung vs Kidney 0.98 (0.73-1.30) 0.01 0.9278 
 Heart vs Kidney 1.38 (0.97-1.96) 3.25 0.0714 
 Heart vs Lung 1.41 (0.92-2.18) 2.48 0.1154 
Measurement point 6 months post Tx vs pre-Tx 1.30 (1.13-1.49) 14.19 0.0002 
 12 months post Tx vs 6 months post Tx 0.83 (0.71-0.96) 6.06 0.0138 
 24 months post Tx vs 6 months post Tx 0.79 (0.66-0.94) 6.65 0.0099 
 24 months post Tx vs 12 months post Tx 0.96 (0.80-1.14) 0.22 0.6370 
 36 months post Tx vs 6 months post Tx 0.84 (0.67-1.04) 2.40 0.1210 
 36 months post Tx vs 12 months post Tx 1.02 (0.82-1.26) 0.02 0.8795 
 36 months post Tx vs 24 months post Tx 1.06 (0.86-1.30) 0.32 0.5709 
 
Health-status 
SQ significantly predicted patient’s health status (p<.0001). Those with poor SQ 
scored on average 10 points lower on the 100-points VAS scale measuring health status 
(Table 4). 
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Table 4: Modeling Health-Related Quality of Life: prediction by sleep quality  
Parameters Contrast Estimate 
Standard 
Error 
DF t value p| 
Intercept   64.67 2.72 1663 23.82 <.0001 
Sleep 
Optimal vs 
suboptimal 
11.21 0.56 3283 19.89 <.0001 
Age   -0.03 0.03 3283 -1.1 0.2715 
Gender   -0.06 0.75 3283 -0.08 0.9393 
Depressive symptoms   -0.47 0.15 3283 -3.09 0.002 
Number of months 
pre-transplant 
  -0.07 0.03 3283 -2 0.0454 
Measurement point 0 -15.55 0.83 3283 -18.75 <.0001 
  6 -0.49 0.85 3283 -0.57 0.5657 
  12 1.87 0.86 3283 2.17 0.0303 
  24 1.48 0.90 3283 1.64 0.101 
  36 0.00 . . . . 
Organ Heart 1.00 1.68 3283 0.59 0.5529 
  Kidney 8.50 1.15 3283 7.38 <.0001 
  Liver 5.54 1.35 3283 4.12 <.0001 
  Lung 0.00 . . . . 
 
6.5. Discussion 
This study provided relevant clinical insights in view of prevalence and evolution of poor 
SQ in the different solid organ Tx recipients. This study also provided insights that SQ has 
an impact on health status being the first step in the exploration of the clinical importance 
of health status in solid organ Tx. This paper reports to our knowledge the largest study 
sample of self-reported SQ in solid organ Tx recipients simultaneously studied with the 
same methods.  
Poor SQ is prevalent from pre to post Tx, showing variability among organ groups. SQ 
improved significantly from pre to post Tx over all organs, confirming sleep studies in solid 
organ Tx recipients. Our prevalence for pre RTx is around 15% lower than the prevalence 
reported in the Dialysis Outcomes and Practice Patterns Study (49%) [9]. The prevalence at 
6 months is 7% lower and at 1 year 11% lower than the study of Silva et al. (2012) (36.7% 
respectively 38.3%) including only a small sample of 60 RTx[14]. Compared to the recent 
study of Reilly-Spong et al. [91] (41.6%) we had a 15% lower prevalence. Overall SQ 
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improved after RTx, remaining on 27% to 27% to 26% plateau level at 1, 2 and 3 year post 
Tx, suggesting a chronification of sleep disturbances.  
In LiTx patients we found as well lower prevalence compared to other reports. Compared 
to the study of Rodrigue et al (2010) (73% respectively 77%) we had 22% lower prevalence 
at pre LiTx and 40% lower at post LiTx [70]. We assume that these two small studies might 
be biased as patients having a poor SQ were more inclined to fill in a survey about sleep. 
Compared to 25 LiTx transplanted in the mean 4.5±4.9 years ago (48% poor SQ) we had a 
11% lover prevalence[91]. 
For HTx and LuTx recipients there is only one study that measured sleep quality in a 
sample of 13 HTx and 12 LuTx[91] recipients. The prevalence was 38.5% of poor HTx 
sleepers assessed in the mean 9.5±6.1 year after Tx and 27.3% at 3.4±3.5 year after 
LuTx[91]. Our prevalence at 3 years are 17% lover for HTx and 6% higher for LuTx. We hope 
that the small sample biased the results and that Reilly-Spong et al. overestimated the 
prevalence for HTx and that we overestimated the prevalence for LTx. 
The prevalence data found in our study are lower than other study reports however higher 
as population based prevalence (4% of poor SQ in a face to face interview study including a 
sample of 2559 [92]). Poor SQ was highest pre LiTx (51%) and lowest in LuTx (30%) 
patients. A reason for this huge difference might be that for liver patients the Tx priority is 
determined by the MELD (model for end-stage liver disease) score [93], implying that pre-
Tx patients have a very low heath status [94]. Two years post LiTx the prevalence is 24% (a 
27% drop) this is in line with the quality of life improvement after LiTx [95].  
We were surprised by the low prevalence of poor SQ in pre LuTx patients, as another 
studies reported a high prevalence of sleep apnea (44%) [71]. However sleep apnea and 
insufficient breath with hypercarbia might have hindered the awareness of the real 
seriousness of poor SQ [96]. This prevalence is contrasting with the low prevalence at 1 
year post LuTx (22%) and the high prevalence (34%) three years post LuTx. This worsening 
result might be looming a beginning condition of infection or broncholithiasis obliterans: 
according to the most recent data of International Society for Heart and Lung 
Transplantation (ISHLT), actual survival is 79%, 63%, 52% and 29% at 1, 3, 5 and 10 years 
respectively, with a current overall survival half-life of 5.3 years, and more than 7 years 
for those who survived 1 year or more [97]. However, survival depends on different 
parameters such as underlying disease, data relative to the donor, the recipient and/or the 
Tx procedure [98]. The most frequent causes of death between 1 and 3 years post-lung Tx 
are broncholithiasis (25.4%), infection (22.9%) and graft failure (19.3%) [99]. Another 
hypothesis for the worsening is the increase in prevalence of obstructive sleep apnea, 
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resulting from an increase in body weight and blood pressure[71, 72]. In addition this 
aggravation must be considered carefully as the sample size is very small (N=44). 
SQ improves significantly from pre (44%) to post Tx (21%) for HTx recipients. HTx recipients 
undergo very stringent selection criteria and some live with mechanically assisted 
circulatory support before Tx; that may be reflected in the positive trend for good SQ in 
these patients [100]. A further reason might be that heart failure patients require 
numerous medications that can affect sleep, such as beta blockers or antihypertensive 
drugs [101]. HTx recipients benefit most from Tx compared to the other solid organ 
transplant recipients,[102], in spite of high rate of graft failure (23%) [99]. According to 
the registry of the ISHLT, HTx recipients experience a major improvement in quality of life 
in the first year after Tx [103, 104], as can be seen from our results on SQ.  
Finally our analysis showed that pre Tx poor SQ is somewhat indicative for post Tx poor SQ. 
This fact highlights the importance of behavioral changes going along with the 
transplantation. As soon as the surgery is over new sleep-wake pattern and lifestyles have 
to be established. 
SQ significantly predicted patient’s health status, this is in line with the study of Silva et 
al. (2012) that reported that poor sleepers had lower scores in health related quality of 
life [14]. An area of future study might be to see if poor SQ could be a predictor of acute 
rejection and graft loss. Of high interest and relevance will be in a near future the analysis 
of the predictive value of SQ in view of mortality in the STCS. These data could then be 
compared to the Dialysis and Outcome Practice Pattern Study that is using the same 
measurement tool for SQ [9]. The regular assessment of psychosocial variables belonging to 
a chronically ill follow up program is becoming of increasing importance as short-term 
outcomes after Tx are good and long term outcomes need improvement. Psychosocial 
outcomes themselves influence long-term post Tx morbidity and mortality rates [105, 106]. 
For clinical practice the regular screening for poor SQ and health status and the following 
assessment in case of a positive screening might be preventive for chronic sleep disorders, 
subtle infections or heath status deterioration. Interventions to counteract this high 
prevalence of poor SQ must be evaluated from pre to post Tx including comorbid 
conditions bearing the risk of aggravating the already poor SQ or to trigger a new 
condition.  
Limitation of Study 
This study was a secondary data analysis using data from the STCS. The psychosocial 
questionnaire including SQ, depressive symptomatology and health status had an item 
restriction to keep the participant’s burden low, in addition these items are unspecific and 
therefore not comparable to full assessment questionnaires, yet they showed validity (see 
Chapter 6 
 
176 
method section). Further, we included only the most frequent Tx organ groups (heart, 
liver, lung, and kidney) to have large sub samples and enough statistical power for the 
inferential analysis. This prospective cohort study that did not reach yet steady state has 
decreasing sample sizes per organ group over time. As the cohort study started in 2008, we 
did not have data on 24 months follow up on patients included in 2010. However, the STCS 
will allow us to follow up SQ of patients for the next years. Furthermore, a reassessment 
for patients on the waiting list is planned to have more precise assessments pre-Tx. 
Conclusion 
Poor SQ affects around a third of Tx recipients. In addition, SQ improves following 
Tx, however, variability among organ Tx groups exists. As we reported that sleep predict 
health status, we have a further argument to increase the awareness for sleep disorders in 
solid organ Tx recipients. However, further analyses on our data registry are necessary to 
evaluate the predictive validity of this cut-off value for negative patient outcomes, such as 
graft loss and mortality. 
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7.1. Abstract  
Background 
The aim of this study was to evaluate the feasibility and the outcomes of morning light 
therapy in renal transplant (RTx) recipients with diagnosed sleep-wake disturbances 
(primary outcome: bedtime; secondary outcome: circadian and sleep parameters, 
depressive symptomatology, subjective feelings and cognitive executive function). 
Methods 
A randomized controlled wait-listed pilot trial was conducted. Thirty home-dwelling RTx 
recipients (aged 59.6±12.6y) were assigned 1:1 to the intervention group (3 times 3 weeks: 
baseline, intervention, follow-up) or wait listed group (intervention after 9 weeks usual 
care). Morning light (10’000 lux) was individually scheduled for 30 min daily over a 3-week 
period. Subjects' rest-activity cycles were monitored with wrist actimeters (sleep and 
circadian data). Data were analysed using a random-intercept regression model to test 
group*time interaction. A secondary analysis included full wait listed design (pre-post 
analysis) intervention data. 
Results 
Light therapy was feasible and induced a phase advance in bedtime (20 min) and get-up 
time (25 min). The pre-post analysis showed a phase advance only in get-up time only. 
Light therapy improved mood in the whole group without affecting cognitive executive 
function. 
Conclusion 
This is the first evidence for a beneficial effect of light therapy on sleep and mood in RTx 
recipients with sleep-wake disturbances. 
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7.2. Introduction  
About half (49%) of RTx recipients report poor sleep quality [1, 2] and/or poor daytime 
functioning (34.1%)[1] and 51% say they suffer from daytime sleepiness[2]. The prevalence 
is 8% for insomnia[3] (inability to fall asleep or to stay asleep as long as desired), 4.5% for 
restless legs syndrome[4] and 27% for obstructive sleep apnea[5]. In the previous study, 
belonging to this project we found that insomnia and sleep-wake disturbances are common 
among renal transplant (RTx) recipients[6]; nearly 30% of RTx recipients reported that they 
suffer impaired daytime functioning because of night-time sleep disturbances, daytime 
sleepiness or fatigue[6]. In addition the mean chronotype score of the previous study 
ranging from 16 to 86 [58.61±9.94, mean age 57.73± 13.11 (unpublished data of Burkhalter 
et al.2013)] was lower (more evening chronotypes)[1] compared to a similar age group in 
the general population [7, 8]. Evening chronotypes manifest a delayed sleep phase 
characterized by inability to fall asleep or wake up at the desired time and excessive 
daytime sleepiness[9].  
Pharmacological treatment for sleep-wake disturbances in general population is very 
common[10]; however in RTx recipients only efficacious, reliable and safe drugs should be 
added to the lifelong immunosuppressive regimen. Interventions to reduce sleep-wake 
disturbances after transplantation are needed, and non-pharmacological strategies may be 
preferred due to the complexity of transplant medication regimens[11].  
 
Bright Light Therapy 
Light therapy via the eye is a low-risk non-pharmacological option for treating sleep-wake 
disturbances directly via the biological clock[12]. Neurones in the suprachiasmatic nuclei in 
the anterior hypothalamus generates the circadian rhythms and daily light impinging the 
retina resets their phase, determining the timing of sleep and wake[13]. Proper circadian 
entrainment (i.e. optimal synchronization of the endogenous circadian clock with the 
external 24-h light-dark cycle) is essential for good sleep and healthy functioning in 
general[14] and light is the most powerful agent to do this. Morning light can advance 
circadian rhythm phase (inhibiting the melatonin production), including the sleep-wake 
cycle (Figure 1). This has been applied to effectively treat delayed sleep phase syndrome 
with timed morning light[15, 16]. Light therapy has many applications with little risk of 
adverse side effects: side effects may include agitation, headache, or nausea – but they 
are all rapidly reversible by reducing light intensity or duration[17]. 
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Figure 1: The influence of light and darkness on the circadian rhythm of nocturnal 
melatonin secretion driven by the suprachiasmatic nuclei  
 
 
 
 
Bright light therapy and sleep-wake rhythm consolidation 
Light therapy is used to synchronize abnormal sleep-wake cycles with the external 
environment[18]. This consolidation is hypothesized to improve mood[19], depressive 
symptomatology[20], sleep disturbances[21], and performance (e.g.: reaction time)[22]. In 
addition, light triggers the brain’s production of serotonin (a major neurotransmitter 
involved in mood regulation)[23]. Two meta-analysis have published effect sizes for light 
therapy in non-seasonal depression (ES: 0.84 (95% CI, 0.60–1.08)[24] and (ES: 0.53; 95% CI, 
0.18–0.89)[25] and in seasonal depression (ES: 0.73; 95% CI, 0.37–1.08)[24]. Persons with 
Alzheimer’s disease or related dementia have often a pronounced circadian disruption[12] 
and many studies showed improvements in nighttime sleep and increased daytime 
wakefulness as well as mood and cognition with light therapy. In particular a randomized 
double blind placebo controlled long term intervention showed significant attenuation on 
cognitive deterioration, ameliorated depressive symptoms and improved activities of daily 
living[26] and a further randomized controlled trial with seniors in long term care showed 
significant improvement in cognition[27]. In internal medicine, a pilot study has applied 
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light therapy to sleep-wake disturbances in cirrhosis patients[28]. To our knowledge, there 
are no studies that evaluated a light therapy treatment in RTx recipients. 
To address sleep-wake disturbances in RTx recipients we conducted a randomized 
controlled pilot trial to test the feasibility and the effect of morning bright light therapy 
and its effect on a number of selected functional categories: directly sleep-related 
(bedtime, get-up time, sleep latency and sleep efficiency) and circadian-related 
(characteristics of the sleep-wake cycle such as interdaily stability [IS], intradaily 
variability [IV], relative amplitude [RA][29]) - both evaluated from actimetry; timing of 
nocturnal secretion of the pineal hormone melatonin, the major circadian marker that can 
be measured in saliva (defined as Dim Light Melatonin Onset (DLMO); mood [depressive 
symptomatology[30] and subjective feeling scales]; and cognitive executive function 
[Stroop task[31]].  
The aim of this pilot study was to evaluate the feasibility and outcomes of morning light 
therapy on phase advancing bedtime (primary outcome), circadian and sleep parameters, 
depressive symptomatology, subjective feeling and cognitive executive function (secondary 
outcomes) in RTx recipients diagnosed with sleep-wake disturbances. 
 
7.3. Material & Methods 
Design 
We used a randomized controlled pilot wait-listed design with a 1:1 randomisation 
sequence. The intervention group received morning light therapy early (after 3 weeks), 
while the control group received usual care and bright light therapy following completion 
of the RCT (after 9 weeks) (figure 2). The group the participant was randomized to, was 
concealed from the research team until each RTx recipient opened the envelope 
containing their group information. 
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Figure 2: Randomized controlled wait-listed design including the pre-post design for the 
analysis of the early and late intervention  
 
Legend: T= Time period; DASS 21= Depression, anxiety and stress scale; Stroop task = 
Colour-word interference task to measure cognitive process;    grey  = analysis of the early 
and late intervention; a= Measurement only for the early group; b= Measurement only for 
late group. 
 
Participants, eligibility criteria, and setting 
Participants were recruited at the University Hospitals of Basel, Bern and Zurich from a 
prior study assessing sleep disturbances in adult, home-dwelling RTx recipients[6]. Patients 
previously diagnosed with sleep-wake disturbances were asked to participate in the 
current study. The inclusion criteria were: adult RTx recipients more than 1 year post-
transplant; German speaking; on stable immunosuppressive drugs; no signs of acute organ 
rejection; normal ocular function (by self-report and by chart review) and diagnosed with 
sleep-wake disturbances in the prior study. Exclusion criteria were: acute illness or 
hospitalization.  
Bright Light Therapy Intervention 
Bright light therapy was realized by a bright light box (Philips: bright light Energy HF 3304) 
that each participant received at home. The primary investigator (HB) instructed 
participants on its use. To provide the appropriate intensity (10’000 lux), patients were 
instructed to sit 30-50 cm from the lamp at eye level for 30 minutes every day at the time 
determined by their individual chronotype[6]. We allowed for a 1.5 h deviation from the 
theoretical optimum starting time.  
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Measures 
Bedtime (Primary outcome) 
Bedtime was measured with actimetry (movements of the non-dominant wrist) which 
collects motor activity at 1 min intervals to provide a 24-hour pattern of rest and activity, 
and indirectly, characteristics of sleep. Actimetry has been established as a reliable and 
objective method for the naturalistic study of sleep and wakefulness[32]. Over the entire 
study period, the participants were instructed to continuously wear a wrist-worn 
combination actimeter/light monitor (Daqtometer® by Daqtix GbR, Oetzen Germany)[33]. 
We were unable to use the light exposure data gathered, since several of the participants' 
wrist-worn light monitors were covered by their sleeves a lot of the time. This data would 
have allowed monitoring both adherence to the intervention and overall individual light 
exposure. 
The participants were also provided with diaries in which to log 6 daily items: the time 
they went to bed, the time the lights were turned off, their perceptions of how long it 
took them to fall asleep, the time(s) they got up during the night, the time(s) they awoke, 
and the time period the actimeter was off their wrist[34]. Activity data gaps during the 
daytime, reflecting actimeter removal (e.g., to shower) reported in the diary, were 
replaced with the average activity counts for that 24-h period. If no data were recorded 
for more than 3 hours in any given day, that day was excluded from further analysis. 
Actimetry data were analysed using Sleep and Activity Analysis Software 7.23V (Cambridge 
Neurotechnology Ltd, UK).  
Secondary outcomes 
Sleep and circadian parameters from the rest-activity cycle 
Actimetry data were edited with the self-reported diary of the participant following 
standardized criteria[32]. The actimetry software generates one value for each day. Three 
sleep parameters were assessed via actimetry data: (1) get-up time, (2) sleep latency, and 
(3) sleep efficiency. For circadian parameters of the sleep-wake cycle, non-parametric 
circadian rhythm analysis were used over the 3 week periods: interdaily stability (IS), 
intradaily variability (IV), and relative amplitude (RA) [29]. IS indicates the strength of the 
association between the rest-activity rhythm and the day-night cycle (the consistency of 
activity patterns across the individual days)[29]. The IV index indicates the degree to 
which the subject's sleep rhythm is fragmented (comparing days over a week). Each day's 
RA was calculated from the ratio of the most active 10-h period to the least active 5-h 
period across the averaged 24-h profile[35]. The RA’s are the oscillation amplitude divided 
by the overall mean. 
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Circadian marker (DLMO) 
Dim Light Melatonin Onset (DLMO) is the most reliable marker for human circadian phase 
position, and it can be assayed in sequential evening blood or saliva sampling[36]. To 
determine participants' DLMOs, saliva samples were self-collected using Salivettes 
(Sarstedt AG, Switzerland) over 3 evening periods. For each 24-hour collection period, 
each participant collected up to 11 samples and stored them in his refrigerator: at 1-h 
intervals starting 5 h before and ending at bedtime, at wake-up, on getting up, 1 and 2 h 
after rising, midday and 3pm. The sleep diary included reminders of patients' sampling 
days and times, a checklist for the sampling times and six pictures showing the sample 
collection procedure. 
Melatonin was measured via direct double-antibody radioimmunoassay with an analytical 
sensitivity of 0.2 pg/ml and a functional minimum detectable dose of 0.65 pg/ml 
(Bühlmann Laboratories AG, Allschwil / Switzerland)[37]. DLMO was calculated using the 
Hockey-stick method developed by Danilenko et al.[38] based on the five melatonin values 
collected before bedtime. Saliva melatonin shows normally values during the day below 3 
pg/ml and before bedtime levels up to 10 pg/ml[39] with large individual variability in the 
amount of melatonin secreted with peak values ranging from 2 to 84 pg/ml[40] 
Depressive symptomatology 
Depressive symptomatology was assessed via the Depression, Anxiety and Stress Scale 
(DASS 21), a 21-item self-report instrument (see figure 2 for assessment times). The DASS 
21 measures depressive symptomatology via seven items utilizing a 4-point Likert-type 
severity / frequency scale, on which patients rate the extent to which they experienced 
each state over the past week (0 = did not apply to me; 3 = applied to me very much). 
Only the DASS–depression score (0-4 no depressive symptomatology; 5-6 mild, 7-10 
moderate, 11-13 severe and 14 extremely severe) is reported here[30]. The DASS-21 has 
strong construct[41] and concurrent validity[42] in depressed patients and primary care 
patients[41].  
Subjective feelings 
Subjective feelings (relaxed; physical well-being; alertness, feel sated; mood) were 
assessed daily via diary before bedtime and at get up time on a visual analogue scale from 
0 to 10.  
Cognitive executive function 
Attention, cognitive flexibility and reaction time (executive function) were measured via 
the Stroop color–word interference task [31]. This task has three parts: (1) reading 74 
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colour words printed in black on a white background, (2) reading 74 coloured ink printed 
rectangles and (3) naming 74 colour words printed in non-matching colours. Each part is 
associated with a large decrease in colour naming speed, i.e., “the colour-word 
interference effect”. The task was administered by a member of the research team 2 
respectively 3 times (days 1, 63, and 84). Following the task manual, the time measures 
for each task were analysed for the mean of the interference t-score[43].  
Treatment satisfaction 
At the end of the diary, as a proxy measure for satisfaction, subjects were asked whether 
they would recommend light therapy to a friend (yes/ no), and whether they felt light 
therapy was efficacious (yes/no). 
Feasibility 
Feasibility was measured with the proportion of participants that stayed in the study until 
the end, number of adverse events or side effects and number of extra calls and visits due 
to problems with the study equipment. 
Clinical characteristics 
Clinical characteristics (age in years, gender, years since transplantation, BMI 
(kg/m2), creatinine level (μmol/l), haemoglobin level (g/l) and medications used (including 
sleep drugs)) were retrieved from the participants’ hospital medical charts. Comorbidity 
data were also extracted from patients’ charts and categorized using the Charlson 
comorbidity index[44]. Sleep quality (measured with the Pittsburgh Sleep quality Index), 
daytime sleepiness (measured with the Epworth Sleepiness Scale), and chronotype 
(measured with the Morningness-Eveningness questionnaire) were extracted from the 
preceding study[6] (Table 1). 
Data collection 
The current study was approved by the ethics commissions of Basel, Bern and Zürich. Data 
collection was from December 2010 until September 2012. After providing written 
informed consent, participants were contacted by telephone to arrange a home visit during 
which the researcher explained the study details and answer any questions. At the first 
home visit, the participant opened a randomly allocated opaque envelope containing the 
message early light therapy or the message late light therapy. The actimeter was then 
activated and the respective sleep diary containing information for the early or late light 
therapy was explained. The researcher gave the light box and saliva melatonin kit with 
written and oral information on light box use and saliva melatonin collection to 
participants of both groups during the initial visit. Salivette® samples were to be stored in 
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the participant's home freezer until collected at the end of the study by the first author. 
Participants were provided with the researcher's telephone in case they had questions or 
needed assistance. Follow up calls were planned individually, as the respective diary told 
the participant each day what to do. At least once, specifically on day 63, the researcher 
called each RTx recipient to administer the Stroop task. At study's end, subjects received 
160 Euro as a token of appreciation for their cooperation. 
Statistical analysis 
Descriptive statistics were used as appropriate for the level of measurement and 
distribution. The primary and secondary outcome measures were summarized using 
appropriate descriptive statistics. Hypothesis testing for the RCT was performed via linear 
mixed regression modelling, to which we added ‘patient’ as a random effect and ‘group 
assignment’, ‘time point’ (baseline, intervention, post-intervention) and their interaction 
term as fixed effects, using an unstructured working correlation matrix. We also analysed 
the late intervention data of the control group by pooling them with the data of the early 
intervention group and performing a pre-post analysis using the three weeks' data 
preceding the intervention as baseline data (for the outcome variables of bedtime, get-up 
time, sleep efficiency and sleep latency). Effect sizes were calculated as the standardized 
estimate of the interaction coefficient (RCT) and the time variable (late intervention 
data). For the post-hoc analysis, we controlled for the presence of beta-blockers (BB) and 
(acetylsalicylic acid) ASA. Analyses were performed with the mixed procedure in SAS 9.1.3 
(SAS Institute Inc., Cary, NC, USA). 
7.4. Results 
Of 30 subjects who began the randomized controlled pilot wait-listed study, 14 received 
the early intervention and 14 the usual care. One subject in each group perceived the 
study too burdensome. Twenty-six completed the study (figure 3). Table 1 shows both 
groups' baseline demographics. There were no significant participant differences between 
groups and no meaningful clinical differences.  
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Figure 2: Flow diagram of sample 
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Table 1: Descriptive characteristics of the sample 
 
All (N=30) 
Early intervention 
(N=15) 
Usual care /Late 
intervention (N=15) 
 
N Percentage N Percentage N Percentage 
Centre 1 13 43.33 6 20 7 23.33 
Centre 2 4 13.33 2 6.67 2 6.67 
Centre 3 13 43.33 7 23.33 6 20 
Males 15 50 8 26.67 7 23.33 
       
 
Mean SD Mean SD Mean SD 
Age 59.63 12.65 60.72 10.33 58.54 14.91 
Years since Tx 12.65 6.6 10.33 6.83 14.91 6.6 
Chronotype (MEQ) 62.03 10.3 63 10.29 61.06 10.58 
Comorbidity Index (CCI) 1.47 1.63 1.8 1.79 1.13 1.46 
BMI kg/m² 25.12 5.51 24.44 3.69 25.8 6.95 
Crea µmol/L 144.88 50.94 145.92 60.92 143.85 41.14 
Hb g/l 123.42 11.73 122.86 14.47 124.2 7.92 
Sleep quality (PSQI) 12.3 3.41 13.27 2.84 11.33 3.75 
Daytime sleepiness (ESS) 7.9 3.65 7.93 4.01 7.87 3.4 
       
 
N Percentage N Percentage N Percentage 
Cyclosporin 14 46.67 5 33.33 9 60 
Tacrolimus 12 40 7 46.67 5 33.33 
Sirolimus/Everolimus 2 6.67 2 13.33 0 0 
Mycophenolate mofetil 18 60 9 60 9 60 
Azathioprine 7 23.33 3 20 4 26.67 
Corticosteroids 10 33.33 5 33.33 5 33.33 
Statin 15 50 9 60 6 40 
ACE  5 16.67 2 13.33 3 20 
ARB 14 46.67 7 46.67 7 46.67 
CCB 2 6.67 1 6.67 1 6.67 
B-blocker 11 36.67 6 40 5 33.33 
Diuretika 5 16.67 3 20 2 13.33 
Anticoagulants 9 30 4 26.67 5 33.33 
Acetylsalicine  10 33.33 5 33.33 5 33.33 
Oral antidiabetica 1 3.33 0 0 1 6.67 
Antidepressiva 5 16.67 2 13.33 3 20 
Anxiolytika 1 3.33 1 6.67 0 0 
Antiepilepitica 3 10 3 20 0 0 
Benzodiazepine 1 3.33 0 0 1 6.67 
 
Legend: SD = Standard deviation; MEQ = Morning Eveningness Questionnaire [16-52 evening type; 53-64 
normal type; 65-86 morning type] ; CCI = Charlson Comorbidity Index;  PSQI = Pittsburgh Sleep Quality 
Index [Score >5 means poor sleep quality]; ESS = Epworth Sleepiness Scale [Score >10 means daytime 
sleepiness]; BMI = Body Mass Index; Crea = Creatinine; Hb = Haemoglobin; ACE = angiotensin-
converting-enzyme inhibitor; ARB = angiotensin receptor blocker; CCB = Calcium-channel blockers; 
Randomized Trial Results 
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Primary outcome 
Morning light therapy showed a significant phase advance for get-up time from baseline to 
intervention (+24 min) and a small (+14 min) but significant phase advance for bedtime 
from intervention to follow-up (Table 2 and Figure 4). A phase advance was specified with 
a plus sign and a delay with a minus.  
Figure 4: Bedtime and get up time for the three measurement periods   
 
 
 
 
 
 
 
 
Legend: * = significant outcome; + = Phase advance; - = Phase delay 
 
Secondary outcomes 
Night time sleep latency decreased slightly (-7 min) during therapy and increased again at 
follow-up. The circadian parameters showed no differences. The circadian hormonal 
marker (DLMO) was not significantly changed for the early intervention group (baseline to 
intervention: -13 min and intervention to follow-up: +5 min); however, the usual care 
group, which was expected to remain stable, experienced an overall phase advance 
(baseline 1 to baseline 2: +1hour and 44 min). Figure 5 shows the very low melatonin 
values in our sample, that could have biased the DLMO analysis. Light therapy improved 
(not statistically significant) subjective feelings in the morning (well-being [+3 points on a 
scale from 0-10], alertness [+1] and mood [+3]) and depressive symptomatology in the 
intervention group (baseline-intervention: 5.92-5.75 and intervention to follow-up: 5.75-
4.08 [score >5 means depressive symptomatology]). Cognitive executive function was not 
modified. 
22:59 22:53 22:39 
22:29 22:36 22:34 
+6 Min +14 Min* 
+24 Min* +1 Min 
07:26 07:02 07:01 
07:14 07:10 07:08 
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+4 Min +2 Min 
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Get-up time 
Bedtime 
Get-up time 
Intervention 
group (N=12) 
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group (N=14) 
Randomisation 
Baseline 
Intervention Baseline 
Baseline Baseline 
Follow-up 
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Results of the analysis of the combined early and late intervention datasets 
For this pre-post design, we performed a post hoc analysis, adding baseline of the 
intervention group to baseline 3 of the usual care group and intervention of the early 
intervention group to intervention of the late intervention group (N=26). Morning light 
therapy showed a significant phase advance (+17 min) for get-up time from baseline to 
intervention (Table 2). Other measurements showed no significant effects.  
Table 2: Comparison of outcome variables with time 
 
Post-hoc subgroup analysis of the combined early and late intervention datasets 
Intriguing was the high incidence of low melatonin secretion in many patients (figure 5). 
Beta-blockers (BB) and acetylsalicylic acid (ASA) are known to suppress melatonin[45], 
however it is unclear whether ASA inhibits melatonin secretion via prostaglandin synthesis 
as is known for non-steroidal anti-inflammatory drugs[46].Therefore we postulated the 
following post-hoc hypotheses: RTx recipients taking BB and /or ASA will not show a light 
effect on phase advancing bedtime and get up time, and sleep efficiency and sleep latency 
will not improve. The Post-hoc subgroup analysis of the combined early and late 
intervention datasets showed that in total, 17 patients were taking BB and/or ASA, known 
to possibly block melatonin secretion. Compared to these 17, those using neither BB nor 
ASA showed a non-significant phase advance for both bedtime (SE: -0.08; 95%CI 0.25; 0.10) 
and get-up time (SE: 0.11; 95%CI -0.09; 0.31). A significant result for bedtime or get-up 
time, i.e., with a power of 80%, would require much larger samples (N=260,182 
respectively). For those taking neither BB nor ASA, sleep efficiency increased (4.9%) and 
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sleep latency decreased (6 min), both significantly (SE: 0.42; 95%CI 0.20; 0.65 and SE: -
0.28; 95%CI -0.45; -0.10 respectively), with powers of 87% for sleep efficiency and 96% for 
sleep latency.  
Figure 5: Saliva melatonin (pg/ml) profiles at baseline and after light therapy (N=26) 
 
 
 
 
Legend: Each color sequence represent one participant 
 
03       08         13 clock time 
03       08         13 clock time 
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Treatment satisfaction and adverse reaction 
Twenty of 25 subjects who answered the question wrote that they would recommend light 
therapy to a friend. However, only 13 reported that they considered it helpful. No adverse 
reactions or symptom complaints were registered. Only 2 participants stopped the study 
because it was “too burdensome” and there were no extra calls and visits due to problems 
with the study equipment. 
7.5. Discussion 
This is the first study testing the feasibility and the effect size of morning light therapy on 
improving sleep problems in a sample of chronically ill RTx recipients, measuring circadian 
and sleep parameters over several weeks. Morning light therapy phase advanced bedtime 
and get-up time, but circadian parameters, including the onset of nocturnal melatonin 
secretion, showed no earlier shift. Depressive symptomatology, mood and well-being 
improved, as did alertness, confirming this treatment's previously described benefits[47]. 
Light therapy had no effect on cognitive executive function, which was not impaired at 
baseline when compared with healthy similar age cohorts[48].  
Analysis of the combined early and late intervention data showed only a small phase 
advance after bright light therapy for get-up time, possibly indicating that participants 
adhered to the timing of the intervention resulting in a sleep restriction (because of the 
intervention participants had to get up). However, no direct impact of bright light therapy 
on bedtime was seen for the entire group. 
This relatively small improvement in sleep-wake function indicated that perhaps the 
treatment timing or dosing was inadequate or, that RTx recipients have more complex 
clinical problems that short-term light therapy cannot influence. This is suggested by the 
large inter-individual differences in response. Intriguing was the high incidence of low 
melatonin secretion in many of these patients. Most RTx recipients' medication regimens 
include co-treatment for cardiovascular prophylaxis[49], including BB and ASA[50]. The 
post-hoc analyses indicated a possible connection with BB and /or ASA use inhibiting 
melatonin secretion and thus indirectly affecting sleep. This suggests that BB treatment in 
these patients should preferably be with drugs not suppressing melatonin (nebivolol or 
carvedilol[51]), rather than bisoprolol, which may prevent development of sleep-wake 
disorders. Supplementation with melatonin should be considered, however with caution, as 
melatonin might interact with other drugs[52] and might cause sleepiness and 
dysphoria[53]. No studies have been published on melatonin supplementation in RTx 
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recipients, although it has shown short-term benefits in haemodialysis patients[54] 
regarding sleep efficiency, sleep duration and sleep fragmentation[55]. 
Another reason for the low saliva melatonin profiles could be the calcification of the pineal 
gland and the melatonin pathways[56, 57]. Most RTx recipients have a more or less 
pronounced renal failure that might result in disturbances of bone formation and 
degradation, biochemical blood changes increasing soft-tissue and blood vessel 
calcification. Depending on the therapy adherence for hyperphosphatemia and 
supplementation of active vitamin D, the calcification of the pineal gland and melatonin 
pathways may be more or less pronounced. 
The phase advance of +14 minutes for bedtime was statistically significant. The internal 
clock of humans has an endogenous circadian period of 24.18h [58]–roughly 12 minutes 
longer than the external 24-h day-night cycle–requiring daily phase-advancing 
synchronisation by zeitgebers, primarily light [58]. Thus, a phase advance of a quarter-
hour is also biologically meaningful. 
There are studies suggesting that increasing the duration of light therapy is more effective 
than increasing light intensity[59, 60]. Thus, our 30 minute light treatment may have been 
too brief, and longer expositions may be required – both per day and in number of weeks. 
An analogy is found in major depression – although patients with seasonal affective 
disorder generally improve with the 30 min regimen within two weeks[61], non-seasonal 
depressives require at least an hour of this intensity light for at least five weeks[62]. Using 
a lamp but prescribing additional regular time spent outdoors (where light intensity is 
much greater) may be an effective practicable combination. Another possible reason for 
the lack of a large effect could have been that we did not control the exposure to light in 
the evening, which may have cancelled out the morning light induced phase advance[22]. 
Here, the use of blue-blocking glasses in the evening, which prevent the strong phase 
delaying effect of blue wavelengths, may be helpful[63].  
Strengths and Limitations 
Compared to other RCT or pre-post studies using actimetry and measuring melatonin 
profiles, this was a large study[24]. However, as this was a pilot study, estimation of 
uncertainty in generalizability of relationships found was only of secondary interest; 
therefore no p-values are displayed and no alpha correction has been performed. Future 
studies could limit baseline to two weeks with a two-week follow-up (to reduce study 
burden), although we recommend 5 weeks of light therapy rather than three[47].  
Conclusion 
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This pilot study on the effect of morning light therapy on RTx patients' sleep disorders 
showed a phase advance in bedtime and get-up time and improved depressive mood. A 
number of hypothesis-generating analyses suggest that melatonin production inhibitors 
interfere with the optimal response to light therapy in this population. 
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CHAPTER 8  
GENERAL DISCUSSION OF THE DISSERTATION 
TITLED: “BRIGHT LIGHT THERAPY IN RENAL 
TRANSPLANT RECIPIENTS WITH SLEEP-WAKE 
DISTURBANCE” 
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8.1. Summary of key findings 
This final chapter considers the results of the studies included in this dissertation as a 
whole. Key findings are summarized (section 8.1) and presented in the discussion part 
(section 8.2) from a perspective that goes beyond the discussions of the individual 
manuscripts (Chapters 3 to7), and implications for clinical practice and future research 
are discussed. Our intention to contribute to the international scientific literature as well 
as expanding existing knowledge of sleep-wake disturbances in solid organ transplant 
recipients in Switzerland was achieved through the findings summarized below:  
Sleep survey data of 935 renal transplant recipients allowed us to establish content 
validity and validity in relation to other variables for the short, simple daytime sleepiness 
item (figure 1). Chapter 3 shows this item to be a valid tool to screen daytime sleepiness.  
 
Figure 1: The daytime sleepiness screening question  
 
For the first time the results supply prevalence data on daytime sleepiness in renal 
transplant recipients (51% [1]). These survey data were further used in a secondary data 
analysis (chapter 4) to test a hypothesized theory-based association between daytime 
sleepiness and immunosuppressive non-adherence. We based this hypothesis on the 
integrated model of behavioral prediction, which allowed us to identify an important 
factor (daytime sleepiness) of the immunosuppressive medication adherence outcome. The 
significant positive association between daytime sleepiness and taking, timing, and overall 
non-adherence to immunosuppressive drugs confirmed our hypothesis. These results can be 
implemented in strategies combating daytime sleepiness to improve medication 
adherence. 
As part of our research goal to understand the nature of sleep-wake disturbances, we 
administered sleep assessment interviews to 164 renal transplant patients. The 
respondents' most frequent disturbance was difficulty staying asleep, followed by problems 
falling asleep. The most common sleep disorder (42.5%) was insomnia, followed by 
circadian rhythm sleep disorders (20.1%) (Chapter 5). This is the first study to explore 
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sleep-wake disturbances in solid organ recipients following the diagnostic criteria used in 
sleep medicine. 
Using data from the Swiss Transplant Cohort Study (a prospective nation-wide cohort 
study), we conducted a secondary data analysis (N=1076) to describe the prevalence and 
variability of sleep quality from pre- to two years post-transplantation in kidney, liver, 
lung and heart recipients and to examine the association between impaired sleep quality 
and perceived health status. Our analyses revealed that sleep quality improved from pre- 
to post-transplantation, and that sleep quality predicted health status. The analysis of the 
sleep quality screening item at pre- and yearly post-solid organ transplantation showed 
that, of the four major organ transplantation groups, liver transplant recipients had the 
highest prevalence of poor sleep quality pre-transplantation. At six months post-
transplantation, all organ groups showed improved sleep quality, with prevalence of poor 
sleep quality stabilizing at 22-30%.  
Those individuals diagnosed with sleep-wake disturbances during the sleep assessment 
interview were invited to participate in a pilot randomized controlled bright light 
intervention study. The primary aim was to examine the impact of the intervention on 
bedtime (assessing whether light phase advanced their rhythm). As secondary outcomes, 
the impacts on circadian and sleep parameters, depressive symptomatology, mood and 
selective attention were also analysed. All members of the group (N=30) were treated with 
morning light therapy. They were randomized into two equal groups, with fifteen assigned 
to the intervention group (light therapy after a 3 week baseline assessment) and fifteen to 
the control group (light therapy after a 9 week baseline assessment, wait-listed). 
Compared to the control group, the intervention group showed significant phase 
advances in both bedtime and get-up time, i.e., 19 min and 22 min respectively. (The 
internal clock of humans has an endogenous circadian period of 24.18h [2]–roughly 12 
minutes longer than the external 24-h day-night cycle–requiring daily phase-advancing 
synchronisation by zeitgebers, primarily light.[2] Thus, a phase advance of a quarter-hour 
is biologically meaningful. A second analysis, using full wait-listed design (pre-post 
analysis) intervention data, showed a phase advance only in get-up time (17 min). As saliva 
melatonin profiles were extremely low, changes were difficult to detect. No significant 
phase advance could be determined in the intervention group. However, post-hoc analysis 
revealed that light therapy significantly increased sleep efficiency (4.9%) and decreased 
sleep latency (6 min) in renal transplant recipients taking neither beta-blockers nor 
acetylsalicylic acid (substances with known potentials to inhibit melatonin secretion). Light 
therapy also improved depression and mood in the entire group without affecting selective 
attention. 
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8.2. Discussion and implication for practice 
The results of this research program emphasize the principle that sleep is a central 
function that needs to be incorporated into long-term follow-up after solid organ 
transplantation [3]. In the introduction to section 1.7.2, we reviewed studies showing 
short-term outcomes following solid organ transplantation [4-10]. These studies show that 
solid organ transplantation has become a routine procedure, allowing expansion of the 
criteria for transplantation [11]. Still, while there have been major improvements in short-
term sleep-related outcomes following transplantation, the same improvements have not 
been observed in long-term outcomes [12]. This short-term improvement is basically a 
reduction in acute rejection rates, leaving a strong need to understand and control the 
side effects and long-term consequences of immunosuppressive treatment [11, 13]. 
Improving long-term outcomes in view of sleep, health-related quality of life, morbidity 
and mortality requires a holistic follow-up program rooted in the chronic illness framework 
[14, 15]. In the Chronic Care Model, Wagner et al. (2001) defined essential elements of a 
system to increase care quality beyond the capacity of the acute care model. Cross-linked 
(community, health system, self-management support, delivery system design, decision 
support and clinical information systems) evidence-based concepts foster productive 
interactions between informed patients who take an active part in their care and providers 
with resources and expertise [16]. Recapitulating, the chronic illness management 
approach combines four basic components: (1) ensuring access to and continuity of care; 
(2) increasing opportunities for patients to participate in their care process; (3) 
coordinating care between care settings; and (4) providing continuous self-management 
support.  
8.2.1. Sleep tracking in the chronic illness 
management 
Psychosocial outcomes have their own influence on long-term post-transplant morbidity 
and mortality rates [17, 18]. Quality of life improves from pre- to post-transplantation, 
however there is no consistently positive change in psychological health [19]. The 
longitudinal study of Silva et al (2012) shows excellent evidence that sleep improves from 
pre- to post-renal transplantation; however, in long-term follow-up, sleep remains poor 
and poor sleep remains associated with poorer perceived health status [12]. In other 
chronically ill patients, sleep disturbances are among the factors shown to negatively 
impact long-term outcomes, and are associated with higher risks of cardiovascular disease 
[20], metabolic derangements [21-25], diabetes [26], chronic inflammation [27, 28] and 
accelerated mortality [29-33] in the general population. Likewise, short sleep times (<5 
Chapter 8 
 
 
209 
hours) are associated with coronary artery calcification [34], with increased risks of overall 
cardiovascular events and myocardial infarction [35]. Finally, sleep duration of less than 6 
hours or more than 8 hours has been associated with depression [36]. The best survival rate 
was found among those who slept 7 hours per night [37].  
Considering these results, our research supports the importance of addressing 
sleep-related issues in the follow-up care of transplant recipients. Using a single validated 
item (Chapter 3) to measure daytime sleepiness, we demonstrated the high prevalence of 
this sleep-related disturbance in renal transplant recipients. Just over half of the 935 renal 
transplant recipients surveyed reported daytime sleepiness. An extensive review of the 
literature on sleep disorders in transplant recipients revealed only one study that had 
previously measured daytime sleepiness, but which, unfortunately, did not report its 
prevalence. In this same sample (Chapter 4) we found a significant association between 
daytime sleepiness and medication non-adherence–another behavior shown to negatively 
impact long-term transplantation outcomes [38]. We were the first investigators to report 
the prevalence of daytime sleepiness following transplantation and to examine its 
relationship to medication non-adherence in renal transplant recipients. Our association 
confirms the findings of Riegel et al. (2011) [39], who reported that the odds of non-
adherence increased by 11% for each unit increase in the daytime sleepiness score 
(adjusted OR: 1.11; 95% confidence interval: 1.05-1.19; p = .001). Indeed, we found a 9% 
increase for each unit increase in the daytime sleepiness score (adjusted OR: 1.09; 95% 
confidence interval 1.04-1.14; p = .001) [40]. 
The findings of both these studies have important implications for clinical practice 
and research. Both emphasize the importance of screening for daytime sleepiness during 
transplant recipients' follow-up care. When patients report daytime sleepiness, it is 
emphasized that clinicians should assess medication adherence and implement 
interventions, such as reminders and/or cuing systems. Since daytime sleepiness has such a 
high prevalence in renal transplant recipients, it is advisable to examine its prevalence in 
other transplant populations as well, along with its impact on other transplant-related 
outcomes. In addition, future studies should identify effective interventions (interventions 
to target the patient, health care provider, health care organization or health care system) 
against this sleep-related problem to minimize its impact on medication non-adherence. 
8.2.2. Sleep screening in prospective studies 
In the study described in Chapter 6, we examined changes in the prevalence of 
impaired sleep quality from pre- to post-transplant in heart, lung, liver and kidney 
transplant recipients. While we found that reports of poor sleep quality decreased from 
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pre- to 6 months post-transplantation, 32 to 39% of the 1076 patients surveyed continued 
to report impaired sleep quality. Measurements were conducted via the sleep quality item 
validated in our previous research [41, 42], which was subsequently incorporated in the 
ongoing assessment of subjects in the Swiss Transplant Cohort Study.  
In the same cohort of subjects (Chapter 6), we found a positive association between 
sleep quality and perceived health status, i.e., analysis revealed that sleep quality was a 
significant predictor of patients’ health status (p=<.0001). Those with poor sleep quality 
scored on average 10 points lower on the 100-point VAS self-reported health status scale 
[43]. This supports the findings of Silva et al. (2012), who reported that renal transplant 
recipients with poor sleep quality also had lower scores in health related quality of life 
[12]. Conversely, and also consistent with our findings, an epidemiological study using 
personal interviews of 1139 healthy adults reported that good sleep quality was related to 
better physical health (r = 0.26; p<.001)[44]. Further, a study analyzing the 
electroencephalographic sleep parameters of 185 healthy older adults found that, 
controlling for age, gender, and baseline medical burden, individuals with baseline sleep 
latencies greater than 30 minutes were at 2.14 times greater risk of mortality (p=.005, 95% 
CI: 1.25;3.66) within the range of 4.1–19.5 years follow-up time. Those with sleep 
efficiency less than 80% were at 1.93 times greater risk (p=.014, CI: 1.14;3.25). All of these 
points highlight the importance of assessing sleep to improve perceived health status, 
health related quality of life and even mortality rates. 
Plans to examine the predictive value of sleep quality regarding mortality in the 
Swiss Transplant Cohort Study are also both interesting and relevant. The results could 
then be compared to those of the Dialysis and Outcome Practice Pattern Study, which used 
the same sleep quality measurement tool and showed that the relative risk of mortality 
was 16% higher for hemodialysis patients with poor sleep quality [45] within the range of 0-
5.2 years follow-up time. Elder et al. (2008) reported that serum phosphorus (uremia 
related factor) and poor health-related quality of life accounted for the main associations 
with poor sleep quality. 
Our findings in relation to both sleep quality and daytime sleepiness support the 
importance of screening all transplant recipients for these important characteristics. 
Integrating sleep parameters in prospective longitudinal studies is a sign of the paradigm 
change towards a chronic care model, i.e., one focusing on tracking long-term outcomes. 
The two sleep items we validated as part of this research and a previous study [42] provide 
a simple and valid means of screening for sleep disorders in both clinical practice, where 
the time allotted for clinical encounters is often limited, and in research, where subject 
burden needs to be considered during measure selection. Short valid items with predictive 
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value regarding long-term outcomes and mortality rates will have the highest chance of 
integrated into prospective longitudinal cohort studies. In fact, the issue of patient burden 
may soon become decisive for studies' approval. As departments of health and ethics 
commissions are tightening regulations on participants' health and well-being, updated 
guidelines limit the lengths of information documents and questionnaires [46]. By 
developing and testing a short item measuring daytime sleepiness in renal transplant 
recipients, the research presented here contributed to this process by reducing the 
participants' burden (Chapter 3) [1]. 
8.2.3. Importance of in-depth sleep 
assessments 
While screening is the first step in identifying patients with sleep disorders, 
screening questions alone are insufficient to diagnose specific sleep disorders. Poor sleep 
quality and daytime sleepiness can be symptoms of insomnia, circadian rhythm sleep 
disorders, sleep related breathing disorders or sleep related movement disorders. Values 
higher than 4 on the daytime sleepiness item [1] or lower than 6 on the sleep quality item 
[42] should trigger a more detailed assessment by health care professionals. A positive 
screening result could indicate an acute or chronic sleep problem. Therefore, assessment 
questionnaires, such as the “Survey of Sleep” used in our research program (chapter 5), 
are useful in identifying the type of sleep disorder the patient is experiencing as well as 
identifying those patients who should be referred to a sleep specialist.  
While the most effective intervention will vary with the type of sleep disorder the 
patient is experiencing, the sleep hygiene rules (see section 1.6.2) are safe first-line 
interventions for most patients with sleep disorders. All healthcare professional should be 
familiar with these simple and safe interventions, which can be recommended while the 
more detailed assessment is being conducted. The findings on this assessment 
questionnaire, including comments of one or more family members, screen patients for 
chronic sleep disturbances. The questionnaire responses can be evaluated by a certified 
sleep expert, who can then prescribe any further diagnostic measures and eventually 
recommend evidence based interventions. Ideally this should be integrated in a chronic 
illness management approach. 
At this point the follow–up care team needs to be involved to ensure that the 
selected treatment does not compromise immunosuppression or otherwise endanger the 
transplanted organ. According to Buysse (2013), given insomnia's interactions with 
comorbid conditions and medications, primary care physicians or other health care 
professionals (e.g., advanced practice nurses) should have competencies to tailor and 
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deliver the appropriate treatment [47]. A thorough evaluation and treatment by a sleep 
specialist are appropriate when the patient has symptoms or clinical features of another 
sleep disorder, such as excessive daytime sleepiness, narcolepsy, sleep-related breathing 
disorders (apnea, loud snoring or witnessed apneas), circadian rhythm sleep disorders 
(pronounced alteration of sleep timing), or parasomnia (unusual sleep behaviors, including 
somnambulism, that can endanger the patient) [47]. Buysse recommends that transplant 
physicians or advanced practice nurses should be trained in the interpretation of the major 
sleep diagnosis questionnaires (e.g., Survey of Sleep). This implies integration of sleep 
assessment and knowledge into school curricula and routine clinical assessment 
procedures. 
In our study examining the prevalence of specific sleep disorders in renal transplant 
recipients, the prevalence was 42.5% for insomnia, 20.1% for circadian rhythm sleep 
disorders, 4.9% for obstructive sleep apnea and 0.6% for sleep related movement disorders 
[48]. Compared to those reported in previous studies of renal transplant recipients, the 
prevalence of insomnia was higher (8%[49, 50] - 16%[51]), while the rates of obstructive 
sleep apnea (25% [51, 52]), periodic limb movements (16% [53] - 27% [51]) and restless legs 
syndrome (4% to 5% [49, 50, 53-55]) were lower. One possible explanation for these 
discrepancies is that we used a preselected sample, i.e., included only renal transplant 
recipients screened for poor sleep quality and / or daytime sleepiness. Further, we 
assumed that most patients who participated had further “hidden” sleep disorders. Very 
often snoring, sleep apnea and movement disorders are perceived by a patient's spouse 
reported and treated. However, the reliability of spouses' observations is unknown, and our 
medical reports include no sleep reports indicating the prevalence of obstructive sleep 
apnea, periodic limb movements or restless legs syndrome in renal transplant recipients. If 
the assumption is false, i.e., if spouses are actually very poor reporters of such symptoms, 
this could explain the apparently low prevalence in our sample of obstructive sleep apnea, 
periodic limb movements and restless legs syndrome. 
Further, these studies used different methodologies and assessment systems. 
Earlier researchers assessed insomnia with the Athens Insomnia Scale (an 8-item 
questionnaire) [49-51] and no assessment interview. In addition, while the studies 
assessing obstructive sleep apnea, periodic limb movements and restless legs syndrome 
used polysomnography [51, 53] or the restless legs questionnaire [49, 50, 54, 55], we used 
a general assessment interview. These inconsistences in the reported prevalence of 
specific sleep disorders support the need for additional research to characterize both the 
sleep disorders experienced by renal transplant recipients and the risk factors attached to 
those disorders.  
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8.2.4. Bright light therapy for sleep-wake 
disturbances 
While the most appropriate treatment for sleep disorders will vary with the type of 
disorder, in our final research study (Chapter 7), we evaluated the impact of a self-
managed intervention -bright light therapy- in renal transplant recipients with sleep-wake 
disturbances (insomnia and circadian rhythm sleep disorders). We chose this therapy as it 
is safe (no increased risk of skin cancer, no interaction with pharmacological treatment or 
eye damage as ultraviolet rays are filtered [56]), and has been used effectively to 
correctively shift, synchronize, and stabilize circadian rhythms in non-transplant 
populations [57-62].  
Bright light therapy is effective in the early morning to phase advance the circadian 
rhythm [57, 58] and in the early evening to phase delay it [59]. Further, Yoon et al. (2002) 
showed that light therapy aids night shift workers' adaptation to their changed schedules. 
[60] Crowley et al. (2004) added that bright light improved performance, alertness, and 
mood during night-shift work [61]. Eastman et al. (2005) in a lab study to develop a 
practical pre-eastward flight treatment found that morning light therapy combined with 
evening light restriction has significant benefits against eastward flight jet-lag [62], while 
evening light therapy and morning light restriction is useful for westward flights [63]. Light 
therapy was first developed for treating seasonal affective disorder [64]. In Switzerland, 
bright light therapy is the first choice treatment for this disorder and is covered by 
standard health insurance. Furthermore, light therapy has been used efficaciously as an 
adjunct therapy to improve mood [65], sleep [66], major depression[67, 68], antepartum 
depression [69], eating disorders [70], attention deficit hyperactivity disorder [71], 
borderline personality disorder [72], Parkinson's disease [73] and Alzheimer's disease [74]. 
Of two studies using light therapy after surgery, one showed reduced delirium scores [75], 
while, in the other, fewer arrhythmias were recorded [76] in patients following surgery for 
oesophageal cancer.  
Our decision to use bright light therapy was based on the observation that most of 
the patients we assessed had late chronotypes, with complaints including difficulty falling 
asleep and staying asleep at night, and daytime sleepiness [48]. Evening chronotypes 
manifest a delayed sleep phase, characterized by inability to fall asleep or wake up at the 
desired time, followed by excessive daytime sleepiness [77]. Bright light capacity to shift 
the biological clock forward or backward, depending on time of administration, gives it 
particular therapeutic value for circadian rhythm sleep disorders, and for adjusting to shift 
work or jet lag [57]. Light therapy improves the robustness of the circadian rhythm [78-
80]. Circadian rhythm phase shifts can be indirectly measured via the timing of bedtime 
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and wake-up time, core body temperature [81], but most precisely by the onset of 
nocturnal melatonin secretion [82]. 
In our randomized controlled pilot study, we measured significant phase advances 
both for bedtime (14 minutes between the light intervention period and follow-up), and 
for get-up time (24 minutes from baseline to intervention completion). The overall phase 
advance is not surprising, as early morning bright light therapy is commonly used to phase 
advance delayed sleep syndrome [57]. However, it is interesting that more than 3 weeks 
(the intervention period) were necessary to phase advance bedtime. This confirms studies 
suggesting that increasing the duration of light therapy is more effective than increasing 
light intensity [83, 84]. Regarding get-up time, the phase advance was related to the light 
treatment time scheduled according to the chronotype; therefore, this result only reflects 
subjects' adherence to the early morning light therapy. 
Our findings in relation to the onset of melatonin secretion lack a conclusive 
explanation. In the usual care group, whose melatonin levels were expected to remain 
stable, we measured a considerable overall phase advance (baseline 1 to baseline 2: 
+1h:44min). We presume that this phase advance was related to a rise of melatonin in the 
early evening, which might have been an artefact of the low salivary melatonin profiles we 
had originally recorded, compared to those of other studies sampling salivary melatonin 
[72, 79, 85, 86]. Previously reported reasons for lack of melatonin response include 
hormone cycle dysfunction, damaged melatonin receptors or disease-precipitated night-
day rhythm reversal (Smith-Magenis Syndrome, a developmental disorder) [87].  
Reasons for low profiles include: 1) personal characteristics (e.g., individual 
variation, gender [88, 89], age [90] and body size [91, 92]); 2) comorbidities (e.g., 
glaucoma, cataracts, retinal detachment, retinopathy hindering the light to act on the 
pineal gland); 3) medication side-effects (e.g., non-steroidal anti-inflammatory drugs 
(which suppress melatonin)[93]; treatment with calcium channel blockers (which reduce 
melatonin output [94]), oral contraceptives [95], anti-coagulants (warfarin [96]), diabetes 
medications [97], and beta blockers such as bisoprolol (which suppresses melatonin [98])); 
and 4) calcification of the pineal gland (location of melatonin secretion) [99]. Regarding 
the condition of the pineal gland, urinary measurement of melatonin (levels of 6-
sulfatoxymelatonin) positively correlate with the volume of uncalcified pineal tissue [100]. 
Calcification is a cellular degeneration process which increases with age [101, 102].  
Most renal transplant recipients were treated with hemodialysis pre-
transplantation; therefore, they commonly suffer from decreased calcitrol production, 
which leads to a mineral-bone metabolic disorder. This disorder is expressed in abnormal 
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serum calcium, phosphorus and parathyroid hormone levels [103]. Consequently, 
hemodialysed patients have a higher prevalence of aortic calcification compared to the 
general population (79% vs. 37.5%) [104]. It follows that the probability that hemodialysis 
recipients also have calcified pineal glands is very high. This hypothesis should be explored 
further.  
For these reasons the low level of melatonin profiles could be a remnant of end 
stage renal disease. Except beta blockers and acetylsalicylic acid levels, none of the 
described factors were assessed, leaving considerable uncertainty as to which factor was 
the most relevant in our patient group. We assume that beta blockers and acetylsalicylic 
acid were a major factor in our pilot study, as controlling for these medications resulted in 
a significant improvement in sleep efficiency (+4.9%) [Standardized estimates: 0.42; 95%CI 
0.20; 0.65] and sleep latency (-6 min) [Standardized estimates: -0.28; 95%CI -0.45; -0.10]. 
Finally, measures of wellbeing, alertness, mood and depressive symptomatology improved 
(though non-significantly) following light therapy. We presume that this lack of significance 
results from not having included subjects with clinical depression (the baseline score of 
depressive symptomatology was not pathological; bright light therapy known to be 
beneficial in the treatment of patients with depression [105]). Also, in chronic illness 
patients, longer treatment times and/or higher dosages of light may be necessary. In 
summary, our results do not support prescribing bright light therapy for all renal transplant 
recipients with sleep–wake disturbances. Future bright light intervention studies should 
address dosage and duration issues, and be fully powered to allow a stratification of many 
of these factors that might compromise its effects. 
Should future studies support the benefits of light therapy in treating sleep 
disorders in transplant recipients, alternatives to light applied with a special lamp are to 
take a daily walk lasting at least an hour outside (light intensity for a cloudy day 5000 lux), 
[106], or reduce the exposure to light in the evening [57]. One technique for this is the use 
of amber (blue-blocking) glasses in the evening [107]. Since evening light, especially blue 
light, suppresses melatonin production [108]), amber lenses support the melatonin rise in 
the evening, thereby advancing sleep timing [107].  
Another alternative to light therapy is melatonin supplementation in the evening to 
phase advance or stabilize the circadian rhythm. Melatonin has to be prescribed carefully 
in low dosage: it produces soporific effects which are helpful for falling asleep rapidly in 
the evening, but can result in residual morning sleepiness. Compared to other drugs used 
for insomnia, melatonin supplementation has a benign side-effect profile, low cost and 
limited evidence of habituation or tolerance [109]. A recent meta-analysis demonstrated 
that melatonin decreases sleep onset latency, increases total sleep time and improves 
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overall sleep quality [109]. Melatonin supplementation has the strongest effect when taken 
in the late afternoon, 2-4 h before the normal dim light melatonin onset (9-11 h before 
sleep midpoint) [110]. For solid organ transplant recipients no contraindications are 
known; however, all of the aspects mentioned above (section 1.7.4) have to be considered 
before supplementation. 
8.3. Implications for future research 
Implications for future research that can be derived from this thesis include: (a) the need 
for sleep diagnosis prevalence studies in heart, lung and liver transplant recipients; (b) the 
need for prospective studies examining the impact of sleep disorders and their effect on 
long-term outcomes following transplantation, and (c) the need for a full-powered study 
(allowing for the control of potential confounders) to test the beneficial effect of bright 
light therapy. 
To advance the current knowledge regarding sleep prevalence data in kidney, 
heart, lung and liver transplant recipients, larger cohort studies are needed. Future studies 
should collect regular sleep follow-up screening data, as well as including information of 
the assessment, the diagnosis, and treatment of any sleep disorders identified. The sleep 
and daytime sleepiness screening data collected in the Swiss Transplant Cohort Study over 
the coming years should be analyzed in view of acute and chronic rejection and mortality. 
These data could be compared with the Dialysis Outcome and Practice Pattern Study, 
which showed the predictive validity of poor sleep quality in view of mortality in 
hemodialysis patients [45]. 
Our pilot randomized controlled trial revealed a relatively small improvement in 
sleep-wake function, suggesting that renal transplant recipients may have more complex 
clinical problems than short-term light therapy can influence. However, the phase advance 
and the small improvement for depressive symptomatology and subjective feelings in an 
underpowered study might have occluded the effect. From this perspective a fully 
powered study using light therapy as an intervention to synchronize sleep-wake 
disturbances is clearly necessary. Such a study would allow adjustment for beta blockers, 
non-steroidal anti-inflammatory drugs and calcification processes in the pineal gland. A 
longer course of treatment with longer daily light sessions may be useful [83, 84] to ensure 
the minimal exposure of 30 minutes, [111] which we hoped to achieve in our randomized 
controlled pilot study. 
Finally, improving long-term transplantation outcomes will require the integration of 
chronic illness based follow-up programs [112], including screening for sleep, standardized 
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operational procedures for positive screeners and a choice of safe sleep interventions for 
solid organ transplant recipients. Wagner et al. (2001) promoted the concept of the 
informed and active patient [16]. Models that adopt this explicitly patient-oriented 
approach, i.e., “complex intervention research”, are likely to have the greatest effects on 
patient outcomes (Zwar et al., 2006)[113]. The model and its process are complex, as the 
experimental and control interventions include several interacting components, and the 
main focus is effectiveness in everyday practice [114]. Another framework for intricate 
interventions is the intervention mapping approach [115, 116]–a protocol for complex 
guidance and a tool for the planning and development of health promotion interventions 
[115]. The planning process is iterative rather than linear, and the program planners move 
back and forth between tasks and steps. The process is cumulative, i.e., each step is based 
on the results of previous steps, so inattention at one stage may lead to later mistakes and 
inadequate decisions [116].  
8.4. Conclusion 
The multicenter sleep survey described here provided interesting prevalence data for 
daytime sleepiness (prevalence 51%; mean age: 58.0±12.3 y.; mean years since 
transplantation: 10.6±7.6) in renal transplant recipients. Furthermore, validation of the 
single item measuring daytime sleepiness was achieved, allowing quick, easy 
measurements of daytime sleepiness in longitudinal cohort studies with item restrictions. 
Using data from the Swiss Transplant Cohort Study, we found that sleep quality is 
predictive of perceived health status (p<.0001). Analysis of the multicenter sleep survey 
data also confirmed the hypothesized theoretical association between non-adherence and 
daytime sleepiness. Based on multivariate logistic regression analysis, daytime sleepiness 
was a significant predictor (p < 0.001) for taking (1.09 [1.04-1.14]), timing (1.06 [1.03-
1.10]) and overall non-adherence (1.09 [1.05-1.13]) in a sample with a mean age of 
58.0±12.3 y and a mean of 10.6±7.6 y years since renal transplantation. The sleep 
assessment interview study revealed a high prevalence of sleep-wake disturbances in renal 
transplant recipients. Most (49.4%) reported difficulty staying asleep, followed by problems 
falling asleep (32.1%). The assessment interview showed that most suffered from insomnia. 
In the pilot RCT, bright light therapy showed a beneficial effect in a subgroup of patients 
(renal transplant recipients taking neither beta-blockers nor acetylsalicylic acid, both of 
which are known to inhibit melatonin secretion), which provided valuable data on how to 
improve the intervention study, possibly with longer daily doses of light and/or a longer 
duration of treatment, and to plan a larger randomized controlled trial. 
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